<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:MEDS="http://datamedsai.com/20260630"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="meds-20260630.xsd" xlink:type="simple"/>
    <context id="From2026-01-01to2026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-08-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2026-08-17</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_SingleReportableSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MEDS:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_NoSingleCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">MEDS:NoSingleCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_NoSingleCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">MEDS:NoSingleCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_OneCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">MEDS:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_OneCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">MEDS:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_TwoCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">MEDS:TwoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_OneCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">MEDS:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_EquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_EquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_SoftwareDevelopmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_SoftwareDevelopmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_PharmacyRetailSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">MEDS:PharmacyRetailSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_PharmacyRetailSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">MEDS:PharmacyRetailSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_PharmacyRetailSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">MEDS:PharmacyRetailSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_PharmacyRetailSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">MEDS:PharmacyRetailSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_ThirdPartyLogisticsServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">MEDS:ThirdPartyLogisticsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_ThirdPartyLogisticsServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">MEDS:ThirdPartyLogisticsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_ThirdPartyLogisticsServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">MEDS:ThirdPartyLogisticsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_ThirdPartyLogisticsServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">MEDS:ThirdPartyLogisticsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_UnissuedDirecterShareAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MEDS:UnissuedDirecterShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_UnissuedDirecterShareAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MEDS:UnissuedDirecterShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2025-12-10</instant>
        </period>
    </context>
    <context id="AsOf2026-01-20_custom_SecuredConvertiblePromissoryNotesMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:SecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-20</instant>
        </period>
    </context>
    <context id="From2026-01-202026-01-20_custom_SecuredConvertiblePromissoryNotesMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:SecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-20</startDate>
            <endDate>2026-01-20</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_SecuredConvertiblePromissoryNotesMember_custom_AgileCapitalFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:SecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:AgileCapitalFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-04-01_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-01</instant>
        </period>
    </context>
    <context id="From2026-04-012026-04-01_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="From2026-05-202026-05-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2026-05-20</startDate>
            <endDate>2026-05-20</endDate>
        </period>
    </context>
    <context id="From2026-04-022026-04-02_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-02</startDate>
            <endDate>2026-04-02</endDate>
        </period>
    </context>
    <context id="From2026-04-022026-04-02_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-02</startDate>
            <endDate>2026-04-02</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <instant>2026-05-20</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NewConvertiblePromissoryNotesMember_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:NewConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NewConvertiblePromissoryNotesMember_custom_NewNotePurchaseAgreementMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:NewConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NewConvertiblePromissoryNotesMember_custom_NewNotePurchaseAgreementMember_custom_DawsonJamesSecuritiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:NewConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:DawsonJamesSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_FirstDefenseNasalScreenCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:FirstDefenseNasalScreenCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_FirstDefenseNasalScreenCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:FirstDefenseNasalScreenCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_CustomerRelationshipsWoodsageAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:CustomerRelationshipsWoodsageAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CustomerRelationshipsWoodsageAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:CustomerRelationshipsWoodsageAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_CustomerRelationshipsWellgisticsAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:CustomerRelationshipsWellgisticsAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CustomerRelationshipsWellgisticsAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:CustomerRelationshipsWellgisticsAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_TrademarkWellgisticsAcqusitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:TrademarkWellgisticsAcqusitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TrademarkWellgisticsAcqusitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:TrademarkWellgisticsAcqusitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_LicenseRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:LicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LicenseRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:LicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_WoodSageBusinessCombinationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:WoodSageBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_WoodSageBusinessCombinationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:WoodSageBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_WoodSageBusinessCombinationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:WoodSageBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WoodSageBusinessCombinationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:WoodSageBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WellgisticsCustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:WellgisticsCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WellgisticsTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MEDS:WellgisticsTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_MerchantCashAdvanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:MerchantCashAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MerchantCashAdvanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:MerchantCashAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_LoanPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:LoanPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LoanPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:LoanPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_NotePayableSellersOfWellgisticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NotePayableSellersOfWellgisticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NotePayableSellersOfWellgisticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NotePayableSellersOfWellgisticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_NotePayableThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NotePayableThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NotePayableThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NotePayableThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_RevolvingLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:RevolvingLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RevolvingLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:RevolvingLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_ThirdPartyInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ThirdPartyInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-20_custom_MerchantCashAdvanceAgreementMember_custom_CedarAdvanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MerchantCashAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:CedarAdvanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-20</instant>
        </period>
    </context>
    <context id="From2025-10-202025-10-20_custom_MerchantCashAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MerchantCashAdvanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-20</startDate>
            <endDate>2025-10-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-20_custom_MerchantCashAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MerchantCashAdvanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-20</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_MerchantCashAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MerchantCashAdvanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_MerchantCashAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MerchantCashAdvanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_MerchantCashAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MerchantCashAdvanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MerchantCashAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MerchantCashAdvanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-10-292025-10-29_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:FinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:AgileCapitalFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-29</startDate>
            <endDate>2025-10-29</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:FinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:AgileCapitalFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:FinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:AgileCapitalFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:FinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:AgileCapitalFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:FinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:AgileCapitalFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:FinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:AgileCapitalFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-24_custom_WellgisticsLLCMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-24</instant>
        </period>
    </context>
    <context id="AsOf2025-07-24_custom_WellgisticsLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-24</instant>
        </period>
    </context>
    <context id="From2025-07-242025-07-24_custom_WellgisticsLLCMember_custom_FirstAndSecondAnniversariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MEDS:FirstAndSecondAnniversariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="From2025-07-242025-07-24_custom_WellgisticsLLCMember_custom_ThirdAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MEDS:ThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_WellgisticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_WellgisticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_WellgisticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WellgisticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_WellgisticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WellgisticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-02_custom_UnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-02</instant>
        </period>
    </context>
    <context id="AsOf2025-01-02_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:ArvodaConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-02</instant>
        </period>
    </context>
    <context id="From2025-01-022025-01-02_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:ArvodaConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:ArvodaConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:ArvodaConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_UnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_UnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:ArvodaConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:ArvodaConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:ArvodaConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-02_custom_UnsecuredPromissoryNoteAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-02</instant>
        </period>
    </context>
    <context id="AsOf2025-02-02_custom_UnsecuredPromissoryNoteAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:UnsecuredPromissoryNoteAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-02</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:TwoSeparateUnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:TwoSeparateUnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:TwoSeparateUnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:TwoSeparateUnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:TwoSeparateUnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:TwoSeparateUnsecuredPromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-08_custom_PromissoryNoteMember_custom_StrategicEPLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-08</instant>
        </period>
    </context>
    <context id="From2025-04-082025-04-08_custom_StrategicEPLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-08</startDate>
            <endDate>2025-04-08</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_StrategicEPLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PromissoryNoteMember_custom_StrategicEPLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:StrategicEPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ThirdPartyInvestorMember_custom_PromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_custom_ThirdPartyInvestorMember_custom_PromissoryNoteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ThirdPartyInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-30_custom_CreditAgreementMember_custom_MarcoCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">MEDS:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="From2025-12-312025-12-31_custom_CreditAgreementMember_custom_MarcoCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">MEDS:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-01_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ForbearanceAndRepaymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-01</instant>
        </period>
    </context>
    <context id="From2026-05-012026-05-01_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ForbearanceAndRepaymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-01</startDate>
            <endDate>2026-05-01</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ForbearanceAndRepaymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ForbearanceAndRepaymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_NewCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:NewCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_MarcoCapitalIncMember_custom_ForbearanceAndRepaymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ForbearanceAndRepaymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-05-292026-05-29_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ForbearanceAndRepaymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-29</startDate>
            <endDate>2026-05-29</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_MarcoCapitalIncMember_custom_ForbearanceAndRepaymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ForbearanceAndRepaymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MarcoCapitalIncMember_custom_ForbearanceAndRepaymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ForbearanceAndRepaymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:MarcoCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-16_custom_NotePurchaseAgreementMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-16</instant>
        </period>
    </context>
    <context id="From2026-01-162026-01-16_custom_NotePurchaseAgreementMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-16</startDate>
            <endDate>2026-01-16</endDate>
        </period>
    </context>
    <context id="AsOf2026-04-01_custom_NotePurchaseAgreementMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-01</instant>
        </period>
    </context>
    <context id="From2026-04-012026-04-01_custom_NotePurchaseAgreementMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-20_custom_NotePurchaseAgreementMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-20</instant>
        </period>
    </context>
    <context id="From2026-05-202026-05-20_custom_NotePurchaseAgreementMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-20</startDate>
            <endDate>2026-05-20</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-20_custom_NotePurchaseAgreementMember_custom_HolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:HolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-20</instant>
        </period>
    </context>
    <context id="From2026-01-162026-01-16_custom_January2026OriginalNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:January2026OriginalNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-16</startDate>
            <endDate>2026-01-16</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-16_custom_January2026OriginalNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:January2026OriginalNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-16</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_OriginalConvertiblePromissoryNotesMember_custom_NotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:OriginalConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="From2026-05-272026-05-27_custom_ConvertiblePromissoryNotesMember_custom_NotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">MEDS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-27</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NewConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementRolloverNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NewConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementRolloverNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2027-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NewConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2027-05-27</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementNewNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NewConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementNewNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="From2026-01-202026-01-20_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NewConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-20</startDate>
            <endDate>2026-01-20</endDate>
        </period>
    </context>
    <context id="From2026-05-272026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NewConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-27</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="From2026-05-272026-05-27_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-27</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_PIPEWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">MEDS:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_PAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">MEDS:PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="From2026-05-272026-05-27_custom_PIPEWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">MEDS:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-27</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="From2026-05-272026-05-27_custom_PAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">MEDS:PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-27</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_OriginalNotesAndNewNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:OriginalNotesAndNewNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_OriginalNotesAndNewNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:OriginalNotesAndNewNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NewConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementRolloverNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MEDS:NewConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NewNotePurchaseAgreementRolloverNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-05-262026-05-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
        </entity>
        <period>
            <startDate>2026-05-26</startDate>
            <endDate>2026-05-26</endDate>
        </period>
    </context>
    <context id="From2026-01-132026-01-13_custom_ConsultingAgreementMember_custom_HudsonGlobalVenturesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:HudsonGlobalVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-13</startDate>
            <endDate>2026-01-13</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-13_custom_ConsultingAgreementMember_custom_HudsonGlobalVenturesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:HudsonGlobalVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-13</instant>
        </period>
    </context>
    <context id="From2026-05-202026-05-20_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MarketingServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:BoxCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-20</startDate>
            <endDate>2026-05-20</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-20_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MarketingServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:BoxCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-20</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MarketingServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:BoxCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MarketingServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:BoxCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:MarketingServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:BoxCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-02-122026-02-12_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-12</startDate>
            <endDate>2026-02-12</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-12_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-12</instant>
        </period>
    </context>
    <context id="From2026-02-122026-02-12_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-12</startDate>
            <endDate>2026-02-12</endDate>
        </period>
    </context>
    <context id="From2026-03-092026-03-09_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-09</startDate>
            <endDate>2026-03-09</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-09_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-09</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-03-232026-03-23_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-23</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-082026-04-08_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-08</startDate>
            <endDate>2026-04-08</endDate>
        </period>
    </context>
    <context id="From2026-04-102026-04-10_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-10</startDate>
            <endDate>2026-04-10</endDate>
        </period>
    </context>
    <context id="From2026-04-032026-04-03_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-03</startDate>
            <endDate>2026-04-03</endDate>
        </period>
    </context>
    <context id="AsOf2026-04-08_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-08</instant>
        </period>
    </context>
    <context id="AsOf2026-04-10_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-10</instant>
        </period>
    </context>
    <context id="From2026-05-202026-05-20_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-20</startDate>
            <endDate>2026-05-20</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-20_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-20</instant>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:SilverbackCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-18</startDate>
            <endDate>2026-03-18</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_TwoThousandTwentyThrereEquityIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MEDS:TwoThousandTwentyThrereEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_NonEmployeeDirectorMember_custom_FirstCalendarYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MEDS:FirstCalendarYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-07-01_custom_NonEmployeeDirectorMember_custom_SubsequentCalandarYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MEDS:SubsequentCalandarYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-01</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RestrictedStockMember_us-gaap_SellingAndMarketingExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:SellingAndMarketingExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_RestrictedStockMember_us-gaap_SellingAndMarketingExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:SellingAndMarketingExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RestrictedStockMember_us-gaap_GeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_RestrictedStockMember_us-gaap_GeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-03-142025-03-14_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_NonEmployeeDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:NonEmployeeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-02-042026-02-04_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-04</startDate>
            <endDate>2026-02-04</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-04_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-04</instant>
        </period>
    </context>
    <context id="From2026-03-192026-03-19_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-19</startDate>
            <endDate>2026-03-19</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-19_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-19</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-20_custom_PlacementAgentAndItsDesigneesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:PlacementAgentAndItsDesigneesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-20</instant>
        </period>
    </context>
    <context id="From2026-01-202026-01-20_custom_PlacementAgentAndItsDesigneesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:PlacementAgentAndItsDesigneesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-20</startDate>
            <endDate>2026-01-20</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-01-20_custom_PlacementAgentAndItsDesigneesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:PlacementAgentAndItsDesigneesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-20</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="From2026-03-182026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-18</startDate>
            <endDate>2026-03-18</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_WarrantMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_CommonStockMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-27_us-gaap_CommonStockMember_custom_NotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_custom_NotePurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2026-05-27_us-gaap_CommonStockMember_custom_NotePurchaseAgreementMember_custom_PlacementAgentAndItsDesigneesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MEDS:PlacementAgentAndItsDesigneesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_WarrantMember_custom_PrivateInvestmentPublicEquityWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MEDS:PrivateInvestmentPublicEquityWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MEDS:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PrivateInvestmentPublicEquityWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MEDS:PrivateInvestmentPublicEquityWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MEDS:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-31_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-05-31_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-31_custom_WellgisticsLLCMember_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:WellgisticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="From2023-06-092023-06-09_custom_IntergraPharmaSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:IntergraPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-09</startDate>
            <endDate>2023-06-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-09_custom_IntergraPharmaSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:IntergraPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-09</instant>
        </period>
    </context>
    <context id="AsOf2022-01-31_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_ScietechLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:ScietechLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ScietechLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:ScietechLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_FortitudeAdvisorsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:FortitudeAdvisorsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_FortitudeAdvisorsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:FortitudeAdvisorsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_TolloHealthLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:TolloHealthLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_IntegraPharmaSolutionsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:IntegraPharmaSolutionsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_IntegraPharmaSolutionsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:IntegraPharmaSolutionsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_IntegraPharmaSolutionsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:IntegraPharmaSolutionsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_IntegraPharmaSolutionsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:IntegraPharmaSolutionsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_NomadCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:NomadCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_NomadCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:NomadCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_NomadCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:NomadCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_NomadCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:NomadCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_CingoSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:CingoSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_CingoSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:CingoSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_CingoSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:CingoSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_CingoSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:CingoSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_custom_RxERPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:RxERPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_RxERPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:RxERPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-06-30_custom_RxERPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:RxERPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_RxERPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MEDS:RxERPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-08-212024-08-21_custom_BlytheGlobalAdvisorsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:BlytheGlobalAdvisorsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-21</startDate>
            <endDate>2024-08-21</endDate>
        </period>
    </context>
    <context id="From2024-08-212024-08-21_custom_LifsaDrugsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:LifsaDrugsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-21</startDate>
            <endDate>2024-08-21</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-28_custom_LifsaDrugsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MEDS:LifsaDrugsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-28</instant>
        </period>
    </context>
    <context id="AsOf2026-07-07_custom_ClaimRightsConfirmationAndPaymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ClaimRightsConfirmationAndPaymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-07</instant>
        </period>
    </context>
    <context id="From2026-07-072026-07-09_custom_ClaimRightsConfirmationAndPaymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ClaimRightsConfirmationAndPaymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-07</startDate>
            <endDate>2026-07-09</endDate>
        </period>
    </context>
    <context id="From2026-07-072026-07-08_custom_ClaimRightsConfirmationAndPaymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:ClaimRightsConfirmationAndPaymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-07</startDate>
            <endDate>2026-07-08</endDate>
        </period>
    </context>
    <context id="AsOf2026-07-24_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MEDS:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-24</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_VendorDemandLetterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">MEDS:VendorDemandLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_InvesteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MEDS:InvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_EOSTechnologyHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MEDS:EOSTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_ScilexHoldingCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MEDS:ScilexHoldingCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_DatavaultAIIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MEDS:DatavaultAIIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_HealthBridgeAdvisorsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MEDS:HealthBridgeAdvisorsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_FortitudeAdvisorsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MEDS:FortitudeAdvisorsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_ExistingPublicStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002030763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MEDS:ExistingPublicStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>MEDS:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-01-01to2026-06-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2026-01-01to2026-06-30" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2026-01-01to2026-06-30" id="Fact000005">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2026-01-01to2026-06-30" id="Fact000006">0002030763</dei:EntityCentralIndexKey>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0062"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2026-06-30"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-06-30"
      id="xdx2ixbrl0130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:GainsLossesOnExtinguishmentOfVenderObligation
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:GainsLossesOnExtinguishmentOfVenderObligation
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:GainsLossesOnContractTerminationFee
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:GainsLossesOnContractTerminationFee
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:SettlementFees
      contextRef="From2026-04-012026-06-30"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:SettlementFees
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:SettlementFees
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToAtPublicOfferings
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToDirectors
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedIssuanceOfCommitmentSharesUnderEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedIssuanceOfCommitmentSharesUnderEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPartialSettlementOfSellersNote
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfLegalFees
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0448"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursuanceOfExerciseOfWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursanceOfContractTerminationFees
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-04-012026-06-30"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:GainsLossesOnExtinguishmentOnVendorObligation
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:GainsLossesOnOnContractTerminationFee
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommercialPaper
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:RepaymentOfSellerPromissoryNote
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:ProceedsFromMerchantCashAdvance
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:RepaymentOfMerchantCashAdvance
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfOtherShortTermDebt
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:ProceedsFromCommonStockIssuedPursuantToPublicOffering
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0664"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:IssuanceOfCommonStockAndWarrantsInSettlementOfAccruedCompensation
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0695"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:IssuanceOfCommonStockAndWarrantsInSettlementOfVendorAndDebtObligation
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:FairValueOfPipeAndPlacementAgentWarrants
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:ConvertibleNotesIssuedInLieuOfCashForPlacementAgentFee
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl0704"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:SubscriptionReceivable
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:IssuanceOfCommitmentSharesUnderEquityPurchaseAgreement
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:CommonStockIssuedInPartialSettlementOfSellersNote
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="AsOf2026-06-30_us-gaap_LeaseholdImprovementsMember"
      id="xdx2ixbrl0776">http://fasb.org/us-gaap/2026#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_custom_UnissuedDirecterShareAwardsMember"
      id="xdx2ixbrl0830"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember"
      id="xdx2ixbrl0833"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_us-gaap_ConvertibleDebtSecuritiesMember"
      id="xdx2ixbrl0836"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_LoanPayableMember"
      id="xdx2ixbrl1109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_RevolvingLineOfCreditMember"
      id="xdx2ixbrl1118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_ConvertibleNotesMember"
      id="xdx2ixbrl1122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1611"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1613"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1619"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1621"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl1693"
      unitRef="Shares"
      xsi:nil="true"/>
    <MEDS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl1695"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-04-012026-06-30_custom_IntegraPharmaSolutionsLLCMember"
      id="xdx2ixbrl1861"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-04-012025-06-30_custom_IntegraPharmaSolutionsLLCMember"
      id="xdx2ixbrl1862"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-01-012026-06-30_custom_IntegraPharmaSolutionsLLCMember"
      id="xdx2ixbrl1863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-04-012026-06-30_custom_NomadCapitalLLCMember"
      id="xdx2ixbrl1866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-04-012025-06-30_custom_NomadCapitalLLCMember"
      id="xdx2ixbrl1867"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-01-012026-06-30_custom_NomadCapitalLLCMember"
      id="xdx2ixbrl1868"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-04-012026-06-30_custom_CingoSolutionsMember"
      id="xdx2ixbrl1871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-01-012026-06-30_custom_CingoSolutionsMember"
      id="xdx2ixbrl1873"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-04-012026-06-30_custom_RxERPMember"
      id="xdx2ixbrl1876"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-01-012026-06-30_custom_RxERPMember"
      id="xdx2ixbrl1878"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-04-012026-06-30_custom_RxERPMember"
      id="xdx2ixbrl1881"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2026-01-012026-06-30_custom_RxERPMember"
      id="xdx2ixbrl1883"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:LossOnExtinguishmentOfVendorObligation
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl1950"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:LossOnExtinguishmentOfVendorObligation
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl1952"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl1955"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl1957"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:GainsLossesOnContractTerminationFee
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl1960"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:GainsLossesOnContractTerminationFee
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl1962"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:SettlementFees
      contextRef="From2026-04-012026-06-30"
      id="xdx2ixbrl1964"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:SettlementFees
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl1965"
      unitRef="USD"
      xsi:nil="true"/>
    <MEDS:SettlementFees
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl1967"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-04-012026-06-30"
      id="xdx2ixbrl1984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl1985"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-06-30"
      id="xdx2ixbrl1986"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-06-30"
      id="xdx2ixbrl1987"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2026-01-01to2026-06-30" id="Fact000014">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2026-01-01to2026-06-30" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2026-01-01to2026-06-30" id="Fact000016">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2026-01-01to2026-06-30" id="Fact000017">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2026-01-01to2026-06-30" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2026-01-01to2026-06-30" id="Fact000019">001-42530</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2026-01-01to2026-06-30" id="Fact000020">DataMeds AI, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-06-30" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-01-01to2026-06-30" id="Fact000022">93-3264234</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-01-01to2026-06-30" id="Fact000023">3000                                             Bayport Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2026-01-01to2026-06-30" id="Fact000024">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2026-01-01to2026-06-30" id="Fact000025">Tampa</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2026-01-01to2026-06-30" id="Fact000026">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2026-01-01to2026-06-30" id="Fact000027">33607</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2026-01-01to2026-06-30" id="Fact000028">(844)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-01-01to2026-06-30" id="Fact000029">203-6092</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2026-01-01to2026-06-30" id="Fact000030">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2026-01-01to2026-06-30" id="Fact000031">MEDS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2026-01-01to2026-06-30" id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2026-01-01to2026-06-30" id="Fact000033">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2026-01-01to2026-06-30" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2026-01-01to2026-06-30" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-01-01to2026-06-30" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-01-01to2026-06-30" id="Fact000037">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2026-01-01to2026-06-30" id="Fact000038">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2026-01-01to2026-06-30" id="Fact000039">false</dei:EntityShellCompany>
    <dei:EntityListingParValuePerShare
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact000040"
      unitRef="USDPShares">0.0001</dei:EntityListingParValuePerShare>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-08-17"
      decimals="INF"
      id="Fact000041"
      unitRef="Shares">3061919</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000049"
      unitRef="USD">2456373</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">42571</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000052"
      unitRef="USD">1174336</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">1137219</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000055"
      unitRef="USD">1510123</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">1639426</us-gaap:InventoryNet>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">26068</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000061"
      unitRef="USD">465738</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000064"
      unitRef="USD">5632638</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">2819216</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000067"
      unitRef="USD">173879</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">229376</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">2297588</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">1850358</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">719645</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">966893</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">14193923</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">14193923</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">9656751</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">10314675</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000082"
      unitRef="USD">85008</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">85008</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000085"
      unitRef="USD">32759432</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">30459449</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000094"
      unitRef="USD">12612167</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000095"
      unitRef="USD">11665135</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000097"
      unitRef="USD">25500</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000098"
      unitRef="USD">25500</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000100"
      unitRef="USD">25500</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000101"
      unitRef="USD">25500</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000103"
      unitRef="USD">7003749</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">6407722</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">225000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000109"
      unitRef="USD">12101803</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000112"
      unitRef="USD">7104225</us-gaap:SecuredDebtCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">10887520</us-gaap:SecuredDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000115"
      unitRef="USD">566379</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">569251</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000118"
      unitRef="USD">39413823</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">29780128</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2026-06-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000121"
      unitRef="USD">12600000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000122"
      unitRef="USD">12600000</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000124"
      unitRef="USD">249840</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">527122</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000127"
      unitRef="USD">52263663</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">42907250</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000139"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">2847198</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">2045792</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">2836484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">2026150</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000136"
      unitRef="USD">283</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">203</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000155"
      unitRef="USD">117632998</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">98583686</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000158"
      unitRef="USD">-137137512</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">-111031690</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000161"
      unitRef="USD">-19504231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">-12447801</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000164"
      unitRef="USD">32759432</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">30459449</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">1779860</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">7790865</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">3339423</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">18654308</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">1597656</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000173"
      unitRef="USD">7285113</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">2986998</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">17455915</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">182204</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">505752</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">352425</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">1198393</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000187"
      unitRef="USD">7056671</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000188"
      unitRef="USD">4859949</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">11925606</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">36032869</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000192"
      unitRef="USD">113990</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">343383</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">1073990</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">408600</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000197"
      unitRef="USD">356597</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000198"
      unitRef="USD">802796</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">713421</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">1605668</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000202"
      unitRef="USD">7527258</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000203"
      unitRef="USD">6006128</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000204"
      unitRef="USD">13713017</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000205"
      unitRef="USD">38047137</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000207"
      unitRef="USD">-7345054</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-5500376</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-13360592</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-36848744</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000217"
      unitRef="USD">1561240</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000218"
      unitRef="USD">1184040</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">3633919</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">2278530</us-gaap:InterestExpenseNonoperating>
    <MEDS:GainsLossesOnExtinguishmentOfVenderObligation
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">-320000</MEDS:GainsLossesOnExtinguishmentOfVenderObligation>
    <MEDS:GainsLossesOnExtinguishmentOfVenderObligation
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-60120</MEDS:GainsLossesOnExtinguishmentOfVenderObligation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-8881694</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-8881694</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <MEDS:GainsLossesOnContractTerminationFee
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-766394</MEDS:GainsLossesOnContractTerminationFee>
    <MEDS:GainsLossesOnContractTerminationFee
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000234"
      unitRef="USD">-766394</MEDS:GainsLossesOnContractTerminationFee>
    <MEDS:SettlementFees
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000239"
      unitRef="USD">13000</MEDS:SettlementFees>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000242"
      unitRef="USD">511157</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000243"
      unitRef="USD">11952</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000244"
      unitRef="USD">609897</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000245"
      unitRef="USD">23907</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000247"
      unitRef="USD">-11018171</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-1172088</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-12745230</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000250"
      unitRef="USD">-2254623</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000252"
      unitRef="USD">-18363225</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000253"
      unitRef="USD">-6672464</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000254"
      unitRef="USD">-26105822</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-39103367</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-18363225</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000263"
      unitRef="USD">-6672464</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000264"
      unitRef="USD">-26105822</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000265"
      unitRef="USD">-39103367</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-04-012026-06-30"
      decimals="INF"
      id="Fact000267"
      unitRef="Shares">2574669</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-04-012026-06-30"
      decimals="INF"
      id="Fact000269"
      unitRef="Shares">2574669</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000271"
      unitRef="Shares">1235423</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">1235423</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact000275"
      unitRef="Shares">2335557</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact000277"
      unitRef="Shares">2335557</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-06-30"
      decimals="INF"
      id="Fact000279"
      unitRef="Shares">1137274</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-06-30"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">1137274</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-04-012026-06-30"
      decimals="INF"
      id="Fact000283"
      unitRef="USDPShares">-7.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-04-012026-06-30"
      decimals="INF"
      id="Fact000285"
      unitRef="USDPShares">-7.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000287"
      unitRef="USDPShares">-5.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000289"
      unitRef="USDPShares">-5.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact000291"
      unitRef="USDPShares">-11.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact000293"
      unitRef="USDPShares">-11.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-06-30"
      decimals="INF"
      id="Fact000295"
      unitRef="USDPShares">-34.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-06-30"
      decimals="INF"
      id="Fact000297"
      unitRef="USDPShares">-34.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000304"
      unitRef="Shares">1021110</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">102</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">16491504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">-9757160</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000302"
      unitRef="USD">6734446</us-gaap:StockholdersEquity>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedPursuantToPublicOfferingShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000311"
      unitRef="Shares">17778</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedPursuantToPublicOfferingShares>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToAtPublicOfferings
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000306"
      unitRef="USD">2</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToAtPublicOfferings>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToAtPublicOfferings
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">3999998</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToAtPublicOfferings>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToAtPublicOfferings
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">4000000</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToAtPublicOfferings>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000318"
      unitRef="Shares">3040</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">543520</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">543520</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">19722</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">2875558</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">2875560</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToDirectors
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">167250</MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToDirectors>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToDirectors
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">17</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToDirectors>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToDirectors
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">24278741</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToDirectors>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToDirectors
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">24278758</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToDirectors>
    <MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000339"
      unitRef="Shares">300</MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToEmployees>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">75584</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">75584</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">1598196</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">1598196</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000348"
      unitRef="USD">-32430903</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000349"
      unitRef="USD">-32430903</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">1229200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">123</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">46666708</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-42188063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000354"
      unitRef="USD">4478768</us-gaap:StockholdersEquity>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedPursuantToPublicOffering
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000363"
      unitRef="Shares">23101</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedPursuantToPublicOffering>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">2</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToEquityPurchaseAgreement>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">1149415</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToEquityPurchaseAgreement>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000361"
      unitRef="USD">1149417</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedPursuantToEquityPurchaseAgreement>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedIssuanceOfCommitmentSharesUnderEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">3040</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedIssuanceOfCommitmentSharesUnderEquityPurchaseAgreement>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedIssuanceOfCommitmentSharesUnderEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">594320</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedIssuanceOfCommitmentSharesUnderEquityPurchaseAgreement>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedIssuanceOfCommitmentSharesUnderEquityPurchaseAgreement
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000368"
      unitRef="USD">594320</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedIssuanceOfCommitmentSharesUnderEquityPurchaseAgreement>
    <MEDS:StockIssuedDuringPeriodSharesIssuedInPartialSettlementOfSellersNote
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000377"
      unitRef="Shares">6667</MEDS:StockIssuedDuringPeriodSharesIssuedInPartialSettlementOfSellersNote>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPartialSettlementOfSellersNote
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">1</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPartialSettlementOfSellersNote>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPartialSettlementOfSellersNote
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">1499999</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPartialSettlementOfSellersNote>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPartialSettlementOfSellersNote
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000375"
      unitRef="USD">1500000</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPartialSettlementOfSellersNote>
    <MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000384"
      unitRef="Shares">889</MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToEmployees>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000380"
      unitRef="USD">354563</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000382"
      unitRef="USD">354563</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">499349</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000389"
      unitRef="USD">499349</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-6672464</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000394"
      unitRef="USD">-6672464</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">1262896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">126</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000397"
      unitRef="USD">49765656</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000398"
      unitRef="USD">-48860527</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000399"
      unitRef="USD">905255</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">2026150</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">203</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">98583686</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000405"
      unitRef="USD">-111031690</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000406"
      unitRef="USD">-12447801</us-gaap:StockholdersEquity>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000415"
      unitRef="Shares">200000</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">20</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000411"
      unitRef="USD">2589560</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">2589580</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInCommonStockAndWarrantsIssuedInSettlementOfAccruedCompensation>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000422"
      unitRef="Shares">129320</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfVendorObligation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000417"
      unitRef="USD">13</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000418"
      unitRef="USD">1356607</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">1356620</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfLegalFees
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000429"
      unitRef="Shares">8000</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfLegalFees>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfLegalFees
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">1</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfLegalFees>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfLegalFees
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">51999</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfLegalFees>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfLegalFees
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">52000</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfLegalFees>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000436"
      unitRef="Shares">24490</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000432"
      unitRef="USD">514283</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000434"
      unitRef="USD">514285</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">416965</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">416965</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">169853</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000446"
      unitRef="USD">169853</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000451"
      unitRef="USD">28646</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">28646</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000457"
      unitRef="USD">-7742597</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">-7742597</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000465"
      unitRef="Shares">2387960</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">239</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">103711599</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">-118774287</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000463"
      unitRef="USD">-15062449</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000472"
      unitRef="Shares">2387960</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">239</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000468"
      unitRef="USD">103711599</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000469"
      unitRef="USD">-118774287</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000470"
      unitRef="USD">-15062449</us-gaap:StockholdersEquity>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedPursuantToConsultingAgreementShares
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000479"
      unitRef="Shares">200000</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedPursuantToConsultingAgreementShares>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursuanceOfExerciseOfWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">20</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursuanceOfExerciseOfWarrants>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursuanceOfExerciseOfWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000475"
      unitRef="USD">11011</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursuanceOfExerciseOfWarrants>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursuanceOfExerciseOfWarrants
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000477"
      unitRef="USD">11031</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursuanceOfExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000486"
      unitRef="Shares">14085</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000481"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000482"
      unitRef="USD">149717</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000484"
      unitRef="USD">149718</us-gaap:StockIssuedDuringPeriodValueOther>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000493"
      unitRef="Shares">100000</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfVendorObligation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000488"
      unitRef="USD">10</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000489"
      unitRef="USD">644990</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000491"
      unitRef="USD">645000</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfVendorObligation>
    <MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInPursanceOfContractTerminationFees
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000500"
      unitRef="Shares">125465</MEDS:StockIssuedDuringPeriodSharesCommonStockIssuedInPursanceOfContractTerminationFees>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursanceOfContractTerminationFees
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000495"
      unitRef="USD">13</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursanceOfContractTerminationFees>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursanceOfContractTerminationFees
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000496"
      unitRef="USD">766379</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursanceOfContractTerminationFees>
    <MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursanceOfContractTerminationFees
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000498"
      unitRef="USD">766392</MEDS:StockIssuedDuringPeriodValueCommonStockIssuedInPursanceOfContractTerminationFees>
    <MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000507"
      unitRef="Shares">8929</MEDS:StockIssuedDuringPeriodSharesVestedRestrictedStockGrantedToEmployees>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000503"
      unitRef="USD">1104129</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees>
    <MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000505"
      unitRef="USD">1104129</MEDS:StockIssuedDuringPeriodValueVestedRestrictedStockGrantedToEmployees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000510"
      unitRef="USD">2685666</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000512"
      unitRef="USD">2685666</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000515"
      unitRef="USD">10047930</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000517"
      unitRef="USD">10047930</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">1488423</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000522"
      unitRef="USD">1488423</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000529"
      unitRef="Shares">45</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000533"
      unitRef="USD">-18363225</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000534"
      unitRef="USD">-18363225</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000541"
      unitRef="Shares">2836484</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000536"
      unitRef="USD">283</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000537"
      unitRef="USD">117632998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000538"
      unitRef="USD">-137137512</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000539"
      unitRef="USD">-19504231</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000548"
      unitRef="Shares">2836484</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000543"
      unitRef="USD">283</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">117632998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000545"
      unitRef="USD">-137137512</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000546"
      unitRef="USD">-19504231</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000553"
      unitRef="USD">-26105822</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000554"
      unitRef="USD">-39103367</us-gaap:NetIncomeLoss>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000559"
      unitRef="USD">213787</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000560"
      unitRef="USD">200454</us-gaap:ProvisionForDoubtfulAccounts>
    <MEDS:GainsLossesOnExtinguishmentOnVendorObligation
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000562"
      unitRef="USD">-60120</MEDS:GainsLossesOnExtinguishmentOnVendorObligation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000565"
      unitRef="USD">-8881694</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <MEDS:GainsLossesOnOnContractTerminationFee
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000568"
      unitRef="USD">-766394</MEDS:GainsLossesOnOnContractTerminationFee>
    <MEDS:AmortizationOfDebtDiscount
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000571"
      unitRef="USD">2343252</MEDS:AmortizationOfDebtDiscount>
    <MEDS:AmortizationOfDebtDiscount
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000572"
      unitRef="USD">33411</MEDS:AmortizationOfDebtDiscount>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000574"
      unitRef="USD">2562514</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000575"
      unitRef="USD">28708643</us-gaap:ShareBasedCompensation>
    <us-gaap:InventoryWriteDown
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000577"
      unitRef="USD">72967</us-gaap:InventoryWriteDown>
    <us-gaap:Depreciation
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000580"
      unitRef="USD">55497</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000581"
      unitRef="USD">79538</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000583"
      unitRef="USD">657924</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000584"
      unitRef="USD">1526129</us-gaap:AdjustmentForAmortization>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000589"
      unitRef="USD">250904</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000590"
      unitRef="USD">-362911</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000592"
      unitRef="USD">-56336</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000593"
      unitRef="USD">-487465</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000595"
      unitRef="USD">410010</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000596"
      unitRef="USD">65001</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000599"
      unitRef="USD">-332</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000601"
      unitRef="USD">2432030</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000602"
      unitRef="USD">3141897</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000604"
      unitRef="USD">2640868</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000605"
      unitRef="USD">1145749</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000607"
      unitRef="USD">-32906</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000608"
      unitRef="USD">-5720</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <MEDS:IncreaseDecreaseInRelatedPartiesNet
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000610"
      unitRef="USD">251068</MEDS:IncreaseDecreaseInRelatedPartiesNet>
    <MEDS:IncreaseDecreaseInRelatedPartiesNet
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000611"
      unitRef="USD">-61112</MEDS:IncreaseDecreaseInRelatedPartiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000613"
      unitRef="USD">-6307328</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000614"
      unitRef="USD">-3426447</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000619"
      unitRef="USD">447230</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000620"
      unitRef="USD">405059</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000622"
      unitRef="USD">-447230</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000623"
      unitRef="USD">-405059</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000628"
      unitRef="USD">1000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommercialPaper
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000632"
      unitRef="USD">615000</us-gaap:ProceedsFromIssuanceOfCommercialPaper>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000634"
      unitRef="USD">36751</us-gaap:RepaymentsOfNotesPayable>
    <MEDS:RepaymentOfSellerPromissoryNote
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000638"
      unitRef="USD">137141</MEDS:RepaymentOfSellerPromissoryNote>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000641"
      unitRef="USD">703366</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000644"
      unitRef="USD">17146000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000646"
      unitRef="USD">1643923</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000647"
      unitRef="USD">18697494</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000649"
      unitRef="USD">14200000</us-gaap:ProceedsFromConvertibleDebt>
    <MEDS:ProceedsFromMerchantCashAdvance
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000653"
      unitRef="USD">234157</MEDS:ProceedsFromMerchantCashAdvance>
    <MEDS:RepaymentOfMerchantCashAdvance
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000655"
      unitRef="USD">89909</MEDS:RepaymentOfMerchantCashAdvance>
    <us-gaap:RepaymentsOfOtherShortTermDebt
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000658"
      unitRef="USD">2104557</us-gaap:RepaymentsOfOtherShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000662"
      unitRef="USD">567722</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <MEDS:ProceedsFromCommonStockIssuedPursuantToPublicOffering
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000665"
      unitRef="USD">4000000</MEDS:ProceedsFromCommonStockIssuedPursuantToPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000667"
      unitRef="USD">1157500</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000668"
      unitRef="USD">1208498</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000670"
      unitRef="USD">9168360</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000671"
      unitRef="USD">3223112</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000673"
      unitRef="USD">2413802</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000674"
      unitRef="USD">-608394</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">42571</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000677"
      unitRef="USD">1028336</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000679"
      unitRef="USD">2456373</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000680"
      unitRef="USD">419942</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000688"
      unitRef="USD">516505</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000689"
      unitRef="USD">1477713</us-gaap:InterestPaidNet>
    <MEDS:IssuanceOfCommonStockAndWarrantsInSettlementOfAccruedCompensation
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000694"
      unitRef="USD">2599611</MEDS:IssuanceOfCommonStockAndWarrantsInSettlementOfAccruedCompensation>
    <MEDS:IssuanceOfCommonStockAndWarrantsInSettlementOfVendorAndDebtObligation
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000697"
      unitRef="USD">2001620</MEDS:IssuanceOfCommonStockAndWarrantsInSettlementOfVendorAndDebtObligation>
    <MEDS:FairValueOfPipeAndPlacementAgentWarrants
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000700"
      unitRef="USD">12733596</MEDS:FairValueOfPipeAndPlacementAgentWarrants>
    <MEDS:ConvertibleNotesIssuedInLieuOfCashForPlacementAgentFee
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000703"
      unitRef="USD">133985</MEDS:ConvertibleNotesIssuedInLieuOfCashForPlacementAgentFee>
    <MEDS:SubscriptionReceivable
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000707"
      unitRef="USD">581695</MEDS:SubscriptionReceivable>
    <MEDS:IssuanceOfCommitmentSharesUnderEquityPurchaseAgreement
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000710"
      unitRef="USD">594320</MEDS:IssuanceOfCommitmentSharesUnderEquityPurchaseAgreement>
    <MEDS:CommonStockIssuedInPartialSettlementOfSellersNote
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000713"
      unitRef="USD">1500000</MEDS:CommonStockIssuedInPartialSettlementOfSellersNote>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000715">&lt;p id="xdx_80E_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zqVooKLgUBaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1. &lt;span id="xdx_820_zOC08gsKFGN1"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;DataMeds
AI, Inc. (formerly known as Wellgistics Health, Inc.) (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;)
is a Delaware corporation headquartered in Tampa, Florida. The Company was initially organized as Ayan Sponsors LLC on September 6, 2022,
and subsequently incorporated as Danam Health, Inc. on November 15, 2022. On October 4, 2024, the Company changed its corporate name
to Wellgistics Health, Inc. by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. On July 20, 2026,
the Company filed a further Certificate of Amendment to its Amended and Restated Certificate of Incorporation to change its corporate
name to DataMeds AI, Inc., effective July 22, 2026. See Note 15 &#x2014; Subsequent Events for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as a holding company with Wood Sage LLC (&#x201c;Wood Sage&#x201d;) as a directly held intermediate holding company subsidiary,
Wellgistics Tech &amp;amp; Hub, LLC and Wellgistics Pharmacy, LLC as indirect operating subsidiaries, and Wellgistics, LLC as a direct operating
subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2024, the Company closed on the acquisition of Wood Sage (the &#x201c;Wood Sage Acquisition&#x201d;), acquiring two operating subsidiaries:
Wellgistics Tech &amp;amp; Hub, LLC (f/k/a Alliance Pharma Solutions LLC d/b/a DelivMeds), a pharmaceutical technology hub, and Wellgistics
Pharmacy, LLC (f/k/a Community Specialty Pharmacy, LLC), a retail community specialty pharmacy. On August 30, 2024, the Company closed
on the acquisition of Wellgistics, LLC (the &#x201c;Wellgistics Acquisition&#x201d;), a wholesale pharmaceutical distributor serving a
network of independent pharmacies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;b&gt;Healthstar Technologies, LLC&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;On April 13, 2026, the Company entered into a Collaboration
Agreement with Kare Rx Hub, LLC (&#x201c;Kare Hub&#x201d;) and Kare Pharmtech, LLC (&#x201c;Kare Pharmtech&#x201d;), providing for the formation
of Healthstar Technologies, LLC (&#x201c;Healthstar&#x201d;), a limited liability company in which the Company holds a 51% membership interest
and Kare Hub holds a 49% membership interest. Healthstar was formed under the laws of the State of Florida on June 18, 2026, with the
Company&#x2019;s President serving as its sole authorized manager.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company evaluated its interest in Healthstar under
ASC 810, &lt;i&gt;Consolidation&lt;/i&gt;, and concluded that the Company holds a controlling financial interest in Healthstar through its 51% membership
interest and sole management authority. Accordingly, Healthstar is consolidated in the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;As of June 30, 2026, Healthstar had not
commenced operations, and Kare Hub had not transferred any assets to Healthstar pursuant to the Collaboration Agreement. Accordingly,
Healthstar had no assets, liabilities, revenues, or expenses as of and for the three and six months ended June 30, 2026, and its formation
and consolidation had no material impact on the Company&#x2019;s condensed consolidated financial statements. There were no material transactions
between the Company and Healthstar during the period from Healthstar&#x2019;s formation on June 18, 2026 through June 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
description of the Company&#x2019;s significant accounting policies and other financial information is included in the Company&#x2019;s
audited consolidated financial statements filed on March 20, 2026, with the SEC in the Company&#x2019;s Annual Report on Form 10-K for
the year ended December 31, 2025 (the &#x201c;&lt;i&gt;Form 10-K&lt;/i&gt;&#x201d;). These policies have been applied consistently in these unaudited
condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unaudited
Interim Financial Information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form
10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for
complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring
items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of
June 30, 2026 and for the three and six months then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited interim financial statements should be read in conjunction with the Company&#x2019;s audited financial statements
and the notes thereto for the year ended December 31, 2025 included in the Form 10-K filed with the SEC on March 20, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zCXb0w5t3Ihg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zJrs1paMOihb"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s fiscal year ends on December 31.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S.GAAP&#x201d;) in all material respects and have been consistently applied in preparing
the accompanying unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements include the consolidated financial statements of Wood Sage since the acquisition on June
16, 2024 and financial statements of Wellgistics, LLC since the acquisition on August 30, 2024. All inter-company balances and transactions
are eliminated on consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zh75SBvVd3V1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zB4y3AzFc6Il"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Descriptions of significant
accounting policies are included in the notes to the consolidated financial statements in our Annual Report on Form 10-K for the year
ended December 31, 2025. Management evaluates these estimates and assumptions on an ongoing basis using historical experience and other
factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. Actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zzJF4X4cc2K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zGihBpr2w25c"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other
than those with stockholders. For the three and six months ended June 30, 2026 and 2025, there was no difference between net loss and
comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z3yhdACkcA5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zlbe8gU0bxg"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, Segment Reporting (&#x201c;ASC 280&#x201d;), we identify our
operating segments according to how our business activities are managed and evaluated. ASC 280 establishes standards for companies to
report financial statement information about operating segments, products, services, geographic areas, and major customers. Operating
segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated
by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), or group, in deciding how to allocate resources and assess
performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CODM has been identified as the Chief Executive Officer, who reviews the operating results for the Company as a whole to make decisions
about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_z4kDudXu6ane" title="Number of operating segment"&gt;one&lt;/span&gt;
operating and reportable segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key measures of segment profit or loss reviewed
by our CODM are consolidated gross margin, operating income, and net income. These metrics are reviewed and monitored by the CODM to manage
and forecast cash. The CODM also reviews operating costs monitor compliance with the Company&#x2019;s contractual obligations and budgeted spending.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 13 for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zq14yMwuvHBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zte4aUBXYx02"&gt;Concentration
of Credit Risks, Major Customers and Vendors&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and six months ended June 30, 2026, no single customer accounted for more than &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260401__20260630__srt--MajorCustomersAxis__custom--NoSingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zU9Je7QIRxT2" title="Concentration risk, percentage"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260630__srt--MajorCustomersAxis__custom--NoSingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxHDKDx6y0Ab" title="Concentration risk, percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% of the Company&#x2019;s total revenues. For
the six months ended June 30, 2025, one customer accounted for approximately &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250630__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOCx9kHXSb87" title="Concentration risk, percentage"&gt;15&lt;/span&gt;% of total revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, two customers accounted for approximately &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260630__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7OhGrRUrfb3" title="Concentration risk, percentage"&gt;22.37&lt;/span&gt;% and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260630__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zN9uIa78o0gc" title="Concentration risk, percentage"&gt;11.26&lt;/span&gt;%, respectively, of gross accounts receivable. As of June
30, 2025, one customers accounted for approximately &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250630__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlKIXvlHwRQb" title="Concentration risk, percentage"&gt;23.68&lt;/span&gt;%, of gross accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s revenues and accounts receivable are subject to concentration risk due to its reliance on a limited number of significant
customers. The loss of any one of these customers, or a material reduction in their purchase volumes, could have a material adverse effect
on the Company&#x2019;s business, financial condition, and results of operations. Management continues to actively pursue opportunities
to broaden and diversify the Company&#x2019;s customer base in order to reduce its exposure to this concentration risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z2Xy5ndlMeJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z7YRFvUo1lMg"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash, accounts receivable, deposits, accounts payable, accrued liabilities, notes payable and short-term debt approximate
their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates fair value
because the debt is based on current rates at which the Company could borrow funds with similar maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_ziXA8aLrEVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z6RkXMF3dxwc"&gt;Accounts
Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are recorded at the net invoiced amount, net of allowance for credit losses, and do not bear interest. Expected credit losses
include losses expected based on known credit issues with specific customers as well as a general expected credit loss allowance based
on relevant information, including historical loss rates, current conditions, and reasonable economic forecasts that affect collectability.
The Company reserves for any accounts receivable balances that are determined to be uncollectible in the allowance for credit losses.
Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be
recovered. Actual write-offs may be in excess of the Company&#x2019;s estimated allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a loss rate method to estimate its allowance for credit losses. The determination of the current expected credit loss rate
begins with our review of historical loss experience as a percentage of accounts receivable. To determine the current allowance for credit
losses, we combine the historical and expected credit loss rates and apply them to our period end accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides for a &lt;span id="xdx_901_eus-gaap--FinancingReceivablePercentPastDue1_iI_pid_dp_uPure_c20260630__srt--RangeAxis__srt--MinimumMember_zVUuilF28Kbf" title="Percentage of accounts receivable due"&gt;95&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--FinancingReceivablePercentPastDue1_iI_pid_dp_uPure_c20260630__srt--RangeAxis__srt--MaximumMember_zSXiOOMUiJA7" title="Percentage of accounts receivable due"&gt;100&lt;/span&gt;% loss rate of the accounts receivable which are due over the period of 90 days. For the three
months ended June 30, 2026 and 2025, the Company recognized a provision for credit losses of $&lt;span id="xdx_90F_eus-gaap--ProvisionForOtherCreditLosses_c20260401__20260630_zDSI79ABrpya" title="Provision for credit losses"&gt;120,080&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ProvisionForOtherCreditLosses_c20250401__20250630_zKEtz2vYhYZ6" title="Provision for credit losses"&gt;124,300&lt;/span&gt;, respectively.
For the six months ended June 30, 2026 and 2025, the Company recognized a provision for credit losses of $&lt;span id="xdx_90F_eus-gaap--ProvisionForOtherCreditLosses_c20260101__20260630_z7svru28U9Uk" title="Provision for credit losses"&gt;213,787&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ProvisionForOtherCreditLosses_c20250101__20250630_zA7RQENDwSSa" title="Provision for credit losses"&gt;200,454&lt;/span&gt;,
respectively, within general and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_z6kBZL3fkUec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zu79dcqzlGWi"&gt;Inventories,
Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost and net realizable value. Cost is determined on a first in first out (&#x201c;FIFO&#x201d;) basis. Cost
of inventory is determined as the sum of the applicable expenditures and charges directly or indirectly incurred in bringing an article
to its existing condition and location. On a quarterly basis, we evaluate inventory for net realizable value using estimates based on
historical experience, current or projected pricing trends, specific categories of inventory, age and expiration dates of on-hand inventory
and manufacturer return policies. If actual conditions are less favorable than our assumptions, additional inventory write-downs may
be required, and no reserve is maintained as obsolete or expired inventories are written off and are presented in cost of net revenues
in the accompanying consolidated statements of operations and comprehensive loss. We believe that the inventory valuation provides a
reasonable approximation of the current value of inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--CapitalizedSoftwareDevelopmentPolicyTextBlock_zVCkTt5dGTki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zZWV40vAu9el"&gt;Capitalized
Software&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the guidance of ASC 350-40, &#x201c;&lt;i&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal Use Software&lt;/i&gt;&#x201d;,
in accounting for our internally developed system projects that it utilizes to provide our services to customers. These system projects
generally relate to software of the Company that is not intended for sale or otherwise marketed. Internal and external costs incurred
during the preliminary project stage are expensed as they are incurred. Once a project has reached the development stage, the Company
capitalizes direct internal and external costs until the software is substantially complete and ready for our intended use. Costs for
upgrades and enhancements are capitalized, whereas costs incurred for maintenance are expensed as incurred. These capitalized software
costs are amortized on a project-by-project basis over the expected economic life of the underlying software on a straight-line basis,
which is generally three to five years. Amortization commences when the software is available for our intended use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026 and December 31, 2025, the Company capitalized $&lt;span id="xdx_900_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260630_z7MBVALWo6wk" title="Intangible assets under development"&gt;2,946,773&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251231_zjxcQgJpd777" title="Intangible assets under development"&gt;2,499,553&lt;/span&gt;, respectively, in software development pertaining
to the Delivmeds platform via its DelivMeds subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
platform has not yet been placed in service and accordingly, amortization has not commenced.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zczB5u2eGup3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zpBNSwFA8iw4"&gt;Property,
Plant and Equipment, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment, net (&#x201c;PP&amp;amp;E&#x201d;) is stated at cost less accumulated depreciation and amortization and any accumulated
impairment losses. Depreciation and amortization are computed using the straight-line method over the assets&#x2019; estimated useful
lives. The estimated useful lives of PP&amp;amp;E are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment
&#x2013; &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zpEfWzGW23tg" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zLZnlku7YOhb" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
and Fixtures &#x2013; &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXJnQEgRDem2" title="Property plant and equipment useful life"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software
&#x2013; &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember__srt--RangeAxis__srt--MinimumMember_zqiONxwaoTBd" title="Property plant and equipment useful life"&gt;3&lt;/span&gt; &#x2013; &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember__srt--RangeAxis__srt--MaximumMember_zxTuDQcg0FSc" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements &#x2013; &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4dXtnbUqnc1" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;Shorter of the estimate useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Major
renewals and improvements are capitalized. Replacements, maintenance, and repairs, which do not significantly improve or extend the useful
life of the assets, are expensed when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the sale or retirement of assets, costs and the related accumulated depreciation and amortization are removed from the accounts and any
gain or loss is included in the results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its long-lived assets or asset groups for indicators of possible impairment by determining whether there were any triggering
events that could impact the Company&#x2019;s assets. If events or changes in circumstances indicate the carrying amount of an asset or
asset group may not be recoverable the Company performs a comparison of the carrying amount to future net undiscounted cash flows expected
to be generated by such asset or asset group. Should an impairment exist, the impairment loss is measured based on the excess carrying
value of the asset over the asset&#x2019;s fair value generally determined by estimates of future discounted cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has &lt;span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20260101__20260630_z5EbayFRinEl" title="Impairment loss on property plant and equipment net"&gt;&lt;span id="xdx_908_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20250101__20250630_zqr0tfk6E7I4" title="Impairment loss on property plant and equipment net"&gt;no&lt;/span&gt;&lt;/span&gt;t identified any such impairment losses for the three and six months ended June 30, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zWYBsQRZQuf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zPfFYNdyLHej"&gt;Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Goodwill represents the excess of the cost over
the fair market value of net assets acquired in business combinations. In accordance with Intangibles &#x2013; Goodwill and Other (Topic
350), goodwill is not amortized but is tested for impairment at least annually, or more frequently if indicators of potential impairment
exist. Goodwill is tested for impairment at the reporting unit level. As the Company operates as a single operating and reportable segment,
as described in Note 13, and no components below the segment level are separately reviewed by segment management, the Company has determined
that it has a single reporting unit, coextensive with the Company as a whole, and all goodwill is tested for impairment on a consolidated
basis.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying value. Qualitative factors assessed for each of the applicable reporting units include, but are not limited
to, changes in macroeconomic conditions, industry and market considerations, cost factors, discount rates, competitive environments,
and financial performance of the reporting units. If the qualitative assessment indicates that it is more likely than not that the carrying
value of a reporting unit exceeds its estimated fair value, a quantitative test is required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Alternatively,
the Company may proceed directly to the quantitative test. Under the quantitative test, the estimated fair value of each reporting unit
is compared to its carrying value, including goodwill. If the carrying value of the reporting unit, including goodwill, exceeds its fair
value, an impairment charge equal to the excess is recognized, up to the maximum amount of goodwill allocated to that reporting unit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--GoodwillImpairmentLoss_do_c20260101__20260630_zCe5DQ89Uev4" title="Goodwill impairment loss"&gt;&lt;span id="xdx_90A_eus-gaap--GoodwillImpairmentLoss_do_c20250101__20250630_z38rxm6atjYk" title="Goodwill impairment loss"&gt;No&lt;/span&gt;&lt;/span&gt;
goodwill impairment was identified during the three and six months ended June 30, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z7Z4dNKkMNSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_za3n5uUVEb29"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be
recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by
determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total
of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess
of the carrying amount over the fair value of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the
carrying value of the asset may not be recoverable. In accordance with ASC 350, &#x201c;Intangibles&#x2014;Goodwill and Other,&#x201d; intangible
assets with finite lives, such as trademarks and customer relationships, are amortized over their estimated useful lives. The Company
compares the carrying value of the intangible asset to its fair value, which is determined based on projected future cash flows. If the
carrying value of the asset exceeds its fair value, an impairment loss is recognized, and the asset is written down to its fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;As described in Note 6, the Company&#x2019;s distribution business experienced a significant decline in revenue during the
six months ended June 30, 2026. Management evaluated this decline and believes the Company has sufficient plans in place, including the
financing transactions and strategic initiatives described in Note 2, to address its underlying causes. Based on this evaluation, no impairment
of long-lived assets was identified during the three and six months ended June 30, 2026 or 2025.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_z62Wr4CYg7K5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zLJ0fjuoHy87"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases under ASC 842, &lt;i&gt;Leases&lt;/i&gt;. Under this guidance, arrangements meeting the definition of a lease are
classified as operating or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and lease
liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s
incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset
is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset
result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of
the right of use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the right of use asset and lease liability, the Company has elected not to combine lease and non-lease components. The non-lease
components are accounted for separately and recognized as expenses when incurred. The Company excludes short-term leases having initial
terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis
over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_z463AYtPvAy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zepCYxxw8pW5"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue from contracts with customers under ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale. The majority of orders are placed via the Company&#x2019;s website. Customers
generally pay by credit card at the time they place their order. The Company does have larger customers to whom they have extended terms
for payment. Generally, payments from these customers are due within 30 days of their order being shipped. However, a few customers have
been given terms extending out to 45 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Distribution&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wellgistics,
LLC provides distribution and third party logistics services to both pharmaceutical manufacturers and independent retail pharmacies.
The Company recognizes revenue when goods are delivered to the customer. The gross product revenues are subject to a variety of deductions,
which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents
chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such,
knowledge and judgment are considered when estimating the impact of these revenue deductions on gross sales for a reporting period. All
revenue for the Company is recognized at the point-in-time when delivered to customer based on contractual obligations. Any amount collected
from customers for goods not yet delivered is recorded as a contract liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Pharmacy&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is in the retail pharmacy business. and fills prescriptions for drugs written by a doctor and recognizes revenue at the time
the patient confirms delivery of the prescription. Customer returns are not material. The following are the steps taken to recognize
revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
One: Identify the contract with the customer &#x2014; The prescription is written by a doctor for a customer and delivered to the Company.
The prescription identifies the performance obligations in the contract. The Company fills the prescription and delivers to the Customer
the prescription, fulfilling the contract. The collection is probable because there is confirmation that the customer has insurance for
the reimbursement to the Company prior to filling of the prescription.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
Two: Identify the performance obligations in the contract &#x2014; Each prescription is distinct to the Customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
Three: Determine the transaction price &#x2014; The consideration is not variable. The transaction price is determined to be the price
of the prescription at the time of delivery which considers the expected reimbursements from third party payors (e.g., pharmacy benefit
managers, insurance companies and government agencies).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
Four: Allocate the transaction price &#x2014; The price of the prescription invoiced represents the expected amount of reimbursement from
third party payors. There is no difference between contract price and &#x201c;stand-alone selling price&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
Five: Recognize revenue when or as the entity satisfies a performance obligation &#x2014; Revenue is recognized upon the delivery of the
prescription.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zHVX5tX04ssb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the disaggregation of revenue for the three and six months ended June 30, 2026 and 2025:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zzMSycj4YmS8" style="display: none"&gt;SCHEDULE OF DISAGGREGATION OF REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260401__20260630_zOgPzKu4hMUa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250401__20250630_zMrerjNHSuad" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260101__20260630_zZkv3kIKreH1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250630_zAB5QkhKWFal" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zBwszmJHXH1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Product revenue - distribution services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;66,765&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,548,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;292,430&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;18,216,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PharmacyRetailSalesMember_zoQg4vRbmVjb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Pharmacy retail sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,590,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,724,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ThirdPartyLogisticsServicesMember_zk1pDh0dTd8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Third party logistics services&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;122,728&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;164,509&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;322,210&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;244,989&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z20GcAB7kFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Net revenues&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,779,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,790,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,339,423&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,654,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zUeA8JSAB2N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
revenue for the three and six months ended June 30, 2026, and 2025, were within the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Assets and Liabilities &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
assets would include costs and services incurred on contracts with open performance obligations. These amounts would be included in contract
assets on the consolidated balance sheets. Contract liabilities include payment received for incomplete performance obligations and are
included in Unearned revenue on the unaudited condensed consolidated balance sheets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2026, and December 31, 2025, the Company had contract liabilities of $&lt;span id="xdx_904_eus-gaap--ContractWithCustomerLiability_iI_c20260630_zmpNRX7z5al1" title="Contract liabilities"&gt;26,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ContractWithCustomerLiability_iI_c20251231_zfrZOazvfj15" title="Contract liabilities"&gt;488,229&lt;/span&gt;, respectively, included in accrued expenses
and other current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zZj3WWhuabp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zclpJn0NGbE4"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation in accordance with ASC 718, &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company
measures all stock-based awards granted to employees, directors and non-employee consultants based on the fair value on the date of the
grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of
the respective award. For awards with service-based vesting conditions, the Company records the expense for using the straight-line method.
For awards with performance-based vesting conditions, the Company records the expense if and when the Company concludes that it is probable
that the performance condition will be achieved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies stock-based compensation expenses in its statement of operations in the same manner in which the award recipient&#x2019;s
costs are classified. See Note 9 for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zxKiyGWKTwD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zbQLWED0qA15"&gt;Net
Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted
net loss per share reflects the weighted-average number of common shares outstanding adjusted for the effect of potentially dilutive
securities. For periods in which a net loss is reported, all potentially dilutive securities are excluded from the computation of diluted
net loss per share as their inclusion would be anti-dilutive. Accordingly, basic and diluted net loss per share are the same for the
six months ended June 30, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC46GtkhEu54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities were excluded from the computation of diluted net loss per share for the six months ended June
30, 2026 and 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span&gt;&lt;span id="xdx_8BA_zQJQNvtPEBgc" style="display: none"&gt;SCHEDULE OF POTENTIALLY DILUTIVE ITEMS OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260101__20260630_zpsCH7Z3nSSa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250630_zxW24xA5MzN6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG1vbiGIQWM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Unvested restricted common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;201,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnissuedDirecterShareAwardsMember_zvNvR7k2Nzgg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unissued director share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoUqVSBjYdb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,442,355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z3ZBJEui1wy6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,323,732&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zCCcfbemrJz7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive shares&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,786,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;201,401&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zyCe6J92a7da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z3Tt6pdKRQJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z6RcvdBqaLVf"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;, under which deferred tax assets and liabilities are
recognized for the future tax consequences of temporary differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax bases, using enacted tax rates in effect for the year in which the differences are expected
to reverse. A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will
not be realized. As of June 30, 2026, the Company has recorded a full valuation allowance against its net deferred tax assets, as management
has concluded that it is more likely than not that such assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
interim periods, the Company determines its income tax provision by applying an estimated annual effective tax rate to year-to-date pre-tax
income (loss), with the effect of discrete items recognized in the period in which they occur. As a result of the full valuation allowance
recorded against its net deferred tax assets, the Company did not record a provision for income taxes for the three and six months ended
June 30, 2026 and 2025. The Company recognizes the effect of a tax position only if it is more likely than not to be sustained upon examination
by the relevant taxing authority, based on the technical merits of the position, and measures the tax benefit as the largest amount that
is more than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zYDqBrTSCUN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zwPsZusO516d"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ASU
2025-05 &#x2014; Measurement of Credit Losses for Accounts Receivable and Contract Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2025-05,
&lt;i&gt;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&lt;/i&gt;.
The ASU provides a practical expedient permitting entities to assume that conditions at the balance sheet date remain unchanged over
the life of current accounts receivable and current contract assets when estimating expected credit losses. The Company does not expect
ASU 2025-05 to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ASU
2024-03 &#x2014; Disaggregation of Income Statement Expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;. The ASU requires public business entities to disclose,
in the notes to financial statements, specified information about certain costs and expenses included in expense line items presented
on the face of the income statement. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim
periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03
on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ASU
2025-06 &#x2014; Targeted Improvements to the Accounting for Internal-Use Software&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU 2025-06, &lt;i&gt;Intangibles &#x2014; Goodwill and Other &#x2014; Internal-Use Software (Subtopic 350-40):
Targeted Improvements to the Accounting for Internal-Use Software&lt;/i&gt;. The ASU requires entities to begin capitalizing software development
costs when management has authorized and committed to funding the software project and it is probable that the project will be completed
and the software will be used to perform its intended function (the &#x201c;probable-to-complete recognition threshold&#x201d;). The amendments
are effective for annual reporting periods beginning after December 15, 2027, with early adoption permitted. Entities may apply the amendments
using a prospective, modified retrospective, or retrospective transition approach. The Company is currently evaluating the impact of
ASU 2025-06 and will assess the impact upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ASU
2025-11 &#x2014; Interim Reporting: Narrow-Scope Improvements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2025, the FASB issued ASU 2025-11, &lt;i&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/i&gt;. The ASU requires entities
to disclose events occurring since the end of the last annual reporting period that have a material impact on the entity. The guidance
is effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual reporting periods,
with early adoption permitted. The amendments may be applied either prospectively or retrospectively. The Company expects ASU 2025-11
to impact its disclosures only and does not expect it to affect its results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_851_z7AhTs1u28M2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000717">&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zCXb0w5t3Ihg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zJrs1paMOihb"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s fiscal year ends on December 31.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S.GAAP&#x201d;) in all material respects and have been consistently applied in preparing
the accompanying unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements include the consolidated financial statements of Wood Sage since the acquisition on June
16, 2024 and financial statements of Wellgistics, LLC since the acquisition on August 30, 2024. All inter-company balances and transactions
are eliminated on consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2026-01-01to2026-06-30" id="Fact000719">&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zh75SBvVd3V1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zB4y3AzFc6Il"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Descriptions of significant
accounting policies are included in the notes to the consolidated financial statements in our Annual Report on Form 10-K for the year
ended December 31, 2025. Management evaluates these estimates and assumptions on an ongoing basis using historical experience and other
factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. Actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000721">&lt;p id="xdx_849_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zzJF4X4cc2K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zGihBpr2w25c"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other
than those with stockholders. For the three and six months ended June 30, 2026 and 2025, there was no difference between net loss and
comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000723">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z3yhdACkcA5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zlbe8gU0bxg"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, Segment Reporting (&#x201c;ASC 280&#x201d;), we identify our
operating segments according to how our business activities are managed and evaluated. ASC 280 establishes standards for companies to
report financial statement information about operating segments, products, services, geographic areas, and major customers. Operating
segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated
by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), or group, in deciding how to allocate resources and assess
performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CODM has been identified as the Chief Executive Officer, who reviews the operating results for the Company as a whole to make decisions
about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_z4kDudXu6ane" title="Number of operating segment"&gt;one&lt;/span&gt;
operating and reportable segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key measures of segment profit or loss reviewed
by our CODM are consolidated gross margin, operating income, and net income. These metrics are reviewed and monitored by the CODM to manage
and forecast cash. The CODM also reviews operating costs monitor compliance with the Company&#x2019;s contractual obligations and budgeted spending.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 13 for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2026-01-012026-06-30_custom_SingleReportableSegmentMember"
      decimals="INF"
      id="Fact000725"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2026-01-01to2026-06-30" id="Fact000727">&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zq14yMwuvHBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zte4aUBXYx02"&gt;Concentration
of Credit Risks, Major Customers and Vendors&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and six months ended June 30, 2026, no single customer accounted for more than &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260401__20260630__srt--MajorCustomersAxis__custom--NoSingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zU9Je7QIRxT2" title="Concentration risk, percentage"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260630__srt--MajorCustomersAxis__custom--NoSingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxHDKDx6y0Ab" title="Concentration risk, percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% of the Company&#x2019;s total revenues. For
the six months ended June 30, 2025, one customer accounted for approximately &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250630__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOCx9kHXSb87" title="Concentration risk, percentage"&gt;15&lt;/span&gt;% of total revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, two customers accounted for approximately &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260630__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7OhGrRUrfb3" title="Concentration risk, percentage"&gt;22.37&lt;/span&gt;% and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260630__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zN9uIa78o0gc" title="Concentration risk, percentage"&gt;11.26&lt;/span&gt;%, respectively, of gross accounts receivable. As of June
30, 2025, one customers accounted for approximately &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250630__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlKIXvlHwRQb" title="Concentration risk, percentage"&gt;23.68&lt;/span&gt;%, of gross accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s revenues and accounts receivable are subject to concentration risk due to its reliance on a limited number of significant
customers. The loss of any one of these customers, or a material reduction in their purchase volumes, could have a material adverse effect
on the Company&#x2019;s business, financial condition, and results of operations. Management continues to actively pursue opportunities
to broaden and diversify the Company&#x2019;s customer base in order to reduce its exposure to this concentration risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-04-012026-06-30_custom_NoSingleCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000729"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-06-30_custom_NoSingleCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000731"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-06-30_custom_OneCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000733"
      unitRef="Pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-06-30_custom_OneCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000735"
      unitRef="Pure">0.2237</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-06-30_custom_TwoCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Pure">0.1126</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-06-30_custom_OneCustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000739"
      unitRef="Pure">0.2368</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2026-01-01to2026-06-30" id="Fact000741">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z2Xy5ndlMeJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z7YRFvUo1lMg"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash, accounts receivable, deposits, accounts payable, accrued liabilities, notes payable and short-term debt approximate
their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates fair value
because the debt is based on current rates at which the Company could borrow funds with similar maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2026-01-01to2026-06-30" id="Fact000743">&lt;p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_ziXA8aLrEVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z6RkXMF3dxwc"&gt;Accounts
Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are recorded at the net invoiced amount, net of allowance for credit losses, and do not bear interest. Expected credit losses
include losses expected based on known credit issues with specific customers as well as a general expected credit loss allowance based
on relevant information, including historical loss rates, current conditions, and reasonable economic forecasts that affect collectability.
The Company reserves for any accounts receivable balances that are determined to be uncollectible in the allowance for credit losses.
Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be
recovered. Actual write-offs may be in excess of the Company&#x2019;s estimated allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a loss rate method to estimate its allowance for credit losses. The determination of the current expected credit loss rate
begins with our review of historical loss experience as a percentage of accounts receivable. To determine the current allowance for credit
losses, we combine the historical and expected credit loss rates and apply them to our period end accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides for a &lt;span id="xdx_901_eus-gaap--FinancingReceivablePercentPastDue1_iI_pid_dp_uPure_c20260630__srt--RangeAxis__srt--MinimumMember_zVUuilF28Kbf" title="Percentage of accounts receivable due"&gt;95&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--FinancingReceivablePercentPastDue1_iI_pid_dp_uPure_c20260630__srt--RangeAxis__srt--MaximumMember_zSXiOOMUiJA7" title="Percentage of accounts receivable due"&gt;100&lt;/span&gt;% loss rate of the accounts receivable which are due over the period of 90 days. For the three
months ended June 30, 2026 and 2025, the Company recognized a provision for credit losses of $&lt;span id="xdx_90F_eus-gaap--ProvisionForOtherCreditLosses_c20260401__20260630_zDSI79ABrpya" title="Provision for credit losses"&gt;120,080&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ProvisionForOtherCreditLosses_c20250401__20250630_zKEtz2vYhYZ6" title="Provision for credit losses"&gt;124,300&lt;/span&gt;, respectively.
For the six months ended June 30, 2026 and 2025, the Company recognized a provision for credit losses of $&lt;span id="xdx_90F_eus-gaap--ProvisionForOtherCreditLosses_c20260101__20260630_z7svru28U9Uk" title="Provision for credit losses"&gt;213,787&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ProvisionForOtherCreditLosses_c20250101__20250630_zA7RQENDwSSa" title="Provision for credit losses"&gt;200,454&lt;/span&gt;,
respectively, within general and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="AsOf2026-06-30_srt_MinimumMember"
      decimals="INF"
      id="Fact000745"
      unitRef="Pure">0.95</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="AsOf2026-06-30_srt_MaximumMember"
      decimals="INF"
      id="Fact000747"
      unitRef="Pure">1</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000749"
      unitRef="USD">120080</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000751"
      unitRef="USD">124300</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000753"
      unitRef="USD">213787</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000755"
      unitRef="USD">200454</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000757">&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_z6kBZL3fkUec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zu79dcqzlGWi"&gt;Inventories,
Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost and net realizable value. Cost is determined on a first in first out (&#x201c;FIFO&#x201d;) basis. Cost
of inventory is determined as the sum of the applicable expenditures and charges directly or indirectly incurred in bringing an article
to its existing condition and location. On a quarterly basis, we evaluate inventory for net realizable value using estimates based on
historical experience, current or projected pricing trends, specific categories of inventory, age and expiration dates of on-hand inventory
and manufacturer return policies. If actual conditions are less favorable than our assumptions, additional inventory write-downs may
be required, and no reserve is maintained as obsolete or expired inventories are written off and are presented in cost of net revenues
in the accompanying consolidated statements of operations and comprehensive loss. We believe that the inventory valuation provides a
reasonable approximation of the current value of inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <MEDS:CapitalizedSoftwareDevelopmentPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000759">&lt;p id="xdx_844_ecustom--CapitalizedSoftwareDevelopmentPolicyTextBlock_zVCkTt5dGTki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zZWV40vAu9el"&gt;Capitalized
Software&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the guidance of ASC 350-40, &#x201c;&lt;i&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal Use Software&lt;/i&gt;&#x201d;,
in accounting for our internally developed system projects that it utilizes to provide our services to customers. These system projects
generally relate to software of the Company that is not intended for sale or otherwise marketed. Internal and external costs incurred
during the preliminary project stage are expensed as they are incurred. Once a project has reached the development stage, the Company
capitalizes direct internal and external costs until the software is substantially complete and ready for our intended use. Costs for
upgrades and enhancements are capitalized, whereas costs incurred for maintenance are expensed as incurred. These capitalized software
costs are amortized on a project-by-project basis over the expected economic life of the underlying software on a straight-line basis,
which is generally three to five years. Amortization commences when the software is available for our intended use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026 and December 31, 2025, the Company capitalized $&lt;span id="xdx_900_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260630_z7MBVALWo6wk" title="Intangible assets under development"&gt;2,946,773&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251231_zjxcQgJpd777" title="Intangible assets under development"&gt;2,499,553&lt;/span&gt;, respectively, in software development pertaining
to the Delivmeds platform via its DelivMeds subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
platform has not yet been placed in service and accordingly, amortization has not commenced.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</MEDS:CapitalizedSoftwareDevelopmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000761"
      unitRef="USD">2946773</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000763"
      unitRef="USD">2499553</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000765">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zczB5u2eGup3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zpBNSwFA8iw4"&gt;Property,
Plant and Equipment, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment, net (&#x201c;PP&amp;amp;E&#x201d;) is stated at cost less accumulated depreciation and amortization and any accumulated
impairment losses. Depreciation and amortization are computed using the straight-line method over the assets&#x2019; estimated useful
lives. The estimated useful lives of PP&amp;amp;E are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment
&#x2013; &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zpEfWzGW23tg" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zLZnlku7YOhb" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
and Fixtures &#x2013; &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXJnQEgRDem2" title="Property plant and equipment useful life"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software
&#x2013; &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember__srt--RangeAxis__srt--MinimumMember_zqiONxwaoTBd" title="Property plant and equipment useful life"&gt;3&lt;/span&gt; &#x2013; &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember__srt--RangeAxis__srt--MaximumMember_zxTuDQcg0FSc" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements &#x2013; &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4dXtnbUqnc1" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;Shorter of the estimate useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Major
renewals and improvements are capitalized. Replacements, maintenance, and repairs, which do not significantly improve or extend the useful
life of the assets, are expensed when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the sale or retirement of assets, costs and the related accumulated depreciation and amortization are removed from the accounts and any
gain or loss is included in the results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its long-lived assets or asset groups for indicators of possible impairment by determining whether there were any triggering
events that could impact the Company&#x2019;s assets. If events or changes in circumstances indicate the carrying amount of an asset or
asset group may not be recoverable the Company performs a comparison of the carrying amount to future net undiscounted cash flows expected
to be generated by such asset or asset group. Should an impairment exist, the impairment loss is measured based on the excess carrying
value of the asset over the asset&#x2019;s fair value generally determined by estimates of future discounted cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has &lt;span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20260101__20260630_z5EbayFRinEl" title="Impairment loss on property plant and equipment net"&gt;&lt;span id="xdx_908_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20250101__20250630_zqr0tfk6E7I4" title="Impairment loss on property plant and equipment net"&gt;no&lt;/span&gt;&lt;/span&gt;t identified any such impairment losses for the three and six months ended June 30, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-06-30_us-gaap_EquipmentMember_srt_MinimumMember"
      id="Fact000767">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-06-30_us-gaap_EquipmentMember_srt_MaximumMember"
      id="Fact000769">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-06-30_us-gaap_FurnitureAndFixturesMember"
      id="Fact000771">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-06-30_us-gaap_SoftwareDevelopmentMember_srt_MinimumMember"
      id="Fact000773">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-06-30_us-gaap_SoftwareDevelopmentMember_srt_MaximumMember"
      id="Fact000775">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000778"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000780"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2026-01-01to2026-06-30" id="Fact000782">&lt;p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zWYBsQRZQuf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zPfFYNdyLHej"&gt;Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Goodwill represents the excess of the cost over
the fair market value of net assets acquired in business combinations. In accordance with Intangibles &#x2013; Goodwill and Other (Topic
350), goodwill is not amortized but is tested for impairment at least annually, or more frequently if indicators of potential impairment
exist. Goodwill is tested for impairment at the reporting unit level. As the Company operates as a single operating and reportable segment,
as described in Note 13, and no components below the segment level are separately reviewed by segment management, the Company has determined
that it has a single reporting unit, coextensive with the Company as a whole, and all goodwill is tested for impairment on a consolidated
basis.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying value. Qualitative factors assessed for each of the applicable reporting units include, but are not limited
to, changes in macroeconomic conditions, industry and market considerations, cost factors, discount rates, competitive environments,
and financial performance of the reporting units. If the qualitative assessment indicates that it is more likely than not that the carrying
value of a reporting unit exceeds its estimated fair value, a quantitative test is required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Alternatively,
the Company may proceed directly to the quantitative test. Under the quantitative test, the estimated fair value of each reporting unit
is compared to its carrying value, including goodwill. If the carrying value of the reporting unit, including goodwill, exceeds its fair
value, an impairment charge equal to the excess is recognized, up to the maximum amount of goodwill allocated to that reporting unit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--GoodwillImpairmentLoss_do_c20260101__20260630_zCe5DQ89Uev4" title="Goodwill impairment loss"&gt;&lt;span id="xdx_90A_eus-gaap--GoodwillImpairmentLoss_do_c20250101__20250630_z38rxm6atjYk" title="Goodwill impairment loss"&gt;No&lt;/span&gt;&lt;/span&gt;
goodwill impairment was identified during the three and six months ended June 30, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000784"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000786"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000788">&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z7Z4dNKkMNSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_za3n5uUVEb29"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be
recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by
determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total
of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess
of the carrying amount over the fair value of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the
carrying value of the asset may not be recoverable. In accordance with ASC 350, &#x201c;Intangibles&#x2014;Goodwill and Other,&#x201d; intangible
assets with finite lives, such as trademarks and customer relationships, are amortized over their estimated useful lives. The Company
compares the carrying value of the intangible asset to its fair value, which is determined based on projected future cash flows. If the
carrying value of the asset exceeds its fair value, an impairment loss is recognized, and the asset is written down to its fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;As described in Note 6, the Company&#x2019;s distribution business experienced a significant decline in revenue during the
six months ended June 30, 2026. Management evaluated this decline and believes the Company has sufficient plans in place, including the
financing transactions and strategic initiatives described in Note 2, to address its underlying causes. Based on this evaluation, no impairment
of long-lived assets was identified during the three and six months ended June 30, 2026 or 2025.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000790">&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_z62Wr4CYg7K5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zLJ0fjuoHy87"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases under ASC 842, &lt;i&gt;Leases&lt;/i&gt;. Under this guidance, arrangements meeting the definition of a lease are
classified as operating or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and lease
liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s
incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset
is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset
result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of
the right of use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the right of use asset and lease liability, the Company has elected not to combine lease and non-lease components. The non-lease
components are accounted for separately and recognized as expenses when incurred. The Company excludes short-term leases having initial
terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis
over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000792">&lt;p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_z463AYtPvAy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zepCYxxw8pW5"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue from contracts with customers under ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale. The majority of orders are placed via the Company&#x2019;s website. Customers
generally pay by credit card at the time they place their order. The Company does have larger customers to whom they have extended terms
for payment. Generally, payments from these customers are due within 30 days of their order being shipped. However, a few customers have
been given terms extending out to 45 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Distribution&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wellgistics,
LLC provides distribution and third party logistics services to both pharmaceutical manufacturers and independent retail pharmacies.
The Company recognizes revenue when goods are delivered to the customer. The gross product revenues are subject to a variety of deductions,
which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents
chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such,
knowledge and judgment are considered when estimating the impact of these revenue deductions on gross sales for a reporting period. All
revenue for the Company is recognized at the point-in-time when delivered to customer based on contractual obligations. Any amount collected
from customers for goods not yet delivered is recorded as a contract liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Pharmacy&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is in the retail pharmacy business. and fills prescriptions for drugs written by a doctor and recognizes revenue at the time
the patient confirms delivery of the prescription. Customer returns are not material. The following are the steps taken to recognize
revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
One: Identify the contract with the customer &#x2014; The prescription is written by a doctor for a customer and delivered to the Company.
The prescription identifies the performance obligations in the contract. The Company fills the prescription and delivers to the Customer
the prescription, fulfilling the contract. The collection is probable because there is confirmation that the customer has insurance for
the reimbursement to the Company prior to filling of the prescription.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
Two: Identify the performance obligations in the contract &#x2014; Each prescription is distinct to the Customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
Three: Determine the transaction price &#x2014; The consideration is not variable. The transaction price is determined to be the price
of the prescription at the time of delivery which considers the expected reimbursements from third party payors (e.g., pharmacy benefit
managers, insurance companies and government agencies).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
Four: Allocate the transaction price &#x2014; The price of the prescription invoiced represents the expected amount of reimbursement from
third party payors. There is no difference between contract price and &#x201c;stand-alone selling price&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
Five: Recognize revenue when or as the entity satisfies a performance obligation &#x2014; Revenue is recognized upon the delivery of the
prescription.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zHVX5tX04ssb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the disaggregation of revenue for the three and six months ended June 30, 2026 and 2025:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zzMSycj4YmS8" style="display: none"&gt;SCHEDULE OF DISAGGREGATION OF REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260401__20260630_zOgPzKu4hMUa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250401__20250630_zMrerjNHSuad" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260101__20260630_zZkv3kIKreH1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250630_zAB5QkhKWFal" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zBwszmJHXH1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Product revenue - distribution services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;66,765&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,548,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;292,430&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;18,216,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PharmacyRetailSalesMember_zoQg4vRbmVjb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Pharmacy retail sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,590,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,724,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ThirdPartyLogisticsServicesMember_zk1pDh0dTd8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Third party logistics services&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;122,728&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;164,509&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;322,210&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;244,989&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z20GcAB7kFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Net revenues&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,779,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,790,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,339,423&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,654,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zUeA8JSAB2N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
revenue for the three and six months ended June 30, 2026, and 2025, were within the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Assets and Liabilities &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
assets would include costs and services incurred on contracts with open performance obligations. These amounts would be included in contract
assets on the consolidated balance sheets. Contract liabilities include payment received for incomplete performance obligations and are
included in Unearned revenue on the unaudited condensed consolidated balance sheets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2026, and December 31, 2025, the Company had contract liabilities of $&lt;span id="xdx_904_eus-gaap--ContractWithCustomerLiability_iI_c20260630_zmpNRX7z5al1" title="Contract liabilities"&gt;26,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ContractWithCustomerLiability_iI_c20251231_zfrZOazvfj15" title="Contract liabilities"&gt;488,229&lt;/span&gt;, respectively, included in accrued expenses
and other current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000794">&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zHVX5tX04ssb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the disaggregation of revenue for the three and six months ended June 30, 2026 and 2025:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zzMSycj4YmS8" style="display: none"&gt;SCHEDULE OF DISAGGREGATION OF REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260401__20260630_zOgPzKu4hMUa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250401__20250630_zMrerjNHSuad" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260101__20260630_zZkv3kIKreH1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250630_zAB5QkhKWFal" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zBwszmJHXH1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Product revenue - distribution services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;66,765&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,548,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;292,430&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;18,216,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PharmacyRetailSalesMember_zoQg4vRbmVjb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Pharmacy retail sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,590,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,724,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ThirdPartyLogisticsServicesMember_zk1pDh0dTd8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Third party logistics services&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;122,728&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;164,509&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;322,210&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;244,989&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z20GcAB7kFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Net revenues&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,779,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,790,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,339,423&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,654,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2026-04-012026-06-30_us-gaap_ProductMember"
      decimals="0"
      id="Fact000796"
      unitRef="USD">66765</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-04-012025-06-30_us-gaap_ProductMember"
      decimals="0"
      id="Fact000797"
      unitRef="USD">7548600</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-06-30_us-gaap_ProductMember"
      decimals="0"
      id="Fact000798"
      unitRef="USD">292430</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-06-30_us-gaap_ProductMember"
      decimals="0"
      id="Fact000799"
      unitRef="USD">18216887</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-04-012026-06-30_custom_PharmacyRetailSalesMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">1590367</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-04-012025-06-30_custom_PharmacyRetailSalesMember"
      decimals="0"
      id="Fact000802"
      unitRef="USD">77756</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-06-30_custom_PharmacyRetailSalesMember"
      decimals="0"
      id="Fact000803"
      unitRef="USD">2724783</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-06-30_custom_PharmacyRetailSalesMember"
      decimals="0"
      id="Fact000804"
      unitRef="USD">192432</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-04-012026-06-30_custom_ThirdPartyLogisticsServicesMember"
      decimals="0"
      id="Fact000806"
      unitRef="USD">122728</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-04-012025-06-30_custom_ThirdPartyLogisticsServicesMember"
      decimals="0"
      id="Fact000807"
      unitRef="USD">164509</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-06-30_custom_ThirdPartyLogisticsServicesMember"
      decimals="0"
      id="Fact000808"
      unitRef="USD">322210</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-06-30_custom_ThirdPartyLogisticsServicesMember"
      decimals="0"
      id="Fact000809"
      unitRef="USD">244989</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000811"
      unitRef="USD">1779860</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000812"
      unitRef="USD">7790865</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000813"
      unitRef="USD">3339423</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000814"
      unitRef="USD">18654308</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000816"
      unitRef="USD">26000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000818"
      unitRef="USD">488229</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000820">&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zZj3WWhuabp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zclpJn0NGbE4"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation in accordance with ASC 718, &lt;i&gt;Compensation &#x2013; Stock Compensation. &lt;/i&gt;The Company
measures all stock-based awards granted to employees, directors and non-employee consultants based on the fair value on the date of the
grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of
the respective award. For awards with service-based vesting conditions, the Company records the expense for using the straight-line method.
For awards with performance-based vesting conditions, the Company records the expense if and when the Company concludes that it is probable
that the performance condition will be achieved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies stock-based compensation expenses in its statement of operations in the same manner in which the award recipient&#x2019;s
costs are classified. See Note 9 for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000822">&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zxKiyGWKTwD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zbQLWED0qA15"&gt;Net
Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted
net loss per share reflects the weighted-average number of common shares outstanding adjusted for the effect of potentially dilutive
securities. For periods in which a net loss is reported, all potentially dilutive securities are excluded from the computation of diluted
net loss per share as their inclusion would be anti-dilutive. Accordingly, basic and diluted net loss per share are the same for the
six months ended June 30, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC46GtkhEu54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities were excluded from the computation of diluted net loss per share for the six months ended June
30, 2026 and 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span&gt;&lt;span id="xdx_8BA_zQJQNvtPEBgc" style="display: none"&gt;SCHEDULE OF POTENTIALLY DILUTIVE ITEMS OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260101__20260630_zpsCH7Z3nSSa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250630_zxW24xA5MzN6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG1vbiGIQWM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Unvested restricted common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;201,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnissuedDirecterShareAwardsMember_zvNvR7k2Nzgg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unissued director share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoUqVSBjYdb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,442,355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z3ZBJEui1wy6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,323,732&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zCCcfbemrJz7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive shares&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,786,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;201,401&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zyCe6J92a7da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000824">&lt;p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC46GtkhEu54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities were excluded from the computation of diluted net loss per share for the six months ended June
30, 2026 and 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span&gt;&lt;span id="xdx_8BA_zQJQNvtPEBgc" style="display: none"&gt;SCHEDULE OF POTENTIALLY DILUTIVE ITEMS OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260101__20260630_zpsCH7Z3nSSa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250630_zxW24xA5MzN6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG1vbiGIQWM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Unvested restricted common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;201,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnissuedDirecterShareAwardsMember_zvNvR7k2Nzgg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unissued director share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zoUqVSBjYdb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,442,355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z3ZBJEui1wy6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,323,732&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zCCcfbemrJz7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive shares&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,786,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;201,401&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Shares">10714</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Shares">201401</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-06-30_custom_UnissuedDirecterShareAwardsMember"
      decimals="INF"
      id="Fact000829"
      unitRef="Shares">9200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">9442355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-06-30_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Shares">20323732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact000838"
      unitRef="Shares">29786001</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30"
      decimals="INF"
      id="Fact000839"
      unitRef="Shares">201401</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000841">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z3Tt6pdKRQJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z6RcvdBqaLVf"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;, under which deferred tax assets and liabilities are
recognized for the future tax consequences of temporary differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax bases, using enacted tax rates in effect for the year in which the differences are expected
to reverse. A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will
not be realized. As of June 30, 2026, the Company has recorded a full valuation allowance against its net deferred tax assets, as management
has concluded that it is more likely than not that such assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
interim periods, the Company determines its income tax provision by applying an estimated annual effective tax rate to year-to-date pre-tax
income (loss), with the effect of discrete items recognized in the period in which they occur. As a result of the full valuation allowance
recorded against its net deferred tax assets, the Company did not record a provision for income taxes for the three and six months ended
June 30, 2026 and 2025. The Company recognizes the effect of a tax position only if it is more likely than not to be sustained upon examination
by the relevant taxing authority, based on the technical merits of the position, and measures the tax benefit as the largest amount that
is more than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000843">&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zYDqBrTSCUN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zwPsZusO516d"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ASU
2025-05 &#x2014; Measurement of Credit Losses for Accounts Receivable and Contract Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2025-05,
&lt;i&gt;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&lt;/i&gt;.
The ASU provides a practical expedient permitting entities to assume that conditions at the balance sheet date remain unchanged over
the life of current accounts receivable and current contract assets when estimating expected credit losses. The Company does not expect
ASU 2025-05 to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ASU
2024-03 &#x2014; Disaggregation of Income Statement Expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;. The ASU requires public business entities to disclose,
in the notes to financial statements, specified information about certain costs and expenses included in expense line items presented
on the face of the income statement. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim
periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03
on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ASU
2025-06 &#x2014; Targeted Improvements to the Accounting for Internal-Use Software&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU 2025-06, &lt;i&gt;Intangibles &#x2014; Goodwill and Other &#x2014; Internal-Use Software (Subtopic 350-40):
Targeted Improvements to the Accounting for Internal-Use Software&lt;/i&gt;. The ASU requires entities to begin capitalizing software development
costs when management has authorized and committed to funding the software project and it is probable that the project will be completed
and the software will be used to perform its intended function (the &#x201c;probable-to-complete recognition threshold&#x201d;). The amendments
are effective for annual reporting periods beginning after December 15, 2027, with early adoption permitted. Entities may apply the amendments
using a prospective, modified retrospective, or retrospective transition approach. The Company is currently evaluating the impact of
ASU 2025-06 and will assess the impact upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ASU
2025-11 &#x2014; Interim Reporting: Narrow-Scope Improvements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2025, the FASB issued ASU 2025-11, &lt;i&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/i&gt;. The ASU requires entities
to disclose events occurring since the end of the last annual reporting period that have a material impact on the entity. The guidance
is effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual reporting periods,
with early adoption permitted. The amendments may be applied either prospectively or retrospectively. The Company expects ASU 2025-11
to impact its disclosures only and does not expect it to affect its results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000845">&lt;p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zD8YwHhh7sq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2. &lt;span id="xdx_823_zEDsBPkLvwEf"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and six months ended June 30, 2026, the Company had a net loss of $&lt;span id="xdx_904_eus-gaap--NetIncomeLoss_iN_di_c20260401__20260630_zvne54MaSI2" title="Net loss"&gt;18,363,225&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--NetIncomeLoss_iN_di_c20260101__20260630_zcTymFQ7EZfc" title="Net loss"&gt;26,105,822&lt;/span&gt;, respectively, and had an accumulated
deficit of $&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20260630_zEgaNfzEVUxd" title="Accumulated deficit"&gt;137,137,512&lt;/span&gt; as of June 30, 2026. As of June 30, 2026, the Company had cash and cash equivalents of $&lt;span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260630_zFAMkQZuwpUl" title="Cash and cash equivalents"&gt;2,456,373&lt;/span&gt; and net cash
used in operating activities of $&lt;span id="xdx_904_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20260101__20260630_zKtrUzdTueAd" title="Net cash used in operating activities"&gt;6,307,328&lt;/span&gt; for the six months then ended. In addition, the Company had a stockholders&#x2019; deficit
of $&lt;span id="xdx_908_eus-gaap--StockholdersEquity_iNI_di_c20260630_zljdGfy37Sg1" title="Stockholder's Equity (Deficit)"&gt;19,504,231&lt;/span&gt; as of June 30, 2026. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern
within twelve months from the date these unaudited condensed consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2025, the Company received a notice from The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) indicating that the Company
was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20251210_zePIEO7GrJU" title="Minimum bid price, per share"&gt;1.00&lt;/span&gt; per share. On June 9, 2026, Nasdaq notified the Company that it had regained compliance with this requirement following
the reverse stock split described below, and the matter was closed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 13, 2026,
the Company received a further notice from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1),
which requires a minimum stockholders&#x2019; equity of $2.5 million. The Company was afforded 45 calendar days from the date of the notice, or until May 28, 2026, to submit a plan to regain compliance. The Company timely submitted such a plan. On June 9, 2026, Nasdaq granted the Company an extension until October
12, 2026 to evidence compliance with the stockholders&#x2019; equity requirement, either by furnishing a public report following completion of a transaction or event that satisfies the requirement,
or by furnishing a public report including a pro forma balance sheet evidencing compliance. If the Company
does not evidence compliance by the time it files its Annual Report on Form 10-K for the year ending December 31, 2026, the Company&#x2019;s
common stock may be subject to delisting from the Nasdaq Capital Market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Management
Plans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
is actively pursuing multiple initiatives to address the Company&#x2019;s liquidity position and going concern uncertainty:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 20, 2026, the Company issued secured convertible promissory notes to a group of investors in an aggregate principal amount of
$&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20260120__us-gaap--ShortTermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zww0fTwbeIk4" title="Aggregate principal amount"&gt;8,125,000&lt;/span&gt;, reflecting a &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260120__us-gaap--ShortTermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zhRlce2foBmi" title="Debt instrument original issue discount"&gt;20&lt;/span&gt;% original issue discount on net proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromConvertibleDebt_c20260120__20260120__us-gaap--ShortTermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z43wQBT09S5c" title="Net proceeds from convertible debt"&gt;6,500,000&lt;/span&gt;. At closing, $&lt;span id="xdx_901_eus-gaap--RepaymentsOfConvertibleDebt_c20260101__20260630__us-gaap--ShortTermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zGeLorobRfui" title="Converible debt repaid"&gt;2,070,000&lt;/span&gt; of the proceeds was applied
directly to repay in full the Company&#x2019;s outstanding obligations to Agile Capital Funding LLC. As described below, these notes were
subsequently extinguished and replaced in May 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 1, 2026, the Company issued an additional convertible promissory note in the principal amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20260401__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z7JvRj4PsL28" title="Aggregate principal amount"&gt;1,500,000&lt;/span&gt;, reflecting a &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260401__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z11uOoQtpfLk" title="Debt instrument original issue discount"&gt;20&lt;/span&gt;% original
issue discount on net proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_c20260401__20260401__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zWWo3HA35dA8" title="Net proceeds from convertible debt"&gt;1,200,000&lt;/span&gt;. This note was also subsequently extinguished and replaced in May 2026, as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 20, 2026, the Company filed a Certificate of Amendment to effect a &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20260520__20260520_zB5yw0fSP72j" title="Reverse stock split"&gt;reverse stock split
of its common stock at a ratio of 1-for-50&lt;/span&gt;, which had been approved by stockholders on April 2, 2026 at a ratio to be determined by the
Board of Directors within a range of &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20260402__20260402__srt--RangeAxis__srt--MinimumMember_z5NMKxfSZXnf" title="Reverse stock split"&gt;1-for-25&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20260402__20260402__srt--RangeAxis__srt--MaximumMember_zwJWW9fbqtN8" title="Reverse stock split"&gt;1-for-200&lt;/span&gt;. The reverse stock split became effective on May 26, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 20, 2026, the Company entered into a Letter of Intent (the &#x201c;Term Sheet&#x201d;) with EOS Technology Holdings, Inc., Scilex Holding
Company, Datavault AI, Inc., HealthBridge Advisors, LLC, and Fortitude Advisors, LLC with respect to a proposed transaction, as further
described in Note 10. In connection with the proposed transaction, the Term Sheet contemplates a concurrent minimum investment of $&lt;span id="xdx_907_eus-gaap--Investments_iI_c20260520_zHlLn62do8d7" title="Concurrent minimum investment"&gt;2,000,000&lt;/span&gt;
from investors associated with the Company&#x2019;s placement agent, the filing of an at-the-market offering facility, and additional
financing support for the Company. The proposed transaction remains subject to negotiation and execution of definitive agreements, stockholder
and other approvals, and other customary closing conditions, and there can be no assurance that any of the contemplated financing will
be obtained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 27, 2026, the Company entered into a new Note Purchase Agreement with substantially the same group of investors that held the notes
issued in January and April 2026, together with certain additional investors. Pursuant to this agreement, the previously outstanding
notes were extinguished and replaced with new convertible promissory notes in an aggregate principal amount comprised of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--ShortTermDebtTypeAxis__custom--NewConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zCfLc2IJ3iPk"&gt;9,625,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;rolled over from the previously outstanding notes and $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--ShortTermDebtTypeAxis__custom--NewConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zyl7c01Epm5e"&gt;6,500,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of new money from investors, before giving effect to the original
issue discount. Additionally, $&lt;span id="xdx_908_ecustom--PlacementAgentsFeePayable_iI_c20260527__us-gaap--ShortTermDebtTypeAxis__custom--NewConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember__dei--LegalEntityAxis__custom--DawsonJamesSecuritiesIncMember_z3N3tJBFop38"&gt;133,985&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of the placement agent&#x2019;s fee payable to Dawson James
Securities, Inc. in connection with this financing was settled through the issuance of a note in lieu of cash, bringing the aggregate
principal amount of notes issued to $&lt;span id="xdx_90D_eus-gaap--LongTermDebt_iI_c20260527__us-gaap--ShortTermDebtTypeAxis__custom--NewConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember__dei--LegalEntityAxis__custom--DawsonJamesSecuritiesIncMember_zYc7TB6Vju16"&gt;20,323,732&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
In connection with this refinancing, the Company recognized a loss on extinguishment of debt of $&lt;span id="xdx_906_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zKDJC3LtMKs8" title="Loss on extinguishment of debt"&gt;&lt;span id="xdx_90C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zvdKY0od1pmb" title="Loss on extinguishment of debt"&gt;8,378,189&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the three and six months ended June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;i&gt;Wellgistics, LLC Distribution Business&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Product revenue from distribution services declined significantly during the six months ended June 30, 2026 as compared
to the corresponding period in 2025, primarily due to liquidity constraints that limited the Company&#x2019;s ability to procure and fulfill
product orders, as described under &#x201c;Results of Operations&#x201d; in Item 2 of this Quarterly Report. Management has evaluated this
decline and believes the Company has sufficient plans in place, including the financing transactions and strategic initiatives described
above, to address its underlying causes. Based on this evaluation, management concluded that the carrying value of the goodwill and other
intangible assets attributable to the distribution business was not impaired as of June 30, 2026.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and
do not include any adjustments that might result from the outcome of this uncertainty. In accordance with FASB ASU 2014-15, &lt;i&gt;Disclosures
of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;, management has concluded that the conditions described
above raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for the twelve months following the date
these financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000847"
      unitRef="USD">-18363225</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000849"
      unitRef="USD">-26105822</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000851"
      unitRef="USD">-137137512</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000853"
      unitRef="USD">2456373</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000855"
      unitRef="USD">-6307328</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000857"
      unitRef="USD">-19504231</us-gaap:StockholdersEquity>
    <us-gaap:SharePrice
      contextRef="AsOf2025-12-10"
      decimals="INF"
      id="Fact000859"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-01-20_custom_SecuredConvertiblePromissoryNotesMember_custom_InvestorsMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">8125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-01-20_custom_SecuredConvertiblePromissoryNotesMember_custom_InvestorsMember"
      decimals="INF"
      id="Fact000863"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-01-202026-01-20_custom_SecuredConvertiblePromissoryNotesMember_custom_InvestorsMember"
      decimals="0"
      id="Fact000865"
      unitRef="USD">6500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2026-01-012026-06-30_custom_SecuredConvertiblePromissoryNotesMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact000867"
      unitRef="USD">2070000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-04-01_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000869"
      unitRef="USD">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-04-01_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact000871"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-04-012026-04-01_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000873"
      unitRef="USD">1200000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-05-202026-05-20" id="Fact000875">reverse stock split
of its common stock at a ratio of 1-for-50</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2026-04-022026-04-02_srt_MinimumMember"
      id="Fact000877">1-for-25</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2026-04-022026-04-02_srt_MaximumMember"
      id="Fact000879">1-for-200</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:Investments
      contextRef="AsOf2026-05-20"
      decimals="0"
      id="Fact000881"
      unitRef="USD">2000000</us-gaap:Investments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_NewConvertiblePromissoryNotesMember_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact000882"
      unitRef="USD">9625000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_NewConvertiblePromissoryNotesMember_custom_NewNotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="0"
      id="Fact000883"
      unitRef="USD">6500000</us-gaap:DebtInstrumentFaceAmount>
    <MEDS:PlacementAgentsFeePayable
      contextRef="AsOf2026-05-27_custom_NewConvertiblePromissoryNotesMember_custom_NewNotePurchaseAgreementMember_custom_DawsonJamesSecuritiesIncMember"
      decimals="0"
      id="Fact000884"
      unitRef="USD">133985</MEDS:PlacementAgentsFeePayable>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-05-27_custom_NewConvertiblePromissoryNotesMember_custom_NewNotePurchaseAgreementMember_custom_DawsonJamesSecuritiesIncMember"
      decimals="0"
      id="Fact000885"
      unitRef="USD">20323732</us-gaap:LongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-04-012026-06-30_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact000887"
      unitRef="USD">8378189</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-012026-06-30_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact000889"
      unitRef="USD">8378189</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000891">&lt;p id="xdx_803_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zFfo0q2lM5Te" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3. &lt;span id="xdx_827_zrZeb0k040Nk"&gt;ACCOUNTS RECEIVABLE, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zVhTV4MO3qbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zaCaUSEJDVB9" style="display: none"&gt;SCHEDULE OF ACCOUNTS RECEIVABLE, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260630_zJyJRXnyzMF8" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_zn7Zne7STgMc" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsReceivableGross_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_z9sMj4JMGC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; width: 60%; text-align: left"&gt;Billed &#x2013; Third party&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;2,218,473&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;1,984,424&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsReceivableGross_iI_maARNCzgb5_zgXiMxSOETm3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total Accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,218,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,984,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_di_msARNCzgb5_zjAsPnwS6Ff6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,044,137&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(847,205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsReceivableNet_iTI_mtARNCzgb5_zN2qUnlubqS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,174,336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,137,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z4Oiz9HqWoyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000893">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zVhTV4MO3qbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zaCaUSEJDVB9" style="display: none"&gt;SCHEDULE OF ACCOUNTS RECEIVABLE, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260630_zJyJRXnyzMF8" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_zn7Zne7STgMc" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsReceivableGross_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_z9sMj4JMGC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; width: 60%; text-align: left"&gt;Billed &#x2013; Third party&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;2,218,473&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;1,984,424&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsReceivableGross_iI_maARNCzgb5_zgXiMxSOETm3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total Accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,218,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,984,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_di_msARNCzgb5_zjAsPnwS6Ff6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,044,137&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(847,205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsReceivableNet_iTI_mtARNCzgb5_zN2qUnlubqS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,174,336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,137,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross
      contextRef="AsOf2026-06-30_custom_ThirdPartyMember"
      decimals="0"
      id="Fact000895"
      unitRef="USD">2218473</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross
      contextRef="AsOf2025-12-31_custom_ThirdPartyMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">1984424</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000898"
      unitRef="USD">2218473</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000899"
      unitRef="USD">1984424</us-gaap:AccountsReceivableGross>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000901"
      unitRef="USD">1044137</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000902"
      unitRef="USD">847205</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000904"
      unitRef="USD">1174336</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000905"
      unitRef="USD">1137219</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000907">&lt;p id="xdx_809_eus-gaap--InventoryDisclosureTextBlock_z1TG4Oeffzt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4. &lt;span id="xdx_821_zlA5OUarDCYj"&gt;INVENTORIES, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLwK9s9QImh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zwpzpfuELG4c" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260630_zLwzIcBLM4mc" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zR2BlMQ5lcbd" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--FirstDefenseNasalScreenCorp_iI_maIGzZGh_zWU7I4xYy4qe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;First Defense Nasal Screen Corp (&#x201c;FDNS&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,988,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,988,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryFinishedGoods_iI_maIGzZGh_zxYzbcf4om6d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,016,649&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,072,985&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryGross_iTI_maINzdSP_mtIGzZGh_z5JVQt4cb8l8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total inventory, at cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,004,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,061,242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryValuationReserves_iNI_di_msINzdSP_zkzURoO48ya" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: reserve for obsolescence&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,494,783&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,421,816&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtINzdSP_zXuRzT3UDGhg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Inventories, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,510,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,639,426&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zlxmVMx9iL88" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FDNS inventory consists of products purchased by Wellgistics, LLC from First Defense Nasal Screen Corp (&#x201c;FDNS&#x201d;). Following
a legal dispute with the supplier, the Company was awarded $&lt;span id="xdx_90D_ecustom--InventoryUponLegalDisputed_iI_pn5n6_c20260630__dei--LegalEntityAxis__custom--FirstDefenseNasalScreenCorpMember_z2YWwLGUyCLj" title="Inventory upon legal disputed"&gt;4.6&lt;/span&gt; million, which has not been recognized due to uncertainty of receipt.
Pursuant to the United States Bankruptcy Court order dated March 15, 2023, the Company was awarded full possession of the FDNS inventory
and receives a monthly plan payment of $&lt;span id="xdx_900_eus-gaap--OtherIncome_c20260101__20260630__dei--LegalEntityAxis__custom--FirstDefenseNasalScreenCorpMember_zi2L5RwQVVZk" title="Other income"&gt;3,014&lt;/span&gt;, which is recognized in other income in the unaudited condensed consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FDNS inventory has experienced minimal sales activity and management has determined there is no active market for the product. Based
on this assessment, the carrying value was deemed not recoverable, and a reserve for obsolescence of $&lt;span title="Write off of inventory"&gt;&lt;span id="xdx_905_eus-gaap--InventoryWriteDown_c20250101__20251231_zOZeG6hUiO88" title="Write off of inventory"&gt;5,988,257&lt;/span&gt;&lt;/span&gt; was fully recorded during
the year ended December 31, 2025 and remained unchanged as of June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and six months ended June 30, 2026, the Company recorded a reserve for obsolescence of $&lt;span id="xdx_90B_eus-gaap--InventoryWriteDown_c20260401__20260630_zM4rwxe2ryca" title="Write off of inventory"&gt;55,000&lt;/span&gt; and $&lt;span title="Inventory finished goods"&gt;&lt;span id="xdx_90B_eus-gaap--InventoryWriteDown_c20260101__20260630_zYik0yZEMXCa" title="Write off of inventory"&gt;72,967&lt;/span&gt;&lt;/span&gt;, respectively related
to finished goods inventory, included in cost of net revenues in the unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000909">&lt;p id="xdx_898_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLwK9s9QImh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zwpzpfuELG4c" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260630_zLwzIcBLM4mc" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zR2BlMQ5lcbd" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--FirstDefenseNasalScreenCorp_iI_maIGzZGh_zWU7I4xYy4qe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;First Defense Nasal Screen Corp (&#x201c;FDNS&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,988,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,988,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryFinishedGoods_iI_maIGzZGh_zxYzbcf4om6d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,016,649&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,072,985&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryGross_iTI_maINzdSP_mtIGzZGh_z5JVQt4cb8l8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total inventory, at cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,004,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,061,242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryValuationReserves_iNI_di_msINzdSP_zkzURoO48ya" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: reserve for obsolescence&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,494,783&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,421,816&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtINzdSP_zXuRzT3UDGhg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Inventories, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,510,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,639,426&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <MEDS:FirstDefenseNasalScreenCorp
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000911"
      unitRef="USD">5988257</MEDS:FirstDefenseNasalScreenCorp>
    <MEDS:FirstDefenseNasalScreenCorp
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000912"
      unitRef="USD">5988257</MEDS:FirstDefenseNasalScreenCorp>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000914"
      unitRef="USD">2016649</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000915"
      unitRef="USD">2072985</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000917"
      unitRef="USD">8004906</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000918"
      unitRef="USD">8061242</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000920"
      unitRef="USD">6494783</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000921"
      unitRef="USD">6421816</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000923"
      unitRef="USD">1510123</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000924"
      unitRef="USD">1639426</us-gaap:InventoryNet>
    <MEDS:InventoryUponLegalDisputed
      contextRef="AsOf2026-06-30_custom_FirstDefenseNasalScreenCorpMember"
      decimals="-5"
      id="Fact000926"
      unitRef="USD">4600000</MEDS:InventoryUponLegalDisputed>
    <us-gaap:OtherIncome
      contextRef="From2026-01-012026-06-30_custom_FirstDefenseNasalScreenCorpMember"
      decimals="0"
      id="Fact000928"
      unitRef="USD">3014</us-gaap:OtherIncome>
    <us-gaap:InventoryWriteDown
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact000930"
      unitRef="USD">5988257</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000932"
      unitRef="USD">55000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000934"
      unitRef="USD">72967</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000936">&lt;p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zD4gfERC8s81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5. &lt;span id="xdx_82B_z2OGeXWkC5h5"&gt;PROPERTY, PLANT AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_z60glc5t3NHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zdGH4KshdLoh" style="display: none"&gt;SCHEDULE
OF PROPERTY, PLANT AND EQUIPMENT, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260630_zdngzAXtgfad" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zd26vFc3h647" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzKMc_zEdtxpSiIqnc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;766,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;766,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzKMc_zVekiV7bN2ab" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;589,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;589,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzKMc_zikhaw2k0Gdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Furniture &amp;amp; Fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;152,161&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;152,161&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzKMc_maPPAENzd6g_zMEKFmkDOcs6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,507,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,507,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzd6g_zentAYJheN0d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,333,957&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,278,460&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzd6g_zvVK4qmkoUR2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;173,879&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;229,376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zimemUO0ubr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_904_eus-gaap--Depreciation_c20260401__20260630_zuwjeGHTEE0f" title="Depreciation expense"&gt;27,635&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--Depreciation_c20250401__20250630_zmTEQHLP62Kl" title="Depreciation expense"&gt;39,731&lt;/span&gt; for the three months ended June 30, 2026 and 2025, respectively, and $&lt;span id="xdx_90C_eus-gaap--Depreciation_c20260101__20260630_zIpT7jKEENZ8" title="Depreciation expense"&gt;55,497&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--Depreciation_c20250101__20250630_z46PFmYPE2O2" title="Depreciation expense"&gt;79,538&lt;/span&gt; for the six
months ended June 30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000938">&lt;p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_z60glc5t3NHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zdGH4KshdLoh" style="display: none"&gt;SCHEDULE
OF PROPERTY, PLANT AND EQUIPMENT, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260630_zdngzAXtgfad" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zd26vFc3h647" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzKMc_zEdtxpSiIqnc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;766,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;766,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzKMc_zVekiV7bN2ab" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;589,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;589,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzKMc_zikhaw2k0Gdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Furniture &amp;amp; Fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;152,161&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;152,161&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzKMc_maPPAENzd6g_zMEKFmkDOcs6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,507,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,507,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzd6g_zentAYJheN0d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,333,957&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,278,460&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzd6g_zvVK4qmkoUR2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;173,879&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;229,376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000940"
      unitRef="USD">766467</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000941"
      unitRef="USD">766467</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000943"
      unitRef="USD">589208</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000944"
      unitRef="USD">589208</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000946"
      unitRef="USD">152161</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000947"
      unitRef="USD">152161</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000949"
      unitRef="USD">1507836</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000950"
      unitRef="USD">1507836</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000952"
      unitRef="USD">1333957</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000953"
      unitRef="USD">1278460</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000955"
      unitRef="USD">173879</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000956"
      unitRef="USD">229376</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000958"
      unitRef="USD">27635</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000960"
      unitRef="USD">39731</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact000962"
      unitRef="USD">55497</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact000964"
      unitRef="USD">79538</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000966">&lt;p id="xdx_809_eus-gaap--IntangibleAssetsDisclosureTextBlock_zMd3XSPWjGXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6. &lt;span id="xdx_82A_zAnAZeORLMnd"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_zbdoc20JSI3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zmDEmrTQrB0l" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260630_zJRpCeGIXYF6" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_z9R5BE6SDJaf" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzYrE_zTH5OtVrd0k8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Software development costs - Delivmeds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,946,773&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,499,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzYrE_zFhkmRD3ndp3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated impairment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(649,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(649,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzYrE_zqHIJaXECfW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Capitalized software&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,297,588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,850,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsWoodsageAcquisitionMember_zLZtbTPTBacb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships - Woodsage acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsWellgisticsAcquisitionMember_zoocHrRxKM6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships - Wellgistics acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,256,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,256,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkWellgisticsAcqusitionMember_zT3gkih3xJv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trademark - Wellgistics acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,143,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,143,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicenseRightsMember_zC9DysZC25ah" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;License rights&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzDEV_zP5C65wTr0Kf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,293,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,293,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzDEV_zLbaMA1oG6T2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accumulated amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,757,231&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,099,307&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FiniteLivedIntangibleAssetsAccumulatedImpairment_iNI_di_msFLIANzDEV_zJKHiRwQXH5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated impairment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,879,075&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,879,075&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzDEV_zyxTPgGp1guh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Other intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,656,751&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,314,675&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zANapHGTFE84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Capitalized
Software&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software
development costs relate to the Wellgistics Tech &amp;amp; Hub, LLC platform. As of June 30, 2026 and December 31, 2025, the Company had
gross capitalized software development costs of $&lt;span id="xdx_903_eus-gaap--CapitalizedComputerSoftwareGross_iI_c20260630_zmrZce2F1v2" title="Capitalized software development costs"&gt;2,946,773&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--CapitalizedComputerSoftwareGross_iI_c20251231_z2Wec4iXZ0lf" title="Capitalized software development costs"&gt;2,499,543&lt;/span&gt;, respectively. Accumulated impairment of $&lt;span id="xdx_908_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iI_c20251231_z4nPQx2wnTB4" title="Accumulated impairment"&gt;649,185&lt;/span&gt;, recorded
during the year ended December 31, 2025, remained unchanged as of June 30, 2026, resulting in a net carrying value of $&lt;span id="xdx_903_eus-gaap--CapitalizedComputerSoftwareNet_iI_c20260630_zpUMu0JeB9Ff" title="Net carrying value"&gt;2,297,588&lt;/span&gt; and
$&lt;span id="xdx_909_eus-gaap--CapitalizedComputerSoftwareNet_iI_c20251231_zSq33KMDmhB6" title="Net carrying value"&gt;1,850,358&lt;/span&gt; as of June 30, 2026 and December 31, 2025, respectively. The platform has not yet been placed in service and accordingly,
amortization has not commenced as of June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Customer
Relationships and Trademark&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets of $&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsWoodsageAcquisitionMember_z4fYfRSuVChg" title="Intangible assets"&gt;393,853&lt;/span&gt; represent customer relationships identified and measured at fair value pursuant to the Wood Sage business combination
completed in June 2024. Amortization expense related to these intangible assets was $&lt;span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20260401__20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WoodSageBusinessCombinationMember_zvAF5OmtjI4f" title="Amortization of intangible assets"&gt;12,308&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20250401__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WoodSageBusinessCombinationMember_z0192U1v1DDl" title="Amortization of intangible assets"&gt;24,616&lt;/span&gt; for the three months ended June
30, 2026, and 2025, respectively, and $&lt;span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WoodSageBusinessCombinationMember_zYG09tcq17Yd" title="Amortization of intangible assets"&gt;12,308&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WoodSageBusinessCombinationMember_zZakmVBslaHh" title="Amortization of intangible assets"&gt;24,616&lt;/span&gt; for the six months ended June 30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets of $&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsWellgisticsAcquisitionMember_ztgWNBebbkg3" title="Intangible assets"&gt;11,256,067&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkWellgisticsAcqusitionMember_zoJd1xIgPcG7" title="Intangible assets"&gt;10,143,137&lt;/span&gt; represent customer relationships and trademarks, respectively, identified and measured at fair
value in connection with the Wellgistics, LLC business combination completed in August 2024, amortized over their estimated useful lives.
During the year ended December 31, 2025, the Company recognized impairment charges of $&lt;span id="xdx_905_ecustom--ImpairmentChargesOfIntangibleAssetsFinitelived_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WellgisticsCustomerRelationshipsMember_zsOTvemg3VLg" title="Impairment charge of intangible assets"&gt;5,314,027&lt;/span&gt; related to Wellgistics customer relationships
and $&lt;span id="xdx_90C_ecustom--ImpairmentChargesOfIntangibleAssetsFinitelived_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WellgisticsTrademarkMember_zR3yJY5AD2O7" title="Impairment charge of intangible assets"&gt;4,565,048&lt;/span&gt; related to the Wellgistics trademark, for a total intangible asset impairment charge of $&lt;span id="xdx_900_ecustom--ImpairmentChargesOfIntangibleAssetsFinitelived_c20250101__20251231_zma0LRLI5iMa" title="Impairment charge of intangible assets"&gt;9,879,075&lt;/span&gt;, recorded within goodwill
and intangible asset impairment in the consolidated statements of operations. &lt;span id="xdx_907_eus-gaap--AssetImpairmentCharges_do_c20260401__20260630_zJkrp2cnJMxa" title="Impairment charges"&gt;&lt;span id="xdx_907_eus-gaap--AssetImpairmentCharges_do_c20260101__20260630_z9BYMpDCbnTh" title="Impairment charges"&gt;No&lt;/span&gt;&lt;/span&gt; impairment charges were recognized during the three
and six months ended June 30, 2026. The Company&#x2019;s distribution business experienced a significant decline in
revenue during the six months ended June 30, 2026, as described in Note 2. Management evaluated this decline and believes the Company
has sufficient plans in place, including the financing transactions and strategic initiatives described in Note 2, to address its underlying
causes. Based on this evaluation, no impairment was identified as of June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense related to Wellgistics customer relationships was $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_c20260401__20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zYbKzYJSTxZh" title="Amortization of intangible assets"&gt;183,932&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_c20250401__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zm2C3MUJ6zXh" title="Amortization of intangible assets"&gt;469,003&lt;/span&gt; for the three months ended June 30, 2026 and 2025, respectively
and $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z3ie67P7jbd3" title="Amortization of intangible assets"&gt;367,865&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zQCADleNE399" title="Amortization of intangible assets"&gt;938,006&lt;/span&gt; for the six months ended June 30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense related to the Wellgistics trademark was $&lt;span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20260401__20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zid9A6EWmDqb" title="Amortization of intangible assets"&gt;132,722&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20250401__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zOMP21a0puPj" title="Amortization of intangible assets"&gt;281,754&lt;/span&gt; for the three months ended June 30, 2026 and 2025, respectively
and $&lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z2mpC78Wzzu" title="Amortization of intangible assets"&gt;265,444&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zGGPTGtm8zW5" title="Amortization of intangible assets"&gt;563,508&lt;/span&gt; for the six months ended June 30, 2026 and 2025 respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
amortization expense related to other intangible assets was $&lt;span id="xdx_90C_eus-gaap--AmortizationOfDeferredCharges_c20260401__20260630_zKrJHqoc2J7j" title="Amortization of intangible assets"&gt;328,962&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AmortizationOfDeferredCharges_c20250401__20250630_zc5k1aJ7fk0k" title="Amortization of intangible assets"&gt;763,064&lt;/span&gt; for the three months ended June 30, 2026 and 2025,
respectively and $&lt;span id="xdx_90F_eus-gaap--AmortizationOfDeferredCharges_c20260101__20260630_zR3PFwIih3L" title="Amortization of intangible assets"&gt;657,924&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AmortizationOfDeferredCharges_c20250101__20250630_zyVZghTzVika" title="Amortization of intangible assets"&gt;1,526,129&lt;/span&gt; for the six months ended June 30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJZJImDnnVrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the future amortization of intangible assets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zavfDrtX0b23" style="display: none"&gt;SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLES ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20260630_zbCvJfWEi6Tf"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzrja_zXnLgxzGy799" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;2026 (remaining 6 months)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;836,495&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzrja_zeK0VHbBNYVb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzrja_zy54ThgSg6bc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzrja_z0KuE7eN6tX7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzrja_zm6t5OZ17LU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,423,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzrja_zkuyKbxkhYw7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,378,238&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzrja_z4p9YbFk1fza" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,656,751&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zWlvfgujMF7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact000968">&lt;p id="xdx_892_eus-gaap--ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_zbdoc20JSI3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zmDEmrTQrB0l" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260630_zJRpCeGIXYF6" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_z9R5BE6SDJaf" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzYrE_zTH5OtVrd0k8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Software development costs - Delivmeds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,946,773&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,499,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzYrE_zFhkmRD3ndp3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated impairment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(649,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(649,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzYrE_zqHIJaXECfW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Capitalized software&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,297,588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,850,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsWoodsageAcquisitionMember_zLZtbTPTBacb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships - Woodsage acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsWellgisticsAcquisitionMember_zoocHrRxKM6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships - Wellgistics acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,256,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,256,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkWellgisticsAcqusitionMember_zT3gkih3xJv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trademark - Wellgistics acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,143,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,143,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicenseRightsMember_zC9DysZC25ah" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;License rights&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzDEV_zP5C65wTr0Kf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,293,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,293,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzDEV_zLbaMA1oG6T2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accumulated amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,757,231&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,099,307&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FiniteLivedIntangibleAssetsAccumulatedImpairment_iNI_di_msFLIANzDEV_zJKHiRwQXH5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated impairment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,879,075&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,879,075&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzDEV_zyxTPgGp1guh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Other intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,656,751&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,314,675&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000970"
      unitRef="USD">2946773</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000971"
      unitRef="USD">2499543</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000973"
      unitRef="USD">649185</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000974"
      unitRef="USD">649185</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000976"
      unitRef="USD">2297588</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000977"
      unitRef="USD">1850358</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-06-30_custom_CustomerRelationshipsWoodsageAcquisitionMember"
      decimals="0"
      id="Fact000979"
      unitRef="USD">393853</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-12-31_custom_CustomerRelationshipsWoodsageAcquisitionMember"
      decimals="0"
      id="Fact000980"
      unitRef="USD">393853</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-06-30_custom_CustomerRelationshipsWellgisticsAcquisitionMember"
      decimals="0"
      id="Fact000982"
      unitRef="USD">11256067</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-12-31_custom_CustomerRelationshipsWellgisticsAcquisitionMember"
      decimals="0"
      id="Fact000983"
      unitRef="USD">11256067</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-06-30_custom_TrademarkWellgisticsAcqusitionMember"
      decimals="0"
      id="Fact000985"
      unitRef="USD">10143137</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-12-31_custom_TrademarkWellgisticsAcqusitionMember"
      decimals="0"
      id="Fact000986"
      unitRef="USD">10143137</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-06-30_custom_LicenseRightsMember"
      decimals="0"
      id="Fact000988"
      unitRef="USD">2500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-12-31_custom_LicenseRightsMember"
      decimals="0"
      id="Fact000989"
      unitRef="USD">2500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000991"
      unitRef="USD">24293057</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000992"
      unitRef="USD">24293057</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000994"
      unitRef="USD">4757231</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000995"
      unitRef="USD">4099307</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <MEDS:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000997"
      unitRef="USD">9879075</MEDS:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <MEDS:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000998"
      unitRef="USD">9879075</MEDS:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001000"
      unitRef="USD">9656751</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001001"
      unitRef="USD">10314675</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001003"
      unitRef="USD">2946773</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001005"
      unitRef="USD">2499543</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001007"
      unitRef="USD">649185</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001009"
      unitRef="USD">2297588</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001011"
      unitRef="USD">1850358</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-06-30_custom_CustomerRelationshipsWoodsageAcquisitionMember"
      decimals="0"
      id="Fact001013"
      unitRef="USD">393853</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-04-012026-06-30_custom_WoodSageBusinessCombinationMember"
      decimals="0"
      id="Fact001015"
      unitRef="USD">12308</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-04-012025-06-30_custom_WoodSageBusinessCombinationMember"
      decimals="0"
      id="Fact001017"
      unitRef="USD">24616</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-012026-06-30_custom_WoodSageBusinessCombinationMember"
      decimals="0"
      id="Fact001019"
      unitRef="USD">12308</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-06-30_custom_WoodSageBusinessCombinationMember"
      decimals="0"
      id="Fact001021"
      unitRef="USD">24616</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-06-30_custom_CustomerRelationshipsWellgisticsAcquisitionMember"
      decimals="0"
      id="Fact001023"
      unitRef="USD">11256067</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-06-30_custom_TrademarkWellgisticsAcqusitionMember"
      decimals="0"
      id="Fact001025"
      unitRef="USD">10143137</us-gaap:FiniteLivedIntangibleAssetsGross>
    <MEDS:ImpairmentChargesOfIntangibleAssetsFinitelived
      contextRef="From2025-01-012025-12-31_custom_WellgisticsCustomerRelationshipsMember"
      decimals="0"
      id="Fact001027"
      unitRef="USD">5314027</MEDS:ImpairmentChargesOfIntangibleAssetsFinitelived>
    <MEDS:ImpairmentChargesOfIntangibleAssetsFinitelived
      contextRef="From2025-01-012025-12-31_custom_WellgisticsTrademarkMember"
      decimals="0"
      id="Fact001029"
      unitRef="USD">4565048</MEDS:ImpairmentChargesOfIntangibleAssetsFinitelived>
    <MEDS:ImpairmentChargesOfIntangibleAssetsFinitelived
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact001031"
      unitRef="USD">9879075</MEDS:ImpairmentChargesOfIntangibleAssetsFinitelived>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001033"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001035"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-04-012026-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      id="Fact001037"
      unitRef="USD">183932</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-04-012025-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      id="Fact001039"
      unitRef="USD">469003</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-012026-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      id="Fact001041"
      unitRef="USD">367865</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      id="Fact001043"
      unitRef="USD">938006</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-04-012026-06-30_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact001045"
      unitRef="USD">132722</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-04-012025-06-30_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact001047"
      unitRef="USD">281754</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-012026-06-30_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact001049"
      unitRef="USD">265444</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-06-30_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact001051"
      unitRef="USD">563508</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001053"
      unitRef="USD">328962</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001055"
      unitRef="USD">763064</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001057"
      unitRef="USD">657924</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001059"
      unitRef="USD">1526129</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001061">&lt;p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJZJImDnnVrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the future amortization of intangible assets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zavfDrtX0b23" style="display: none"&gt;SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLES ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20260630_zbCvJfWEi6Tf"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzrja_zXnLgxzGy799" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;2026 (remaining 6 months)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;836,495&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzrja_zeK0VHbBNYVb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzrja_zy54ThgSg6bc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzrja_z0KuE7eN6tX7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzrja_zm6t5OZ17LU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,423,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzrja_zkuyKbxkhYw7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,378,238&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzrja_z4p9YbFk1fza" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,656,751&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001063"
      unitRef="USD">836495</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001065"
      unitRef="USD">1672991</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001067"
      unitRef="USD">1672991</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001069"
      unitRef="USD">1672991</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001071"
      unitRef="USD">1423045</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <MEDS:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001073"
      unitRef="USD">2378238</MEDS:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001075"
      unitRef="USD">9656751</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001077">&lt;p id="xdx_802_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zWYA8HxonK2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7. &lt;span id="xdx_82C_zGD5sdmPTuS6"&gt;ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zPe4nsZSfuFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zO0vas05e7p9" style="display: none"&gt;SCHEDULE
OF ACCRUED
EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260630_zx4AXXYsi0L8" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_zyQdNFrWty1e" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AccruedPersonnelCosts_iI_maALAOLzO8o_zYix9FtZ0K17" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued personnel costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,016,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,588,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALAOLzO8o_zaIETjIg2prj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156,454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedExpenses_iI_maALAOLzO8o_zkJPbvvZI0Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CreditCardObligation_iI_maALAOLzO8o_zVzo3WXrrPH7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit card obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166,291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--UnearnedRevenue_iI_maALAOLzO8o_ztSZsHpV9LDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unearned revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;488,229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InterestPayableCurrent_iI_maALAOLzO8o_zpzIQSRHWEnh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,486,101&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;833,647&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzO8o_zhWNtgEoEHdi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued expenses and
    other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,003,749&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,407,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zjri5IKrXSo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001079">&lt;p id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zPe4nsZSfuFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zO0vas05e7p9" style="display: none"&gt;SCHEDULE
OF ACCRUED
EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260630_zx4AXXYsi0L8" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_zyQdNFrWty1e" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AccruedPersonnelCosts_iI_maALAOLzO8o_zYix9FtZ0K17" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued personnel costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,016,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,588,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALAOLzO8o_zaIETjIg2prj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156,454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedExpenses_iI_maALAOLzO8o_zkJPbvvZI0Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CreditCardObligation_iI_maALAOLzO8o_zVzo3WXrrPH7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit card obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166,291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--UnearnedRevenue_iI_maALAOLzO8o_ztSZsHpV9LDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unearned revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;488,229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InterestPayableCurrent_iI_maALAOLzO8o_zpzIQSRHWEnh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,486,101&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;833,647&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzO8o_zhWNtgEoEHdi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued expenses and
    other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,003,749&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,407,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <MEDS:AccruedPersonnelCosts
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001081"
      unitRef="USD">5016766</MEDS:AccruedPersonnelCosts>
    <MEDS:AccruedPersonnelCosts
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001082"
      unitRef="USD">4588421</MEDS:AccruedPersonnelCosts>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001084"
      unitRef="USD">156454</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001085"
      unitRef="USD">114429</us-gaap:AccruedProfessionalFeesCurrent>
    <MEDS:AccruedExpenses
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001087"
      unitRef="USD">152137</MEDS:AccruedExpenses>
    <MEDS:AccruedExpenses
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001088"
      unitRef="USD">199053</MEDS:AccruedExpenses>
    <MEDS:CreditCardObligation
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001090"
      unitRef="USD">166291</MEDS:CreditCardObligation>
    <MEDS:CreditCardObligation
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001091"
      unitRef="USD">183943</MEDS:CreditCardObligation>
    <MEDS:UnearnedRevenue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001093"
      unitRef="USD">26000</MEDS:UnearnedRevenue>
    <MEDS:UnearnedRevenue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001094"
      unitRef="USD">488229</MEDS:UnearnedRevenue>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001096"
      unitRef="USD">1486101</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001097"
      unitRef="USD">833647</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001099"
      unitRef="USD">7003749</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001100"
      unitRef="USD">6407722</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001102">&lt;p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_znQlVNGNnVCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8. &lt;span id="xdx_824_zl4TBIY3Uq1i"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zHwEAv4VPDLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
debt consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zHCNMtg6aG23" style="display: none"&gt;SCHEDULE
OF OUTSTANDING
DEBT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260630_zu7oMhowv3G5" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_z0gMdbp0Diti" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--MerchantCashAdvanceMember_zrwzucyocG76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Merchant cash advance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,654,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,744,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--LoanPayableMember_zlYVz8fVq4Wg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loan payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,601,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--NotePayableSellersOfWellgisticsMember_zPjT6DRkHReh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Note payable - owners of Wellgistics&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--NotePayableThirdPartyMember_z08wu2PWqX36" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Note payable - third party, net of debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;898,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--RevolvingLineOfCreditMember_zppsjU4S7uFg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revolving line of credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,643,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_z3oVdUf1hPa1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,101,803&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtCurrent_iI_zoYe90Lih3ik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Current portion of debt obligations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,206,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,887,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_hus-gaap--DebtInstrumentAxis__custom--ThirdPartyInvestorMember_zX6xYJpLtOhf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Third party investor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_hus-gaap--DebtInstrumentAxis__custom--NotePayableSellersOfWellgisticsMember_zz431Lg0ldDg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Note payable - owners of Wellgistics&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_zKMSrDYFbf9i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LongTermDebt_iI_z3Iw8XvppW4h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,806,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,487,520&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zkKluoAQv2D2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026 and December 31, 2025, unamortized debt discount was $&lt;span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260630_zG7iO69YFRd9" title="Debt instrument, unamortized discount"&gt;8,818,103&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251231_ztlTdHcgyEP3" title="Debt instrument, unamortized discount"&gt;1,568,776&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Merchant
Cash Advance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 20, 2025, the Company entered into a merchant cash advance agreement with Cedar Advance LLC (the &#x201c;October 2025 MCA&#x201d;).
Under the October 2025 MCA, the stated purchase price was $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20251020__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember__dei--LegalEntityAxis__custom--CedarAdvanceLLCMember_z5yrlRdrMeYj" title="Principal balance"&gt;2,898,000&lt;/span&gt;, of which $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20251020__20251020__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zMDtaEfn1oul" title="Issuance of debt"&gt;1,198,800&lt;/span&gt; was applied directly to satisfy the outstanding
balance under the Company&#x2019;s prior merchant cash advance arrangement, and $&lt;span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20251020__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_z0dgwUbDTYPl" title="Carrying amount"&gt;701,200&lt;/span&gt; was remitted to the Company for working capital
purposes. The total repayment obligation under the October 2025 MCA resulted in a principal balance of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20251020__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_z5T9n38GTWyj" title="Principal balance"&gt;1,900,000&lt;/span&gt;, repayable in fixed
weekly installments of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20251020__20251020__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zrhIHcoJ1Hnk" title="Periodic payments"&gt;56,800&lt;/span&gt; over an estimated &lt;span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtW_c20251020__20251020__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zvj9qBUzJFo8" title="Debt instrument term"&gt;51&lt;/span&gt;-week term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the merchant cash advance as a debt obligation. The difference between the total repayment obligation and the net
proceeds received has been recorded as a debt discount and is amortized to interest expense over the term of the arrangement using the
effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company and Cedar Advance LLC are currently
in mutual discussions to amend the weekly repayment amount under the October 2025 MCA. During the three months ended June 30, 2026, the
Company made reduced weekly payments of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_z4qnxmLuP1yl" title="Periodic payments"&gt;10,000&lt;/span&gt;, compared to the contractual weekly installment of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20251020__20251020__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zXI1936M4FFh" title="Periodic payments"&gt;56,800&lt;/span&gt;. As of June 30, 2026, the Company
had not received a notice of default under the October 2025 MCA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and six months ended June 30, 2026, the Company made total repayments of $&lt;span id="xdx_90E_eus-gaap--RepaymentsOfDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_z6tcpMDZEZM3" title="Repayments of debt"&gt;115,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--RepaymentsOfDebt_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zmB2Q1Xloh9g" title="Repayments of debt"&gt;296,800&lt;/span&gt;, respectively, under the merchant
cash advance arrangement. For the three months ended June 30, 2026, interest expense of $&lt;span id="xdx_90C_eus-gaap--InterestExpenseDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zE788YatHG32" title="Interest expenses debt"&gt;115,000&lt;/span&gt; was recognized from amortization of
the related debt discount. For the six months ended June 30, 2026, $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zlMu3UsYQKOb" title="Principal balance"&gt;89,909&lt;/span&gt; of the total repayments represented a reduction of the carrying
value of the arrangement. For the three and six months June 30, 2026, $&lt;span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zgivTPfBqo55" title="Amortization of the debt discount"&gt;115,372&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_z0J8UsDVuQ1g" title="Amortization of the debt discount"&gt;206,891&lt;/span&gt;, respectively, represented amortization of
the related debt discount, recorded as interest expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, the gross contractual repayment obligation under the merchant cash advance was $&lt;span id="xdx_90A_eus-gaap--ContractualObligation_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zrN6G3VrC5Bf" title="Contractual repayment obligation"&gt;2,250,400&lt;/span&gt;. The related unamortized
debt discount was $&lt;span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zyZalg4SJEsj" title="Unamortized debt discount"&gt;596,175&lt;/span&gt;, resulting in a net carrying amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zxt43kbeIx8g" title="Net carrying amount"&gt;1,654,225&lt;/span&gt;, classified as a current liability in the condensed consolidated
balance sheet. As of December 31, 2025, the gross contractual repayment obligation was $&lt;span id="xdx_90A_eus-gaap--ContractualObligation_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zLuhm4Bcced2" title="Contractual repayment obligation"&gt;2,547,200&lt;/span&gt;. The related unamortized debt discount
was $&lt;span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_z9eM9cn12VYb" title="Unamortized debt discount"&gt;803,066&lt;/span&gt;, resulting in a net carrying amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--MerchantCashAdvanceAgreementMember_zEGvX8XQsZQe" title="Net carrying amount"&gt;1,744,134&lt;/span&gt;, classified as a current liability in the condensed consolidated balance
sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loan
Payable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 29, 2025, the Company entered into a financing arrangement with Agile Capital Funding LLC (&#x201c;Agile&#x201d;) pursuant to which
it received net proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromNotesPayable_c20251029__20251029__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_z7mJtURNnw43" title="Net proceeds from loans payable"&gt;533,889&lt;/span&gt;. Total contractual repayments under the arrangement were $&lt;span id="xdx_903_eus-gaap--RepaymentsOfNotesPayable_c20251029__20251029__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_z5GjroIohgl3" title="Repayments of loans payable"&gt;2,880,000&lt;/span&gt;, with fixed weekly payments
of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20251029__20251029__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zydkmXFDaej4" title="Periodic payments"&gt;75,789&lt;/span&gt; over an estimated &lt;span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtW_c20251029__20251029__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_z04s6DWUtHGc" title="Debt instrument term"&gt;38&lt;/span&gt;-week term. A portion of the proceeds was applied directly to satisfy the outstanding balance of the prior
Agile obligation. The Company accounts for the arrangement as a debt obligation. The difference between the total contractual repayment
amount and the net proceeds received was recorded as a debt discount and is amortized to interest expense over the term of the arrangement
using the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2026, the Company made a scheduled weekly payment of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zntEVyqshh0d"&gt;75,789&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
of which $&lt;span id="xdx_905_eus-gaap--InterestExpenseDebt_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zCvTXoxfGSDe"&gt;41,232&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;represented interest expense from amortization of the related
debt discount and $&lt;span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zdal7OaaMy81"&gt;34,557&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;represented a reduction of principal. Subsequent to that payment,
the Company repaid the remaining outstanding balance under the Agile arrangement prior to its scheduled maturity for total cash payments
of $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfConvertibleDebt_c20260101__20260630__us-gaap--ShortTermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zijq7y7aO2uc"&gt;2,070,000&lt;/span&gt;.
The Company accounted for the settlement as an extinguishment of debt in accordance with ASC 470-50, &lt;i&gt;Debt &#x2014; Modifications and
Extinguishments&lt;/i&gt;. In connection with the extinguishment, the Company derecognized the remaining gross contractual repayment obligation
and the related unamortized debt discount, resulting in a loss on extinguishment of debt of $&lt;span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_z3tF72XU71ea" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;503,505&lt;/span&gt;,
representing the excess of the cash paid over the net carrying amount of the obligation immediately prior to settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized interest expense related to the Agile arrangement of $&lt;span id="xdx_906_eus-gaap--InterestExpenseDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zvOmv4fiT8S6" title="Interest expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--InterestAndDebtExpense_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zbh800eVQDyh" title="Interest expenses"&gt;41,232&lt;/span&gt;, and a loss on extinguishment of debt of $&lt;span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zRjQ4By2lf2d" title="Loss on debt extinguishment"&gt;0&lt;/span&gt; and
$&lt;span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zi3QMenGJW05" title="Loss on debt extinguishment"&gt;503,505&lt;/span&gt;, for the three and six months ended June 30, 2026, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, there were no amounts outstanding under the Agile arrangement. As of December 31, 2025, the net carrying amount of
the Agile obligation was $&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_z9uamjiRimif" title="Net carrying amount"&gt;1,601,056&lt;/span&gt;, net of unamortized debt discount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--FinancingArrangementMember__dei--LegalEntityAxis__custom--AgileCapitalFundingLLCMember_zQtwuXqsJF6b" title="Unamortized debt discount"&gt;765,710&lt;/span&gt;, and was classified as a current liability in the condensed
consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Note
payable &#x2013; sellers of Wellgistics, LLC&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 24, 2025, the Company and the owners of Wellgistics LLC executed the Eighth Amendment to the Membership Interest Purchase Agreement
(&#x201c;MIPA&#x201d;), pursuant to which the principal amount of the seller promissory note was increased from $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250724__srt--OwnershipAxis__custom--WellgisticsLLCMember__srt--RangeAxis__srt--MinimumMember_z3wqCNglJHpb" title="Principal balance"&gt;15.0&lt;/span&gt; million to $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn4n6_c20250724__srt--OwnershipAxis__custom--WellgisticsLLCMember__srt--RangeAxis__srt--MaximumMember_zCqCO88Uya95" title="Principal balance"&gt;17.5&lt;/span&gt;
million. Under the amended note, $&lt;span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20250724__20250724__srt--OwnershipAxis__custom--WellgisticsLLCMember__us-gaap--AwardTypeAxis__custom--FirstAndSecondAnniversariesMember_zLQXTkCl6z0b"&gt;5,000,000&lt;/span&gt; of principal is payable on each of the first and second anniversaries, and $&lt;span id="xdx_905_eus-gaap--RepaymentsOfNotesPayable_c20250724__20250724__srt--OwnershipAxis__custom--WellgisticsLLCMember__us-gaap--AwardTypeAxis__custom--ThirdAnniversaryMember_znBnOqViENje" title="Repayment of promissory note"&gt;7,500,000&lt;/span&gt; of
principal is payable on the third anniversary, of the effective date of the promissory note. The note bears simple interest at a rate
equal to the Prime Rate as published by The Wall Street Journal on January 1 of the applicable year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended June 30, 2026 and 2025, the Company recognized interest expense of $&lt;span id="xdx_901_eus-gaap--InterestExpenseDebt_c20260401__20260630__srt--OwnershipAxis__custom--WellgisticsLLCMember_zCEA3Zm0vfW7" title="Interest expense debt"&gt;370,856&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20250401__20250630__srt--OwnershipAxis__custom--WellgisticsLLCMember_zbZCO5rzfsqh" title="Interest expense debt"&gt;327,182&lt;/span&gt;, respectively, related
to the seller promissory note. For the six months ended June 30, 2026 and 2025, the Company recognized interest expense of $&lt;span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20260101__20260630__srt--OwnershipAxis__custom--WellgisticsLLCMember_z7clLJO2opCi" title="Interest expense debt"&gt;737,637&lt;/span&gt; and
$&lt;span id="xdx_909_eus-gaap--InterestExpenseDebt_c20250101__20250630__srt--OwnershipAxis__custom--WellgisticsLLCMember_zFg1rAdoMxV2" title="Interest expense debt"&gt;645,932&lt;/span&gt;, respectively, related to the seller promissory note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026 and December 31, 2025, accrued interest on the note totaled $&lt;span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260630__srt--OwnershipAxis__custom--WellgisticsLLCMember_zXnwMr4fP1ng" title="Debt instrument increase accrued interest"&gt;1,389,692&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__srt--OwnershipAxis__custom--WellgisticsLLCMember_zhwVy8hdg9S8" title="Debt instrument increase accrued interest"&gt;652,055&lt;/span&gt;, respectively, and is included in
accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. As of June 30, 2026 and December
31, 2025, $&lt;span id="xdx_908_eus-gaap--DebtCurrent_iI_c20260630__srt--OwnershipAxis__custom--WellgisticsLLCMember_z1QUMYckUgG9" title="Debt current"&gt;&lt;span id="xdx_90C_eus-gaap--DebtCurrent_iI_c20251231__srt--OwnershipAxis__custom--WellgisticsLLCMember_zFjBmaODojLh" title="Debt current"&gt;5,000,000&lt;/span&gt;&lt;/span&gt; of the promissory note was classified as a current liability, representing the principal payment due within twelve
months, and the remaining $&lt;span id="xdx_90F_eus-gaap--LongTermDebtNoncurrent_iI_c20260630__srt--OwnershipAxis__custom--WellgisticsLLCMember_zHxiJWycJTqg" title="Other loans payable long term"&gt;&lt;span id="xdx_90A_eus-gaap--LongTermDebtNoncurrent_iI_c20251231__srt--OwnershipAxis__custom--WellgisticsLLCMember_zTEf0F2PwhM3" title="Other loans payable long term"&gt;12,500,000&lt;/span&gt;&lt;/span&gt; was classified as non-current, in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Note
Payable &#x2013; Third party&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 2, 2025, the Company entered into an unsecured promissory note agreement with Arvoda Consulting LLC for a principal amount of
$&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20250102__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember_zzMQtvIzYwz7" title="Principal balance"&gt;448,411&lt;/span&gt;, bearing interest at a rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20250102__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zSqSe3ghubvd" title="Bearing interest rate"&gt;10&lt;/span&gt;% per annum, with both principal and accrued interest due in full on May 15, 2025. In the event
of default, interest accrues at a default rate of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20250102__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zxUwpx0kIVXa" title="Interest rate"&gt;12&lt;/span&gt;% per annum. In connection with this note, the Company received net proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20250102__20250102__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zBVi3O3EFUTd" title="Net proceeds of issuance cost"&gt;415,000&lt;/span&gt;,
with the remaining $&lt;span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20250102__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zfmkal30kGhf" title="Debt discount"&gt;33,411&lt;/span&gt; recognized as a debt discount, which was fully amortized as of December 31, 2025. During the six months ended
June 30, 2026, the Company settled the outstanding principal and accrued interest under the Arvoda note through a combination of share
issuances to Silverback Capital Corporation pursuant to a court-approved settlement agreement under Section 3(a)(10) of the Securities
Act of 1933, and a direct cash payment by the Company. For the three months ended June 30, 2026 and 2025, the Company recognized $&lt;span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zUD85kJEFfjh" title="Interest expense debt"&gt;0&lt;/span&gt; and
$&lt;span id="xdx_902_eus-gaap--InterestExpenseDebt_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_z9G6s40RaZ6d" title="Interest expense debt"&gt;11,210&lt;/span&gt;, respectively, as interest expense, and $&lt;span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember_zj8E5kHvHii1" title="Amortization of debt discount"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember_z6D3HOg0oWoe" title="Amortization of debt discount"&gt;11,304&lt;/span&gt;, respectively, as amortization of debt discount, related to the Arvoda
note. For the six months ended June 30, 2026 and 2025, the Company recognized $&lt;span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zDOFmim8px73" title="Interest expense debt"&gt;399&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--InterestExpenseDebt_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zWbgytFaVVzh" title="Interest expense debt"&gt;22,021&lt;/span&gt;, respectively, as interest expense, and
$&lt;span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zlHUZ9BlrfPc" title="Amortization of debt discount"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zfmsKakEhihh" title="Amortization of debt discount"&gt;33,411&lt;/span&gt;, respectively, as amortization of debt discount, related to the Arvoda note. As of June 30, 2026, the note payable to
Arvoda Consulting LLC had been fully satisfied, and there were no amounts outstanding. As of December 31, 2025, accrued interest payable
on this note was $&lt;span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zIaZ9tsK4jYa" title="Accrued interest payable"&gt;44,442&lt;/span&gt;, and the outstanding principal of $&lt;span id="xdx_904_eus-gaap--DebtCurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--ArvodaConsultingLLCMember_zN0VRp7brtQ6" title="Outstanding principal"&gt;448,411&lt;/span&gt; was classified as a current liability in the condensed consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 2, 2025, the Company entered into two separate unsecured promissory note agreement, each for a principal amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20250202__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementOneMember_z32hmDVzkXLf" title="Debt instrument principal amount"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20250202__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementTwoMember_zj5SSPZRMZAf" title="Debt instrument principal amount"&gt;100,000&lt;/span&gt;&lt;/span&gt;,
bearing interest at a rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250202__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementTwoMember_zjbUTJbkcrGf" title="Bearing interest rate"&gt;10&lt;/span&gt;% per annum, with both principal and accrued interest originally due in full on August 15, 2025. In the
event of default, interest accrues at a default rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250202__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementOneMember_zsDSbd40K2s8" title="Interest rate"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250202__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementTwoMember_zQzwMchwlrDl" title="Interest rate"&gt;12&lt;/span&gt;&lt;/span&gt;% per annum. Under the terms of the promissory note, an event of default occurs
only if the maker fails to pay any amount due within five (5) days after receipt of written notice from the payee. As of June 30, 2026,
the Company had not received any such written notice and, accordingly, no event of default had occurred. For the three months ended June
30, 2026 and 2025, the Company recognized aggregate interest expense of $&lt;span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--TwoSeparateUnsecuredPromissoryNoteAgreementMember_zVtS66VgZIee" title="Interest expense debt"&gt;5,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--InterestExpenseDebt_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--TwoSeparateUnsecuredPromissoryNoteAgreementMember_zgPw2zu5K5Ec" title="Interest expense debt"&gt;5,000&lt;/span&gt;, respectively, related to this note. For the
six months ended June 30, 2026 and 2025, the Company recognized aggregate interest expense of $&lt;span id="xdx_90C_eus-gaap--InterestExpenseDebt_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--TwoSeparateUnsecuredPromissoryNoteAgreementMember_zNxMJPpwTTna" title="Interest expense debt"&gt;10,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--TwoSeparateUnsecuredPromissoryNoteAgreementMember_zXnyhJUF8we6" title="Interest expense debt"&gt;8,123&lt;/span&gt;, respectively. As of
June 30, 2026 and December 31, 2025, aggregate accrued interest payable on this note was $&lt;span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--TwoSeparateUnsecuredPromissoryNoteAgreementMember_z6yAdSE1rqok" title="Accrued interest payable"&gt;28,124&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoSeparateUnsecuredPromissoryNoteAgreementMember_zyJqzQusNFD7" title="Accrued interest payable"&gt;18,124&lt;/span&gt;, respectively, and the aggregate
outstanding principal of $&lt;span id="xdx_905_eus-gaap--DebtCurrent_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--TwoSeparateUnsecuredPromissoryNoteAgreementMember_zqyKO7ONuhid" title="Unsecured promissory note principal amount"&gt;&lt;span id="xdx_90F_eus-gaap--DebtCurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoSeparateUnsecuredPromissoryNoteAgreementMember_zwP25vmFqLda" title="Unsecured promissory note principal amount"&gt;200,000&lt;/span&gt;&lt;/span&gt; is classified as a current liability in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 8, 2025, the Company issued a promissory note to Strategic EP, LLC in the principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20250408__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__dei--LegalEntityAxis__custom--StrategicEPLLCMember_zTmdmFebwkeh" title="Principal amount"&gt;250,000&lt;/span&gt;, bearing interest at a rate
of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250408__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__dei--LegalEntityAxis__custom--StrategicEPLLCMember_ziBxDEVK4FIb" title="Bearing interest rate"&gt;10&lt;/span&gt;% per annum. Under the terms of the agreement, the outstanding principal and accrued interest are payable on the earlier of (i)
April 8, 2026, or (ii) within five business days following the Company&#x2019;s receipt of aggregate gross proceeds of at least $&lt;span id="xdx_905_eus-gaap--ProceedsFromOtherDebt_pn6n6_c20250408__20250408__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z3Aj2X3nwqe" title="Proceeds from other debt"&gt;10&lt;/span&gt; million
from one or more equity or debt financings. On February 27, 2026, the Company received a demand letter from Strategic EP, LLC indicating
that the Company was in default under the terms of the promissory note. Upon the occurrence of a default, interest accrues at a default
rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250408__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z3IqujUbqJx1" title="Interest rate"&gt;18&lt;/span&gt;% per annum. For the three months ended June 30, 2026 and 2025, the Company recognized interest expense of $&lt;span id="xdx_909_eus-gaap--InterestExpenseDebt_c20260401__20260630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zKC4nzoehcyj" title="Interest expense debt"&gt;11,250&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20250401__20250630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zi8tBaiBeafg" title="Interest expense debt"&gt;0&lt;/span&gt;,
respectively, related to this note, accrued at the default rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z7jnT6HHZXLc" title="Interest rate"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zU05PS5bklD" title="Interest rate"&gt;18&lt;/span&gt;&lt;/span&gt;% per annum. For the six months ended June 30, 2026 and 2025, the
Company recognized interest expense of $&lt;span id="xdx_905_eus-gaap--InterestExpenseDebt_c20260101__20260630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zZNGtrtQQtlg" title="Interest expense debt"&gt;22,500&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--InterestExpenseDebt_c20250101__20250630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zfAlLPnm1iQg" title="Interest expense debt"&gt;0&lt;/span&gt;, respectively, related to this note, accrued at the default rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zUBZBeb2Vcra" title="Interest rate"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250630__us-gaap--DebtInstrumentAxis__custom--StrategicEPLLCMember_zwxIoJhSr2n3" title="Interest rate"&gt;18&lt;/span&gt;&lt;/span&gt;% per annum.
As of June 30, 2026 and December 31, 2025, accrued interest payable on this note was $&lt;span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zT2vvRMtPNi5" title="Accrued interest payable"&gt;44,622&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__dei--LegalEntityAxis__custom--StrategicEPLLCMember_z91IqvAhXnMl" title="Accrued interest payable"&gt;22,122&lt;/span&gt;, respectively, and the outstanding
principal of $&lt;span id="xdx_90D_eus-gaap--DebtCurrent_iI_c20260630__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z27Zqrfl0Fif" title="Unsecured promissory note principal amount"&gt;&lt;span id="xdx_90B_eus-gaap--DebtCurrent_iI_c20251231__dei--LegalEntityAxis__custom--StrategicEPLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zudVd0ArWeX3" title="Unsecured promissory note principal amount"&gt;250,000&lt;/span&gt;&lt;/span&gt; is classified as a current liability in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2023, the Company entered into a promissory note agreement with a third party investor for a principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember_zdBgenG42Ygd" title="Principal amount"&gt;100,000&lt;/span&gt;,
bearing interest at a rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_zwPs5ntI75S6" title="Bearing interest rate"&gt;8&lt;/span&gt;% per annum. Under the terms of the note, the lender is entitled to receive &lt;span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230901__20230930__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember_zZi5FGbSqMI7" title="Debt instrument"&gt;35,000&lt;/span&gt; shares of the Company&#x2019;s
common stock upon the consummation of a SPAC transaction or merger. As of June 30, 2026, this condition had not been met and accordingly
no shares have been issued. For the three months ended June 30, 2026 and 2025, the Company recognized interest expense of $&lt;span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_zxxGiYQk6Kr6" title="Interest expense debt"&gt;2,000&lt;/span&gt; and
$&lt;span id="xdx_906_eus-gaap--InterestExpenseDebt_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_zRD2yx5HHx68" title="Interest expense debt"&gt;2,000&lt;/span&gt;, respectively, related to this note. For the six months ended June 30, 2026 and 2025, the Company recognized interest expense
of $&lt;span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_z6DP0KlEV0fh" title="Interest expense debt"&gt;4,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--InterestExpenseDebt_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_zX70GOSQCeCa" title="Interest expense debt"&gt;4,000&lt;/span&gt;, respectively, related to this note. As of June 30, 2026 and December 31, 2025, accrued interest payable on this
note was $&lt;span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_zBuRcvC850Ah" title="Interest payable"&gt;23,666&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_zI6XnhgD3SYk" title="Interest payable"&gt;19,666&lt;/span&gt;, respectively, and the outstanding principal of $&lt;span id="xdx_908_eus-gaap--LongTermDebtNoncurrent_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_zN1GQ1Jg5bMl" title="Debt non current"&gt;&lt;span id="xdx_90A_eus-gaap--LongTermDebtNoncurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_zEeRojUR2l39" title="Debt non current"&gt;100,000&lt;/span&gt;&lt;/span&gt; is classified as a non-current liability in the
condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revolving
line of credit &#x2013; Wellgistics&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, Wellgistics, LLC (&#x201c;Wellgistics&#x201d;), a wholly owned subsidiary of the Company, entered into a credit agreement
with Marco Capital, Inc. (&#x201c;MCI&#x201d;) for a revolving line of credit with a maximum borrowing capacity of $&lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20241130__us-gaap--CreditFacilityAxis__custom--CreditAgreementMember__dei--LegalEntityAxis__custom--MarcoCapitalIncMember_zxHKBLO1dDtj" title="Line of credit maximum borrowing capacity"&gt;10,000,000&lt;/span&gt;. &lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDescription_c20251231__20251231__us-gaap--CreditFacilityAxis__custom--CreditAgreementMember__dei--LegalEntityAxis__custom--MarcoCapitalIncMember_zvB7gVpdsd38" title="Line of credit interest rate, description"&gt;The line
of credit bears interest at a rate equal to Term SOFR plus 11.5% per annum, calculated and prorated daily on the outstanding balance,
representing an aggregate rate of approximately 16.84% per annum as of December 31, 2025&lt;/span&gt;. The line of credit was collateralized by the
accounts receivable and inventory balances of Wellgistics.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2026, Wellgistics entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement (the &#x201c;Forbearance
Agreement&#x201d;) with MCI, pursuant to which Wellgistics acknowledged approximately $&lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityFairValueOfAmountOutstanding_iI_pn4n6_c20260501__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember__dei--LegalEntityAxis__custom--MarcoCapitalIncMember_zzgDAag1KoDe" title="Line of credit,outstanding"&gt;1.77&lt;/span&gt; million of outstanding obligations owed to
MCI under the credit agreement. The Company and certain members of management also entered into the Forbearance Agreement to reaffirm
certain guaranty obligations. Under the Forbearance Agreement, MCI agreed to temporarily forbear from exercising certain rights and remedies
under the existing loan documents through June 15, 2026, and Wellgistics agreed to make bi-weekly payments of $&lt;span id="xdx_90F_eus-gaap--LineOfCreditFacilityPeriodicPayment_c20260501__20260501__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember__dei--LegalEntityAxis__custom--MarcoCapitalIncMember_zNf2OucbM6Wk" title="Periodic payment of debt"&gt;50,000&lt;/span&gt; beginning May 5,
2026, with outstanding obligations continuing to accrue interest at Term SOFR plus &lt;span id="xdx_90F_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_c20260501__20260501__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember__dei--LegalEntityAxis__custom--MarcoCapitalIncMember_zGE1OpoZ8Ja" title="Line of credit interest rate"&gt;11.5&lt;/span&gt;% per annum. The Forbearance Agreement also provided
that a portion of net proceeds from certain future financing transactions by the Company or its affiliates during the forbearance period
could be required to be applied toward repayment of the outstanding obligations, subject to specified thresholds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended June 30, 2026 and 2025, the Company recognized interest expense of $&lt;span id="xdx_905_eus-gaap--InterestExpenseDebt_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember__dei--LegalEntityAxis__custom--MarcoCapitalIncMember_zAs0Jzka0Dv7" title="Interest expenses debt"&gt;199,075&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--InterestExpenseDebt_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember__dei--LegalEntityAxis__custom--MarcoCapitalIncMember_zpeJkPHRg1Sk" title="Interest expenses debt"&gt;332,439&lt;/span&gt;, respectively, related
to the line of credit. For the six months ended June 30, 2026 and 2025, the Company recognized interest expense of $&lt;span id="xdx_909_eus-gaap--InterestExpenseDebt_c20260101__20260630__dei--LegalEntityAxis__custom--NewCreditAgreementMember_zEgTAEQLTF0j" title="Interest expenses debt"&gt;267,302&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20250101__20250630__dei--LegalEntityAxis__custom--MarcoCapitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember_zkYTFEPJI1g" title="Interest expense debt"&gt;614,199&lt;/span&gt;,
respectively, related to the line of credit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 29, 2026, the Company repaid the outstanding balance under the line of credit in full, for a total payment of $&lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityPeriodicPayment_c20260529__20260529__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember__dei--LegalEntityAxis__custom--MarcoCapitalIncMember_znpm82xmWXz5" title="Periodic payment of debt"&gt;1,666,132&lt;/span&gt;, in advance
of the forbearance period end date. As of June 30, 2026, there were &lt;span id="xdx_909_eus-gaap--LineOfCredit_iI_do_c20260630__dei--LegalEntityAxis__custom--MarcoCapitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember_zaQgUIlS0mhe" title="Line of credit"&gt;no&lt;/span&gt; amounts outstanding under the line of credit. As of December 31,
2025, the outstanding balance under the line of credit was $&lt;span id="xdx_900_eus-gaap--LineOfCredit_iI_c20251231__dei--LegalEntityAxis__custom--MarcoCapitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAndRepaymentAgreementMember_z1uC107xREVj" title="Line of credit"&gt;1,643,923&lt;/span&gt;, and was classified as a current liability in the condensed consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Convertible
notes payable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 16, 2026, the Company entered into a Note Purchase Agreement with certain investors pursuant to which the Company issued and
sold secured convertible promissory notes (the &#x201c;Notes&#x201d;) in an aggregate principal amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20260116__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zP6dELchOPDe" title="Principal amount"&gt;8,125,000&lt;/span&gt; for aggregate gross
proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromConvertibleDebt_c20260116__20260116__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zd4m3vhTBhAh" title="Gross proceeds"&gt;6,500,000&lt;/span&gt;, reflecting a &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260116__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zIhDU1FAU4ri" title="Percentage of original issue discount"&gt;20&lt;/span&gt;% original issue discount. On April 1, 2026, the Company issued an additional convertible promissory
note in the principal amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20260401__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zLeXjdlyXGr6" title="Principal amount"&gt;1,250,000&lt;/span&gt; for gross proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20260401__20260401__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zrvKBVPNboie" title="Gross proceeds"&gt;1,000,000&lt;/span&gt;, reflecting a &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260401__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zQgz4eUCxVw" title="Percentage of original issue discount"&gt;20&lt;/span&gt;% original issue discount. On May 20, 2026,
the Company issued a further convertible promissory note in the principal amount of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20260520__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zkivokx8bgS1" title="Principal amount"&gt;250,000&lt;/span&gt; for gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromConvertibleDebt_c20260520__20260520__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zerjZvgD5Z8j" title="Gross proceeds"&gt;200,000&lt;/span&gt;, reflecting
a &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260520__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zeuTkErGRia7" title="Percentage of original issue discount"&gt;20&lt;/span&gt;% original issue discount (together, the &#x201c;Original Notes&#x201d;). The Original Notes bore interest at &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260520__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--HolderMember_zQYgBNpQbEbd" title="Percentage of original issue discount"&gt;0&lt;/span&gt;% per annum, except
upon an event of default, and were convertible into shares of the Company&#x2019;s common stock at the election of the holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the January 2026 Original Note, the Company paid placement agent fees of $&lt;span id="xdx_905_ecustom--PlacementAgentFees_c20260116__20260116__us-gaap--DebtInstrumentAxis__custom--January2026OriginalNoteMember_zd64PjB2B2za" title="PlacementAgentFees"&gt;422,500&lt;/span&gt; and legal fees of $&lt;span id="xdx_904_eus-gaap--LegalFees_c20260116__20260116__us-gaap--DebtInstrumentAxis__custom--January2026OriginalNoteMember_zLfiK6Ozs47" title="Legal fees"&gt;75,000&lt;/span&gt; in cash,
and issued warrants to purchase an aggregate of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260116__us-gaap--DebtInstrumentAxis__custom--January2026OriginalNoteMember_zsUSTozmdHDj" title="Stock issued for the exercise of warrants, number"&gt;21,953&lt;/span&gt; shares of common stock, at an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--DebtInstrumentAxis__custom--January2026OriginalNoteMember_z66JH5sVCT4i" title="Exercise price of warrants"&gt;20.50&lt;/span&gt; per share, to the placement
agent and its designees. The fair value of these warrants, $&lt;span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20260116__20260116__us-gaap--DebtInstrumentAxis__custom--January2026OriginalNoteMember_z5alOPSyJYB7" title="Fair value adjustment of warrants"&gt;416,965&lt;/span&gt;, determined using the Black-Scholes option-pricing model, was recorded
as a debt issuance cost. The Company accounted for the original issue discount, together with debt issuance costs, as a reduction of
the carrying amount of the Original Notes, which is accreted to interest expense over the term of each note using the effective interest
method in accordance with ASC 835-30, &lt;i&gt;Interest &#x2014; Imputation of Interest&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;May
27, 2026 Refinancing&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 27, 2026, the Company entered into a new Note Purchase Agreement with substantially the same group of investors that held the Original
Notes, together with certain additional investors (the &#x201c;New Notes&#x201d;). Pursuant to this agreement, the Original Notes, with
an aggregate face amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--ShortTermDebtTypeAxis__custom--OriginalConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zFcPmK9DJS9j" title="Aggregate principal amount"&gt;9,625,000&lt;/span&gt; and a net carrying value of $&lt;span id="xdx_90C_eus-gaap--LongTermDebtAverageAmountOutstanding_c20260527__20260527__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zsRd45xqA0Bk" title="Debt carrying amount"&gt;8,501,187&lt;/span&gt; immediately prior to the refinancing, were extinguished,
and the Company issued New Notes in an aggregate principal amount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zQ5ZD8Bml72i" title="Principal Amount"&gt;20,323,731&lt;/span&gt;, comprised of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--ShortTermDebtTypeAxis__custom--OriginalConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zYw0yrUxadkh" title="Aggregate principal amount"&gt;9,625,000&lt;/span&gt; attributable to the rollover
of the Original Notes (grossed up to $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementRolloverNoteMember_zw4Eym8Wg6aa" title="Principal amount"&gt;12,031,250&lt;/span&gt; in face value under the New Notes at a &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20270527__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zniRvFTJEdrb" title="Percentage of original issue discount"&gt;20&lt;/span&gt;% original issue discount), $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementNewNotesMember_zViUacWeEdW" title="Principal Amount"&gt;8,125,000&lt;/span&gt; attributable
to new money of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_c20260120__20260120__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zIdPmMST03ah" title="Gross proceeds"&gt;6,500,000&lt;/span&gt;, reflecting a &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260527__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zM5FN9wKWdYe" title="Percentage of original issue discount"&gt;20&lt;/span&gt;% original issue discount, and $&lt;span id="xdx_903_ecustom--PlacementAgentFees_c20260527__20260527__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zbZnwL9TIaM3" title="PlacementAgentFees"&gt;167,481&lt;/span&gt; attributable to a note issued in lieu of cash for
a portion of the placement agent&#x2019;s fee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the extinguishment, the Company calculated the reacquisition price of the Original Notes as the sum of the fair value
of the New Notes issued in respect of the rollover $&lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20260527__20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zukJrXYSqf24" title="Debt instrument shares issued"&gt;9,625,000&lt;/span&gt; and the fair value of warrants issued to the holders of the Original Notes
in connection with the refinancing $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20260527__20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zS6O0Nf7v2dk" title="FairValue of warrants"&gt;7,254,377&lt;/span&gt;, for a total reacquisition price of $&lt;span id="xdx_907_ecustom--ReacquisitionOfDebt_c20260527__20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zF2WSxz15YAd" title="Reacquisition Of Debt"&gt;16,879,377&lt;/span&gt;. The Company recognized a loss on extinguishment
of debt of $&lt;span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_znq8AAM0w2kd" title="Loss on extinguishment of debt"&gt;8,378,189&lt;/span&gt;, representing the excess of the reacquisition price over the $&lt;span id="xdx_90F_ecustom--ExcessValueOverCarryingAmountOfOriginalNotes_c20260527__20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zzjIPlZ1tOMd" title="Excess value over carrying amount of original notes"&gt;8,501,187&lt;/span&gt; net carrying amount of the Original Notes
immediately prior to the refinancing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
New Notes mature on &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_c20260527__20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zob0JFi6PWFf" title="Debt maturity date"&gt;May 27, 2027&lt;/span&gt;, and bear interest at &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_z92QdAd9WpL2" title="Percentage of original issue discount"&gt;0&lt;/span&gt;% per annum, except upon an event of default. The New Notes are convertible,
at the election of the holder, into shares of the Company&#x2019;s common stock and are secured by substantially all of the assets of
the Company and its wholly-owned subsidiaries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the May 27, 2026 financing, the Company issued warrants to purchase an aggregate of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260527__us-gaap--ClassOfWarrantOrRightAxis__custom--PIPEWarrantsMember_zKtJsnJ1uuRf" title="Warrants issued"&gt;7,914,758&lt;/span&gt; shares of common stock
to participating investors (&#x201c;PIPE Warrants&#x201d;) and warrants to purchase an aggregate of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260527__us-gaap--ClassOfWarrantOrRightAxis__custom--PAWarrantsMember_zpSyVsobP148" title="Warrants issued"&gt;1,418,444&lt;/span&gt; shares of common stock to
the placement agent and its designees (&#x201c;PA Warrants&#x201d;). The Company allocated the fair value of the PIPE Warrants between
the rollover and new-money tranches on a pro rata basis based on relative principal amounts. The fair value of the PIPE Warrants allocated
to the rollover tranche, $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20260527__20260527__us-gaap--ClassOfWarrantOrRightAxis__custom--PIPEWarrantsMember_z1Pr2vvD71v8" title="FairValue of warrants"&gt;7,254,377&lt;/span&gt;, was included in the reacquisition price described above. The fair value of the PIPE Warrants allocated
to the new-money tranche, together with the standalone fair value of the New Notes attributable to new money, was allocated between the
New Notes and additional paid-in capital using the relative fair value method, resulting in $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zfXUpE0LGvu7" title="Debt carring amount"&gt;3,706,446&lt;/span&gt; allocated to the New Notes and
$&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zgVmQejJXwq7" title="Debt carrying amount"&gt;2,793,554&lt;/span&gt; allocated to additional paid-in capital as a debt discount. The fair value of the PA Warrants, $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20260527__20260527__us-gaap--ClassOfWarrantOrRightAxis__custom--PAWarrantsMember_zDQfjfhgBY1i" title="Fair value of warrants"&gt;2,685,666&lt;/span&gt;, was recorded as
a debt issuance cost. Cash legal fees of $&lt;span id="xdx_901_eus-gaap--LegalFees_c20260527__20260527__us-gaap--ClassOfWarrantOrRightAxis__custom--PAWarrantsMember_zGYl6IcXrKRe" title="Legal fee"&gt;660,000&lt;/span&gt; and the fair value of the PA Warrants were allocated between debt issuance cost and
equity issuance cost based on the relative fair value of the debt and equity components of the financing, resulting in $&lt;span id="xdx_907_eus-gaap--PaymentsOfDebtIssuanceCosts_c20260527__20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zbUnD4uJF1D7" title="Debt issuance costs"&gt;1,991,227&lt;/span&gt; allocated
to debt issuance cost (a reduction of the carrying amount of the New Notes) and $&lt;span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20260527__20260527__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zMHNFIcJ8ZG9" title="Equity issuance costs"&gt;1,488,424&lt;/span&gt; allocated to equity issuance cost (a reduction
of additional paid-in capital).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the resulting discount and debt issuance costs as a reduction of the carrying amount of the New Notes, which is
accreted to interest expense over the term of the New Notes using the effective interest method in accordance with ASC 835-30.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended June 30, 2026, the Company recognized interest expense related to the Original Notes and New Notes of $&lt;span id="xdx_904_eus-gaap--InterestExpenseDebt_c20260401__20260630__us-gaap--DebtInstrumentAxis__custom--OriginalNotesAndNewNotesMember_z8VAhPCrw2Ek" title="Interest expenses debt"&gt;1,472,095&lt;/span&gt;,
substantially all of which represented non-cash accretion of debt discount and debt issuance costs. For the six months ended June 30,
2026, the Company recognized interest expense related to the Original Notes and New Notes of $&lt;span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20260101__20260630__us-gaap--DebtInstrumentAxis__custom--OriginalNotesAndNewNotesMember_zV9NExWEYM8i" title="Interest expenses debt"&gt;2,343,252&lt;/span&gt;. There was no comparable amount
for the three or six months ended June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, the gross principal amount of the New Notes was $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementMember_zJTFhzaegDl4" title="Principal Amount"&gt;20,323,731&lt;/span&gt;, and the unamortized debt discount and debt issuance costs
were $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementRolloverNoteMember_zje7M9r11fHk" title="Unamortized discount and debt issuance costs"&gt;8,221,928&lt;/span&gt;, resulting in a net carrying amount of $&lt;span id="xdx_906_eus-gaap--DebtCurrent_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--NewNotePurchaseAgreementRolloverNoteMember_z1U0WTg3VF1f" title="Debt currrent"&gt;12,101,803&lt;/span&gt;, classified as a current liability in the condensed consolidated balance
sheets. As of December 31, 2025, no amounts were outstanding under the Original Notes or the New Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zGJWpGHoka96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table is a summary of annual principal payments of the Company&#x2019;s outstanding debt:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_ziQl1zsAwWo3" style="display: none"&gt;SCHEDULE OF ANNUAL PRINCIPAL PAYMENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260630_zdKurB1khi31"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maDICAzMsn_zsgTNfEg2H0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;2026 (Six months ending December 31, 2026)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,700,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzMsn_z5XI9g5eto3f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,423,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzMsn_zRo2cqlkDyJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzMsn_zbfvFYHwg3Y9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principal gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,624,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_zANSs5xGaVz8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less : Unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,818,103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebt_iTI_zH6qgl7XTGMi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principal Payment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,806,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zpoRmYcYsO07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001104">&lt;p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zHwEAv4VPDLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
debt consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zHCNMtg6aG23" style="display: none"&gt;SCHEDULE
OF OUTSTANDING
DEBT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260630_zu7oMhowv3G5" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_z0gMdbp0Diti" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--MerchantCashAdvanceMember_zrwzucyocG76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Merchant cash advance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,654,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,744,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--LoanPayableMember_zlYVz8fVq4Wg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loan payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,601,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--NotePayableSellersOfWellgisticsMember_zPjT6DRkHReh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Note payable - owners of Wellgistics&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--NotePayableThirdPartyMember_z08wu2PWqX36" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Note payable - third party, net of debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;898,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--RevolvingLineOfCreditMember_zppsjU4S7uFg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revolving line of credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,643,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DebtCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_z3oVdUf1hPa1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,101,803&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtCurrent_iI_zoYe90Lih3ik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Current portion of debt obligations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,206,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,887,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_hus-gaap--DebtInstrumentAxis__custom--ThirdPartyInvestorMember_zX6xYJpLtOhf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Third party investor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_hus-gaap--DebtInstrumentAxis__custom--NotePayableSellersOfWellgisticsMember_zz431Lg0ldDg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Note payable - owners of Wellgistics&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_zKMSrDYFbf9i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LongTermDebt_iI_z3Iw8XvppW4h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,806,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,487,520&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_MerchantCashAdvanceMember"
      decimals="0"
      id="Fact001106"
      unitRef="USD">1654225</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_MerchantCashAdvanceMember"
      decimals="0"
      id="Fact001107"
      unitRef="USD">1744134</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_LoanPayableMember"
      decimals="0"
      id="Fact001110"
      unitRef="USD">1601052</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_NotePayableSellersOfWellgisticsMember"
      decimals="0"
      id="Fact001112"
      unitRef="USD">5000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_NotePayableSellersOfWellgisticsMember"
      decimals="0"
      id="Fact001113"
      unitRef="USD">5000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_NotePayableThirdPartyMember"
      decimals="0"
      id="Fact001115"
      unitRef="USD">450000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_NotePayableThirdPartyMember"
      decimals="0"
      id="Fact001116"
      unitRef="USD">898411</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_RevolvingLineOfCreditMember"
      decimals="0"
      id="Fact001119"
      unitRef="USD">1643923</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_ConvertibleNotesMember"
      decimals="0"
      id="Fact001121"
      unitRef="USD">12101803</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001124"
      unitRef="USD">19206028</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001125"
      unitRef="USD">10887520</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2026-06-30_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001127"
      unitRef="USD">100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-12-31_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001128"
      unitRef="USD">100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2026-06-30_custom_NotePayableSellersOfWellgisticsMember"
      decimals="0"
      id="Fact001130"
      unitRef="USD">12500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-12-31_custom_NotePayableSellersOfWellgisticsMember"
      decimals="0"
      id="Fact001131"
      unitRef="USD">12500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001133"
      unitRef="USD">12600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001134"
      unitRef="USD">12600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001136"
      unitRef="USD">31806028</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001137"
      unitRef="USD">23487520</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001139"
      unitRef="USD">8818103</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001141"
      unitRef="USD">1568776</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-10-20_custom_MerchantCashAdvanceAgreementMember_custom_CedarAdvanceLLCMember"
      decimals="0"
      id="Fact001143"
      unitRef="USD">2898000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2025-10-202025-10-20_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001145"
      unitRef="USD">1198800</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2025-10-20_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001147"
      unitRef="USD">701200</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-10-20_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001149"
      unitRef="USD">1900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-10-202025-10-20_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001151"
      unitRef="USD">56800</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2025-10-202025-10-20_custom_MerchantCashAdvanceAgreementMember"
      id="Fact001153">P357D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2026-04-012026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001155"
      unitRef="USD">10000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-10-202025-10-20_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001157"
      unitRef="USD">56800</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-04-012026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001159"
      unitRef="USD">115000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-01-012026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001161"
      unitRef="USD">296800</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001163"
      unitRef="USD">115000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001165"
      unitRef="USD">89909</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2026-04-012026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001167"
      unitRef="USD">115372</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2026-01-012026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001169"
      unitRef="USD">206891</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ContractualObligation
      contextRef="AsOf2026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001171"
      unitRef="USD">2250400</us-gaap:ContractualObligation>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001173"
      unitRef="USD">596175</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-06-30_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001175"
      unitRef="USD">1654225</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-12-31_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001177"
      unitRef="USD">2547200</us-gaap:ContractualObligation>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2025-12-31_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001179"
      unitRef="USD">803066</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_MerchantCashAdvanceAgreementMember"
      decimals="0"
      id="Fact001181"
      unitRef="USD">1744134</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-10-292025-10-29_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001183"
      unitRef="USD">533889</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-10-292025-10-29_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001185"
      unitRef="USD">2880000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-10-292025-10-29_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001187"
      unitRef="USD">75789</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2025-10-292025-10-29_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      id="Fact001189">P266D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2026-01-012026-03-31_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001190"
      unitRef="USD">75789</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-012026-03-31_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001191"
      unitRef="USD">41232</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-03-31_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001192"
      unitRef="USD">34557</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2026-01-012026-06-30_custom_SecuredConvertiblePromissoryNotesMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001193"
      unitRef="USD">2070000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-012026-06-30_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001194"
      unitRef="USD">503505</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001196"
      unitRef="USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2026-01-012026-06-30_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001198"
      unitRef="USD">41232</us-gaap:InterestAndDebtExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-04-012026-06-30_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001200"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-012026-06-30_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001202"
      unitRef="USD">503505</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2025-12-31_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001204"
      unitRef="USD">1601056</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2025-12-31_custom_FinancingArrangementMember_custom_AgileCapitalFundingLLCMember"
      decimals="0"
      id="Fact001206"
      unitRef="USD">765710</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-07-24_custom_WellgisticsLLCMember_srt_MinimumMember"
      decimals="-5"
      id="Fact001208"
      unitRef="USD">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-07-24_custom_WellgisticsLLCMember_srt_MaximumMember"
      decimals="-4"
      id="Fact001210"
      unitRef="USD">17500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-07-242025-07-24_custom_WellgisticsLLCMember_custom_FirstAndSecondAnniversariesMember"
      decimals="0"
      id="Fact001211"
      unitRef="USD">5000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-07-242025-07-24_custom_WellgisticsLLCMember_custom_ThirdAnniversaryMember"
      decimals="0"
      id="Fact001213"
      unitRef="USD">7500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001215"
      unitRef="USD">370856</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-04-012025-06-30_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001217"
      unitRef="USD">327182</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-012026-06-30_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001219"
      unitRef="USD">737637</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-012025-06-30_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001221"
      unitRef="USD">645932</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2026-06-30_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001223"
      unitRef="USD">1389692</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001225"
      unitRef="USD">652055</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001227"
      unitRef="USD">5000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001229"
      unitRef="USD">5000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2026-06-30_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001231"
      unitRef="USD">12500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-12-31_custom_WellgisticsLLCMember"
      decimals="0"
      id="Fact001233"
      unitRef="USD">12500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-01-02_custom_UnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001235"
      unitRef="USD">448411</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-01-02_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="INF"
      id="Fact001237"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-01-02_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="INF"
      id="Fact001239"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2025-01-022025-01-02_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001241"
      unitRef="USD">415000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2025-01-02_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001243"
      unitRef="USD">33411</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001245"
      unitRef="USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-04-012025-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001247"
      unitRef="USD">11210</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2026-04-012026-06-30_custom_UnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001249"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-04-012025-06-30_custom_UnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001251"
      unitRef="USD">11304</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-012026-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001253"
      unitRef="USD">399</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-012025-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001255"
      unitRef="USD">22021</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2026-01-012026-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001257"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-012025-06-30_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001259"
      unitRef="USD">33411</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001261"
      unitRef="USD">44442</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_UnsecuredPromissoryNoteAgreementMember_custom_ArvodaConsultingLLCMember"
      decimals="0"
      id="Fact001263"
      unitRef="USD">448411</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-02_custom_UnsecuredPromissoryNoteAgreementOneMember"
      decimals="0"
      id="Fact001265"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-02_custom_UnsecuredPromissoryNoteAgreementTwoMember"
      decimals="0"
      id="Fact001267"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-02-02_custom_UnsecuredPromissoryNoteAgreementTwoMember"
      decimals="INF"
      id="Fact001269"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-02-02_custom_UnsecuredPromissoryNoteAgreementOneMember"
      decimals="INF"
      id="Fact001271"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-02-02_custom_UnsecuredPromissoryNoteAgreementTwoMember"
      decimals="INF"
      id="Fact001273"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001275"
      unitRef="USD">5000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-04-012025-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001277"
      unitRef="USD">5000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-012026-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001279"
      unitRef="USD">10000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-012025-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001281"
      unitRef="USD">8123</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2026-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001283"
      unitRef="USD">28124</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001285"
      unitRef="USD">18124</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001287"
      unitRef="USD">200000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_TwoSeparateUnsecuredPromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001289"
      unitRef="USD">200000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-04-08_custom_PromissoryNoteMember_custom_StrategicEPLLCMember"
      decimals="0"
      id="Fact001291"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-04-08_custom_PromissoryNoteMember_custom_StrategicEPLLCMember"
      decimals="INF"
      id="Fact001293"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="From2025-04-082025-04-08_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="-6"
      id="Fact001295"
      unitRef="USD">10000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-04-08_custom_PromissoryNoteMember_custom_StrategicEPLLCMember"
      decimals="INF"
      id="Fact001297"
      unitRef="Pure">0.18</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001299"
      unitRef="USD">11250</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-04-012025-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001301"
      unitRef="USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001303"
      unitRef="Pure">0.18</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001305"
      unitRef="Pure">0.18</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-012026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001307"
      unitRef="USD">22500</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-012025-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001309"
      unitRef="USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001311"
      unitRef="Pure">0.18</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-06-30_custom_StrategicEPLLCMember"
      decimals="INF"
      id="Fact001313"
      unitRef="Pure">0.18</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001315"
      unitRef="USD">44622</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_PromissoryNoteMember_custom_StrategicEPLLCMember"
      decimals="0"
      id="Fact001317"
      unitRef="USD">22122</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_StrategicEPLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001319"
      unitRef="USD">250000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-12-31_custom_PromissoryNoteMember_custom_StrategicEPLLCMember"
      decimals="0"
      id="Fact001321"
      unitRef="USD">250000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-09-30_custom_ThirdPartyInvestorMember_custom_PromissoryNoteAgreementMember"
      decimals="0"
      id="Fact001323"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-09-30_custom_ThirdPartyInvestorMember_custom_PromissoryNoteAgreementMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-09-012023-09-30_custom_ThirdPartyInvestorMember_custom_PromissoryNoteAgreementMember"
      decimals="INF"
      id="Fact001327"
      unitRef="Shares">35000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001329"
      unitRef="USD">2000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-04-012025-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001331"
      unitRef="USD">2000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-012026-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">4000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-012025-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001335"
      unitRef="USD">4000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2026-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001337"
      unitRef="USD">23666</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001339"
      unitRef="USD">19666</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2026-06-30_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001341"
      unitRef="USD">100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-12-31_custom_PromissoryNoteAgreementMember_custom_ThirdPartyInvestorMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2024-11-30_custom_CreditAgreementMember_custom_MarcoCapitalIncMember"
      decimals="0"
      id="Fact001345"
      unitRef="USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateDescription
      contextRef="From2025-12-312025-12-31_custom_CreditAgreementMember_custom_MarcoCapitalIncMember"
      id="Fact001347">The line
of credit bears interest at a rate equal to Term SOFR plus 11.5% per annum, calculated and prorated daily on the outstanding balance,
representing an aggregate rate of approximately 16.84% per annum as of December 31, 2025</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="AsOf2026-05-01_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember"
      decimals="-4"
      id="Fact001349"
      unitRef="USD">1770000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="From2026-05-012026-05-01_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember"
      decimals="0"
      id="Fact001351"
      unitRef="USD">50000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2026-05-012026-05-01_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember"
      decimals="INF"
      id="Fact001353"
      unitRef="Pure">0.115</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember"
      decimals="0"
      id="Fact001355"
      unitRef="USD">199075</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-04-012025-06-30_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember"
      decimals="0"
      id="Fact001357"
      unitRef="USD">332439</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-012026-06-30_custom_NewCreditAgreementMember"
      decimals="0"
      id="Fact001359"
      unitRef="USD">267302</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-012025-06-30_custom_MarcoCapitalIncMember_custom_ForbearanceAndRepaymentAgreementMember"
      decimals="0"
      id="Fact001361"
      unitRef="USD">614199</us-gaap:InterestExpenseDebt>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="From2026-05-292026-05-29_custom_ForbearanceAndRepaymentAgreementMember_custom_MarcoCapitalIncMember"
      decimals="0"
      id="Fact001363"
      unitRef="USD">1666132</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:LineOfCredit
      contextRef="AsOf2026-06-30_custom_MarcoCapitalIncMember_custom_ForbearanceAndRepaymentAgreementMember"
      decimals="0"
      id="Fact001365"
      unitRef="USD">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-12-31_custom_MarcoCapitalIncMember_custom_ForbearanceAndRepaymentAgreementMember"
      decimals="0"
      id="Fact001367"
      unitRef="USD">1643923</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-01-16_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="0"
      id="Fact001369"
      unitRef="USD">8125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-01-162026-01-16_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="0"
      id="Fact001371"
      unitRef="USD">6500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-01-16_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="INF"
      id="Fact001373"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-04-01_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="0"
      id="Fact001375"
      unitRef="USD">1250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-04-012026-04-01_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="0"
      id="Fact001377"
      unitRef="USD">1000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-04-01_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="INF"
      id="Fact001379"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-20_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="0"
      id="Fact001381"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-05-202026-05-20_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="0"
      id="Fact001383"
      unitRef="USD">200000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-05-20_custom_NotePurchaseAgreementMember_custom_InvestorsMember"
      decimals="INF"
      id="Fact001385"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-05-20_custom_NotePurchaseAgreementMember_custom_HolderMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Pure">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <MEDS:PlacementAgentFees
      contextRef="From2026-01-162026-01-16_custom_January2026OriginalNoteMember"
      decimals="0"
      id="Fact001389"
      unitRef="USD">422500</MEDS:PlacementAgentFees>
    <us-gaap:LegalFees
      contextRef="From2026-01-162026-01-16_custom_January2026OriginalNoteMember"
      decimals="0"
      id="Fact001391"
      unitRef="USD">75000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-01-16_custom_January2026OriginalNoteMember"
      decimals="INF"
      id="Fact001393"
      unitRef="Shares">21953</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-16_custom_January2026OriginalNoteMember"
      decimals="INF"
      id="Fact001395"
      unitRef="USDPShares">20.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-01-162026-01-16_custom_January2026OriginalNoteMember"
      decimals="0"
      id="Fact001397"
      unitRef="USD">416965</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_OriginalConvertiblePromissoryNotesMember_custom_NotePurchaseAgreementMember"
      decimals="0"
      id="Fact001399"
      unitRef="USD">9625000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtAverageAmountOutstanding
      contextRef="From2026-05-272026-05-27_custom_ConvertiblePromissoryNotesMember_custom_NotePurchaseAgreementMember"
      decimals="0"
      id="Fact001401"
      unitRef="USD">8501187</us-gaap:LongTermDebtAverageAmountOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001403"
      unitRef="USD">20323731</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_OriginalConvertiblePromissoryNotesMember_custom_NotePurchaseAgreementMember"
      decimals="0"
      id="Fact001405"
      unitRef="USD">9625000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementRolloverNoteMember"
      decimals="0"
      id="Fact001407"
      unitRef="USD">12031250</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2027-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember"
      decimals="INF"
      id="Fact001409"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementNewNotesMember"
      decimals="0"
      id="Fact001411"
      unitRef="USD">8125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-01-202026-01-20_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001413"
      unitRef="USD">6500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember"
      decimals="INF"
      id="Fact001415"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <MEDS:PlacementAgentFees
      contextRef="From2026-05-272026-05-27_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">167481</MEDS:PlacementAgentFees>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2026-05-272026-05-27_custom_NewNotePurchaseAgreementMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Shares">9625000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-05-272026-05-27_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001421"
      unitRef="USD">7254377</us-gaap:FairValueAdjustmentOfWarrants>
    <MEDS:ReacquisitionOfDebt
      contextRef="From2026-05-272026-05-27_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">16879377</MEDS:ReacquisitionOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-012026-06-30_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001425"
      unitRef="USD">8378189</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <MEDS:ExcessValueOverCarryingAmountOfOriginalNotes
      contextRef="From2026-05-272026-05-27_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001427"
      unitRef="USD">8501187</MEDS:ExcessValueOverCarryingAmountOfOriginalNotes>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2026-05-272026-05-27_custom_NewNotePurchaseAgreementMember"
      id="Fact001429">2027-05-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-05-27_custom_NewNotePurchaseAgreementMember"
      decimals="INF"
      id="Fact001431"
      unitRef="Pure">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-05-27_custom_PIPEWarrantsMember"
      decimals="INF"
      id="Fact001433"
      unitRef="Shares">7914758</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-05-27_custom_PAWarrantsMember"
      decimals="INF"
      id="Fact001435"
      unitRef="Shares">1418444</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-05-272026-05-27_custom_PIPEWarrantsMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">7254377</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_NotePurchaseAgreementMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">3706446</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-05-27_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">2793554</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-05-272026-05-27_custom_PAWarrantsMember"
      decimals="0"
      id="Fact001443"
      unitRef="USD">2685666</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:LegalFees
      contextRef="From2026-05-272026-05-27_custom_PAWarrantsMember"
      decimals="0"
      id="Fact001445"
      unitRef="USD">660000</us-gaap:LegalFees>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2026-05-272026-05-27_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001447"
      unitRef="USD">1991227</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2026-05-272026-05-27_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001449"
      unitRef="USD">1488424</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-04-012026-06-30_custom_OriginalNotesAndNewNotesMember"
      decimals="0"
      id="Fact001451"
      unitRef="USD">1472095</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-012026-06-30_custom_OriginalNotesAndNewNotesMember"
      decimals="0"
      id="Fact001453"
      unitRef="USD">2343252</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-06-30_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementMember"
      decimals="0"
      id="Fact001455"
      unitRef="USD">20323731</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2026-06-30_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementRolloverNoteMember"
      decimals="0"
      id="Fact001457"
      unitRef="USD">8221928</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtCurrent
      contextRef="AsOf2026-06-30_custom_NewConvertibleNotesMember_custom_NewNotePurchaseAgreementRolloverNoteMember"
      decimals="0"
      id="Fact001459"
      unitRef="USD">12101803</us-gaap:DebtCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001461">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zGJWpGHoka96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table is a summary of annual principal payments of the Company&#x2019;s outstanding debt:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_ziQl1zsAwWo3" style="display: none"&gt;SCHEDULE OF ANNUAL PRINCIPAL PAYMENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260630_zdKurB1khi31"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maDICAzMsn_zsgTNfEg2H0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;2026 (Six months ending December 31, 2026)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,700,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzMsn_z5XI9g5eto3f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,423,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzMsn_zRo2cqlkDyJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzMsn_zbfvFYHwg3Y9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principal gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,624,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_zANSs5xGaVz8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less : Unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,818,103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebt_iTI_zH6qgl7XTGMi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principal Payment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,806,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001463"
      unitRef="USD">7700400</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001465"
      unitRef="USD">25423731</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001467"
      unitRef="USD">7500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001469"
      unitRef="USD">40624131</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001471"
      unitRef="USD">-8818103</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001473"
      unitRef="USD">31806028</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001475">&lt;p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgKhPofBwg53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9. &lt;span id="xdx_82B_znBJ33Ohk4L1"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 26, 2026, the Company effected a &lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20260526__20260526_zU8bRuLHH6Jj" title="Reverse stock split"&gt;1-for-50&lt;/span&gt; reverse stock split for its common stock (the &#x201c;Reverse Stock Split&#x201d;), as described
in Note 2. All shares and per share amounts in these condensed consolidated financial statements and notes thereto have been retroactively
restated for all periods presented to reflect Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2026
Transactions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Consulting
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 13, 2026, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260113__20260113__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--HudsonGlobalVenturesLLCMember_zl17FLT4hr3g" title="Number of shares issued on service"&gt;24,490&lt;/span&gt; shares of its common stock to Hudson Global Ventures, LLC as consideration for consulting
services rendered to the Company. The fair value of the shares, determined based on the closing market price of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_c20260113__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--HudsonGlobalVenturesLLCMember_zuON2p8n2Seg" title="Share price"&gt;21&lt;/span&gt; per share on the
date of issuance, was $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260113__20260113__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--HudsonGlobalVenturesLLCMember_z04TbRTTFUji" title="Number of shares issued on service, value"&gt;514,285&lt;/span&gt;, which was recognized as consulting expense within general and administrative expenses in the condensed
consolidated statements of operations for the three and six months ended June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 4, 2026, the Company entered into a Marketing Services Agreement with Outside The Box Capital Inc. (&#x201c;OTB&#x201d;), pursuant
to which OTB agreed to provide marketing and distribution services to the Company for an initial term from March 5, 2026 through September
5, 2026. On May 20, 2026, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260520__20260520__us-gaap--TypeOfArrangementAxis__custom--MarketingServicesAgreementMember__dei--LegalEntityAxis__custom--BoxCapitalIncMember_zjXxMB7yMWoc" title="Number of shares issued on service"&gt;14,085&lt;/span&gt; shares of common stock to OTB in satisfaction of this obligation. The fair value
of the shares, based on the closing market price of $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20260520__us-gaap--TypeOfArrangementAxis__custom--MarketingServicesAgreementMember__dei--LegalEntityAxis__custom--BoxCapitalIncMember_z9vsWLl2RbT" title="Share price"&gt;10.63&lt;/span&gt; per share on the date of issuance, was $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260520__20260520__us-gaap--TypeOfArrangementAxis__custom--MarketingServicesAgreementMember__dei--LegalEntityAxis__custom--BoxCapitalIncMember_ztdTS2hKBdH1" title="Number of shares issued on service, value"&gt;149,718&lt;/span&gt;. The Company is recognizing
the fair value of the shares as expense within sales and marketing expenses in the condensed consolidated statements of operations over
the remaining term of the agreement. For the three and six months ended June 30, 2026, the Company recognized $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--MarketingServicesAgreementMember__dei--LegalEntityAxis__custom--BoxCapitalIncMember_zHsaTeg5UTf7" title="Expenses related to this agreement"&gt;&lt;span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--MarketingServicesAgreementMember__dei--LegalEntityAxis__custom--BoxCapitalIncMember_z3on9jgWPXeh" title="Expenses related to this agreement"&gt;93,990&lt;/span&gt;&lt;/span&gt; of expense related
to this agreement, with the remaining unamortized balance of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--MarketingServicesAgreementMember__dei--LegalEntityAxis__custom--BoxCapitalIncMember_zYI0goMH9s06" title="Unamortized debt expense"&gt;55,728&lt;/span&gt; recorded as a prepaid and other current assets in the condensed
consolidated balance sheets as of June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Settlement
Agreement &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 28, 2026, the Company entered into a Settlement Agreement and Stipulation with Silverback Capital Corporation (&#x201c;Silverback&#x201d;),
which was approved by the Circuit Court of the Twelfth Judicial Circuit in and for Desoto County, Florida on February 4, 2026, pursuant
to Section 3(a)(10) of the Securities Act of 1933. Under the terms of the settlement, the Company agreed to issue shares of its common
stock to Silverback, the proceeds from the resale of which were applied to satisfy certain outstanding obligations of the Company, including
vendor payables and notes payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the settlement, the Company issued shares to Silverback in three tranches. On February 12, 2026, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260212__20260212__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_z7ca9AN2rbN2" title="Number of shares issued"&gt;46,800&lt;/span&gt; shares
at an agreed settlement price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20260212__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zjaFKufNkLYj" title="Share price"&gt;12.50&lt;/span&gt; per share, for a total settlement value of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20260212__20260212__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_z9fbLNJcCHHb" title="Number of shares issued, value"&gt;$585,000&lt;/span&gt;. The fair value of the shares on the date
of issuance, based on the closing market price of $&lt;span id="xdx_904_ecustom--ClosingMarketSharePrice_iI_c20260212__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_z3KpONWtCh8h" title="Closing market share price"&gt;14&lt;/span&gt; per share, was $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20260212__20260212__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zq07cvTWWR85" title="Fair value of shares"&gt;655,200&lt;/span&gt;. On March 9, 2026, the Company issued an additional &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260309__20260309__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zaXjAThdCdi8" title="Number of shares issued"&gt;82,520&lt;/span&gt;
shares at an agreed settlement price of $&lt;span id="xdx_90D_ecustom--SettlementPrice_iI_c20260309__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zwaayAHBJwWk" title="Settlement price"&gt;12.50&lt;/span&gt; per share, for a total settlement value of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20260309__20260309__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zN6H6VuTDNIi" title="Settlement value"&gt;1,031,500&lt;/span&gt;. The fair value of the shares on
the date of issuance, based on the closing market price of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20260309__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zjCZBPqujV7e" title="Share price"&gt;8.50&lt;/span&gt; per share, was $&lt;span id="xdx_905_ecustom--FairValueOfClosingMarketPriceAmount_c20260309__20260309__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zEGwfRwpVMLd" title="Fair value of closing market price amount"&gt;701,420&lt;/span&gt;. The aggregate carrying amount of the obligations
settled through these two tranches exceeded the aggregate fair value of the shares issued, resulting in a net gain on debt extinguishment
of $&lt;span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_z0xVZGgksv78" title="Gain on debt extinguishment"&gt;259,880&lt;/span&gt;, which is included in other income in the condensed consolidated statements of operations for the three months ended March
31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 23, 2026, the Company issued an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260323__20260323__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zLrFVD122J7j" title="Number of shares issued"&gt;8,000 &lt;/span&gt;shares of its common stock to Silverback in two components &#x2014; &lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesIssuedForSettlementFees_c20260323__20260323__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zx91ytZ9ald7" title="Number of shares issued for settlement fees"&gt;2,000&lt;/span&gt; shares
as consideration for settlement fees and &lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesIssuedForLegalFees_c20260323__20260323__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zQDqGiP9R8o3" title="Number of shares issued as legal fees"&gt;6,000&lt;/span&gt; shares as consideration for legal fees incurred in connection with the settlement arrangement.
The fair value of the shares was determined based on the closing market price of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zgIAKduw6o46" title="Share price"&gt;6.50 &lt;/span&gt;per share on the date of issuance, resulting in
settlement fees of $&lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValueIssuedForSettlementFees_c20260323__20260323__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zlD16K53vCde" title="Number of shares issued as settlement fees, value"&gt;13,000&lt;/span&gt; recognized within other expenses and legal fees of $&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueIssuedForLegalFees_c20260323__20260323__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zv0GSqzKADWd" title="Number of shares issued as legal fees, value"&gt;39,000&lt;/span&gt; recognized within general and administrative expenses
in the condensed consolidated statements of operations for the three months ended March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 3, 2026, the Company delivered a termination letter to Silverback purporting to terminate the Settlement Agreement. In connection
with the purported termination, the Company issued an aggregate of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zDF5VZxdPQi1" title="Number of shares issued"&gt;125,465&lt;/span&gt; shares of common stock to Silverback during the three months
ended June 30, 2026 &#x2014; &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260408__20260408__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_z9XV6XK8K2Pk" title="Number of shares issued"&gt;40,000&lt;/span&gt; shares on April 8, 2026 and &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260410__20260410__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zx9BX8Co4Wmb" title="Number of shares issued"&gt;85,465&lt;/span&gt; shares on April 10, 2026 &#x2014; with an aggregate fair value of
$&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260403__20260403__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_z4hlJY23FTYe" title="Number of shares issued, value"&gt;766,392&lt;/span&gt;, based on closing market prices of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20260408__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_z0AE6CJJLBu9" title="Share price"&gt;6.34&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_c20260410__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_z0DtRGk1nrB2" title="Share price"&gt;6.00&lt;/span&gt; per share, respectively, on the applicable dates of issuance. The aggregate
fair value of these shares was recognized as a loss on contract termination fee within the condensed consolidated statements of operations
for the three and six months ended June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 18, 2026, the Company and Silverback entered into an Agreement Rescinding Termination and Reinstating Settlement Agreement, pursuant
to which the parties rescinded the April 3, 2026 termination letter and reinstated the Settlement Agreement in its entirety, effective
as of that date. Following reinstatement, on May 20, 2026, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260520__20260520__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFxBOUmlac7d" title="Number of shares issued"&gt;100,000&lt;/span&gt; shares of common stock to Silverback at an agreed
settlement price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20260520__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBcYHUHkby4f" title="Settlement price per share"&gt;3.25&lt;/span&gt; per share, in satisfaction of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260520__20260520__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FSQSUrx196" title="Number of shares issued, value"&gt;325,000&lt;/span&gt; of outstanding creditor claims under the Settlement Agreement. The fair
value of the shares issued, based on the closing market price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20260520__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRyQWgqKLmGb" title="Share price"&gt;6.45&lt;/span&gt; per share, was $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20260520__20260520__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7z9FbbwcAye" title="Fair value of shares issued"&gt;645,000&lt;/span&gt;, which exceeded the carrying amount of
the obligations settled, resulting in a loss on extinguishment of vendor obligation $&lt;span id="xdx_903_ecustom--LossOnExtinguishmentOfVendorObligation_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zDC6yAsLOk6d" title="Loss on extinguishment"&gt;&lt;span id="xdx_90C_ecustom--LossOnExtinguishmentOfVendorObligation_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--SilverbackCapitalCorpMember_zLPfFNVxsee8" title="Loss on extinguishment"&gt;320,000&lt;/span&gt;&lt;/span&gt;, which is included in other expense in the
condensed consolidated statements of operations for the three and six months ended June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accrued
Compensation Settlement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2026, the Board of Directors approved the settlement of accrued compensation obligations owed to our Chairman of the Board
and our President and Interim Chief Executive Officer through the issuance of equity securities. Pursuant to the settlement, the Company
issued &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260318__20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zUyDQpWxUjW3"&gt;100,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock to each individual, for an aggregate
of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesOther_c20260318__20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zcekYMDuT8D7" title="Aggregate number of shares"&gt;200,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares, together with &lt;/span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_znebC69hvx56" title="Warrants term"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;five-year
warrants to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zzpmJ4sQahG5"&gt;100,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock issued to each individual, for an aggregate
of &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zfvsGZqecr1g" title="Number of warrants"&gt;200,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants, originally exercisable at $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zQ0V81NPnOSe" title="Exercise price of warrants"&gt;0.50&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The shares were issued on March 31, 2026 pursuant
to Section 4(a)(2) of the Securities Act of 1933.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the shares on the date of issuance, based on the closing market price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zwcnq464Usi5" title="Share price"&gt;6.50&lt;/span&gt; per share, was $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueOther_c20260318__20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zFWjHft6dzt3" title="Fair value of shares"&gt;1,300,000&lt;/span&gt; in aggregate.
The fair value of the warrants on the date of issuance was $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20260318__20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zFaeKYGdlybh" title="Fair value of warrants"&gt;1,289,580&lt;/span&gt; in aggregate, determined using the Black-Scholes option pricing
model with the following assumptions: stock price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_z3TYlUsmsKkh" title="Stock price"&gt;6.50&lt;/span&gt;, exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zD7qRSBLsWGj" title="Exercise price"&gt;0.50&lt;/span&gt;, expected term of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260318__20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_z0hBm9zWWnG6" title="Expected term"&gt;5&lt;/span&gt; years, annualized volatility
of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260318__20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zeIagGLb2Pb6" title="Volatility"&gt;186.0&lt;/span&gt;%, risk-free interest rate of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260318__20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_ztfYBNhFF2z7" title="Risk-free interest rate"&gt;3.87&lt;/span&gt;%, and no expected dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate fair value of the equity consideration issued of $&lt;span id="xdx_90E_eus-gaap--EquityFairValueAdjustment_c20260318__20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zF4YjaUdJPG4" title="Aggregate fair value of the equity consideration"&gt;2,589,580&lt;/span&gt; was applied to settle accrued payroll expenses and accrued bonus
of $&lt;span id="xdx_909_eus-gaap--AccruedPayrollTaxesCurrentAndNoncurrent_iI_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zZEVrnPW275g" title="Accrued payroll expenses"&gt;2,000,000&lt;/span&gt;. The excess of the fair value of equity issued over the carrying amount of the obligations settled of $&lt;span id="xdx_900_eus-gaap--FairValueOptionIneligibleItemsAggregateCarryingAmount_iI_c20260318__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zFvnWnRVMBL3" title="Fair value carrying amount"&gt;589,580&lt;/span&gt; was recognized
as stock-based compensation expense within general and administrative expenses in the condensed consolidated statements of operations
for the three months ended March 31, 2026. The transaction was entirely non-cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended June 30, 2026, the exercise price of the warrants was reduced from $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember__srt--RangeAxis__srt--MaximumMember_zhLvkJnyoFPd" title="Exercise price"&gt;0.50&lt;/span&gt; to $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember__srt--RangeAxis__srt--MinimumMember_zEI3VUr1dkce" title="Exercise price"&gt;0.005&lt;/span&gt; per share. The Company accounted
for the change as a modification in accordance with ASC 718-20, and recognized the incremental fair value of $&lt;span id="xdx_90F_ecustom--IncrementalFairValue_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zTyfH8VQSLpe" title="Incremental fair value"&gt;10,031&lt;/span&gt;, determined using
the Black-Scholes option pricing model with the same assumptions as the original grant other than the revised exercise price, as stock-based
compensation expense within general and administrative expenses in the condensed consolidated statements of operations for the three
and six months ended June 30, 2026. Subsequent to the modification, each individual exercised their warrants in full, and the Company
issued an aggregate of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF8ASE2nVST" title="Number of shares issued"&gt;200,000&lt;/span&gt; shares of common stock for total cash proceeds of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7pApx6UpwGg" title="Number of shares issued, value"&gt;1,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2023
Equity Incentive Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted the 2023 Equity Incentive Plan (the &#x201c;Plan&#x201d;), which provides the issuance of up to &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260630__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThrereEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zy1E3r8Qi2W2" title="Number of shares issued"&gt;870,121&lt;/span&gt; shares of the Company&#x2019;s
common stock (the &#x201c;Initial Limit&#x201d;). Beginning on January 1, 2025, and on each January 1 thereafter, the number of shares
reserved for issuance under the Plan will automatically increase by an amount equal to three percent (3%) of the number of shares of
the Company&#x2019;s common stock outstanding on the immediately preceding December 31, or such lesser amount as may be determined by
the Plan&#x2019;s administrator (the &#x201c;Annual Increase&#x201d;). Shares issued under the Plan may be newly issued shares or reacquired
shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Plan permits the grant of various types of stock-based awards, including incentive stock options, non-qualified stock options, stock
appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares available for
issuance as incentive stock options may not exceed the Initial Limit, as adjusted for any Annual Increases, subject to adjustment as
provided under the terms of the Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
subject to awards that expire, are canceled, or otherwise terminate without having been exercised or settled in full will again become
available for future grant under the Plan. However, shares repurchased by the Company on the open market will not be added back to the
share reserve. Awards that may be settled solely in cash do not count against the share reserve.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Plan also includes a limitation on annual compensation to non-employee directors. The aggregate value of all equity awards granted to
any non-employee director under the Plan, together with any cash compensation paid for service as a non-employee director, may not exceed
(i) $&lt;span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20260101__20260630__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember__us-gaap--AwardDateAxis__custom--FirstCalendarYearMember_z4y4MZBzUUU2" title="Annual compensation"&gt;1,000,000&lt;/span&gt; in the first calendar year of service and (ii) $&lt;span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250701__20250701__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember__us-gaap--AwardDateAxis__custom--SubsequentCalandarYearMember_zf4INAu4WCWg" title="Annual compensation"&gt;750,000&lt;/span&gt; in any subsequent calendar year. The fair value of such awards
is determined based on grant date fair value in accordance with ASC Topic 718, excluding the impact of estimated forfeitures related
to service-based vesting conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Common Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zctc1tglw4Md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of restricted common stock activity for the six months ended June 30, 2026 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zFY15rlosze6" style="display: none"&gt;SCHEDULE OF RESTRICTED COMMON STOCKS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restricted &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Unvested shares as of December 31, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkXW74QkuPOf" title="Restricted Common Stock, Unvested shares, beginning balance"&gt;19,643&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zq1dFEDhk5b4" title="Weighted Average Fair Value, Unvested shares, beginning balance"&gt;131.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwpmvA57IO57" title="Restricted Common Stock, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkGhinNDMh4k" title="Weighted Average Fair Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1613"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zN9GFQJSEHHl" title="Restricted Common Stock, Vested"&gt;(8,929&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNwI96w6Bpv9" title="Weighted Average Fair Value, Vested"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Forfeited and cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFl6WiODAXW9" title="Restricted Common Stock, Forefeited and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zK06N8Fe3Tzj" title="Weighted Average Fair Value, Forefeited and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested shares as of June 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMd6qQ0gRIYi" title="Restricted Common Stock, Unvested shares ending balance"&gt;10,714&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNhsoOZFcpze" title="Weighted Average Fair Value, Unvested shares, ending balance"&gt;145.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zfGvixfkaske" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and six months ended June 30, 2026, the Company recognized stock-based compensation expense of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWNnkDpQhcN" title="Stock-based compensation expense"&gt;1,096,794&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNOswRVy4WTd" title="Stock-based compensation expense"&gt;1,291,878&lt;/span&gt;, respectively,
related to restricted common stock awards, included within general and administrative expenses in the condensed consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and six months ended June 30, 2025, the Company recognized $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNZOzf56ZRzh" title="Stock-based compensation expense"&gt;935,222&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfSP7QiEvZy9" title="Stock-based compensation expense"&gt;28,708,643&lt;/span&gt;, respectively, in stock-based compensation
expense in accordance with ASC 718, &lt;i&gt;Compensation &#x2014; Stock Compensation&lt;/i&gt;, based on the grant-date fair value of restricted
stock awards. Stock-based compensation expense for the three and six months ended June 30, 2025 included within sales and marketing expenses
was $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--SellingAndMarketingExpense_zgWduIGgEwke" title="Stock-based compensation expense"&gt;65,217&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--SellingAndMarketingExpense_zs53dQwhv0Ka" title="Stock-based compensation expense"&gt;400,000&lt;/span&gt;, respectively, and stock-based compensation expense included within general and administrative expenses was
$&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zzRzYy4liEa5" title="Stock-based compensation expense"&gt;870,005&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_z4Lj6xHgPWQ8" title="Stock-based compensation expense"&gt;28,308,643&lt;/span&gt;, respectively. The six months ended June 30, 2025 included $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7W5q4pQB2fk" title="Shares vesting"&gt;27,154,489&lt;/span&gt; attributable to the immediate vesting
of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250314__20250314__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkRe5RPReAH5" title="Shares granted"&gt;187,272 &lt;/span&gt;shares granted on March 14, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, total unrecognized compensation expense related to unvested restricted stock awards was $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeaKB350wef2" title="Unrecognized compensation expense"&gt;1,299,049&lt;/span&gt;, which is expected
to be recognized over a weighted-average remaining period of &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zY1aR82QuzLf" title="Weighted-average remaining period"&gt;2.32&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Unissued
Director Equity Awards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Company&#x2019;s non-employee director compensation policy, upon appointment to the Board of Directors, each non-employee director
is entitled to a grant of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260101__20260630__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember_zK5udWB00PVc"&gt;4,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of restricted common stock, vesting in equal installments
over a &lt;/span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20260101__20260630__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember_zyPxksgQsnck" title="Vesting period"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;three-year
period. These awards are accounted for as restricted stock units under ASC 718; the underlying shares are issued upon vesting rather
than at grant, and accordingly are not reflected in the table above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 4, 2026, the Company granted &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260204__20260204__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zj4KjwNOFBFe" title="Number of restriceted shares"&gt;4,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares under this policy to a newly appointed independent director,
vesting in equal annual installments over a &lt;/span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20260204__20260204__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zeZJVjFocrEa" title="Vesting period"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;three-year
period. The grant date fair value of the award was $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20260204__20260204__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zy7nDvWEiZN6" title="Number of restriceted shares, value"&gt;68,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
determined based on the closing market price of $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20260204__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zru5ZlCgBqQh" title="Share price"&gt;17.00&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share on the date of grant. In addition, the director an
annual equity award of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260204__20260204__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zQ3GJ1wZiNH4" title="Number of shares issued"&gt;1,200&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock under the Plan, issuable in arrears
following the end of each calendar year. As of June 30, 2026, no shares had been issued in connection with this annual equity award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 19, 2026, the Company granted &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260319__20260319__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zoszS3WYSYsh"&gt;4,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares under this policy to a second newly appointed independent
director, vesting in equal annual installments over a &lt;/span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20260319__20260319__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_z1IG43dYLxA4" title="Vesting period"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;four-year
period pursuant to the terms of that director&#x2019;s engagement letter. The grant date fair value of the award was $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20260319__20260319__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zNitdMRGeiS4" title="Number of restriceted shares, value"&gt;23,960&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
determined based on the closing market price of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20260319__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_z5FPZsn608ea" title="Share price"&gt;5.99&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share on the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and six months ended June 30, 2026, the Company recognized stock-based compensation expense of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20260401__20260630__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_z1D3BnKSHLwh" title="Stock-based compensation expense"&gt;7,335&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_c20260101__20260630__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_z5qI25K0C5sa" title="Stock-based compensation expense"&gt;10,748&lt;/span&gt;, respectively,
related to the unissued director equity awards described above, included within general and administrative expenses in the condensed
consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, total unrecognized compensation expense related to unissued director equity awards was $&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c20260101__20260630__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zUGTIGkePMlc" title="Unrecognized compensation expense"&gt;81,212&lt;/span&gt;, which is expected to
be recognized over a weighted-average remaining period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__srt--TitleOfIndividualAxis__custom--IndependentDirectorMember_zZYVoPymOkef" title="Weighted-average remaining period"&gt;3.16&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zdHv9u70rFdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of warrant activity for the six months ended June 30, 2026 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z5DCfsoSVx7b" style="display: none"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Outstanding, December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260630_zFeGdvAkMMgb" title="Warrants, Outstanding, Beginning balance"&gt;87,200&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWeightedAverageExercisePrice_iS_c20260101__20260630_zIaXX9UW1Df3" title="Weighted Average Excerise Price, Outstanding, Beginning balance"&gt;36.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260630_zo3ACnvh9ZOa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Issued"&gt;9,555,155&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630_zdiw1c53so4g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Excerise Price, Issued"&gt;6.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20260101__20260630_z39QBbqU2c5c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Excercised"&gt;(200,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630_z7BjvZ9x2rxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Excerise Price, Excercised"&gt;0.005&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Expired and cancelled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20260101__20260630_zMrXOQhvzzu6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Expired and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630_z8lV9R5qhuFc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Excerise Price, Expired and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1695"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Unvested shares as of June 30, 2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260630_zwthK3PLktt2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Unvested shares"&gt;9,442,355&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWeightedAverageExercisePrice_iE_pid_c20260101__20260630_zxdWoNk8FtC2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Excerise Price, Unvested shares"&gt;7.31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zb4u2a6Or5wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 20, 2026, the Company issued &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_zNbbxE3mjxl6" title="Number of warrants issued"&gt;21,953&lt;/span&gt; warrants to the placement agent and its designees in connection with the convertible note
offering at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_z2bEJhsYGVV7" title="Exercise price"&gt;0.41&lt;/span&gt; per share, expiring &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_z5ZhM5KGIZWa" title="Wwarrants maturity date"&gt;January 20, 2031&lt;/span&gt;. The fair value of these warrants, determined using the Black-Scholes
option pricing model, was $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20260120__20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_zMl0gF7U4orl" title="Fair value of warrants"&gt;416,965&lt;/span&gt; in aggregate, based on a stock price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_z0UtLQo9QnV8" title="Stock price"&gt;19.50&lt;/span&gt; per share, exercise price of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_zGdsJC14G5Bk" title="Eexercise price"&gt;20.50&lt;/span&gt;, expected term
of &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_z6aher3DlZcb" title="Expected term"&gt;5.00&lt;/span&gt; years, expected volatility of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_z8uSsvL3mYf8" title="Volatility"&gt;196.9&lt;/span&gt;%, risk-free interest rate of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260120__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_zHBFLhTUfL21" title="Risk-free interest rate"&gt;3.86&lt;/span&gt;%, and no expected dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2026, the Company issued an aggregate of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zkCgl4mQZCNj" title="Warrants issued"&gt;200,000&lt;/span&gt; warrants to our Chairman of the Board and our President and Interim Chief
Executive Officer in connection with the settlement of accrued compensation obligations, exercisable at $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zwL7198O37th" title="Exercise price"&gt;0.50&lt;/span&gt; per share and expiring
&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zQ9Nyrm2SPml" title="Wwarrants maturity date"&gt;March 18, 2031&lt;/span&gt;. The fair value of the warrants, determined using the Black-Scholes option pricing model, was $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20260318__20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zDMAsQUiW7Qj" title="Fair value of warrants"&gt;1,289,580&lt;/span&gt; in aggregate,
$&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zgIVsLuXc035" title="Warrants Price"&gt;6.45&lt;/span&gt; per warrant, based on a stock price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zgibmxZvsoSc" title="Stock price"&gt;6.50&lt;/span&gt; per share, exercise price of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zNnIpE7vvWqf" title="Eexercise price"&gt;0.50&lt;/span&gt;, expected term of &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260318__20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zWnxt5ytl1Ya" title="Expected term"&gt;5.00&lt;/span&gt; years, expected volatility
of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260318__20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_z4GAeIIjXNOa" title="Volatility"&gt;186.0&lt;/span&gt;%, risk-free interest rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260318__20260318__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_z9HDv07bXtTl" title="Risk-free interest rate"&gt;3.87&lt;/span&gt;%, and no expected dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended June 30, 2026, the exercise price of these warrants was reduced to $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zCzvoKm0lLC6" title="Eexercise price"&gt;0.005&lt;/span&gt; per share. The Company accounted for
the change as a modification in accordance with ASC 718-20, and recognized incremental fair value of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zbqgw5X69wO7" title="Stock-based compensation expense"&gt;10,031&lt;/span&gt; as stock-based compensation
expense within general and administrative expenses in the condensed consolidated statements of operations. Subsequent to the modification,
each holder exercised their warrants in full, and the Company issued an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zLAZ2ZjaAoOg" title="Number of shares issued"&gt;200,000&lt;/span&gt; shares of common stock for total cash proceeds
of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_zGuSx0pLXf66" title="Number of shares issued, value"&gt;1,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 27, 2026, in connection with the Note Purchase Agreement described in Note 8, the Company issued warrants to purchase an aggregate
of &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260527__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_za49PagmTywb" title="Warrants to purchase common stock"&gt;7,914,758&lt;/span&gt; shares of common stock to participating investors, exercisable at $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260527__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPMrmZfmsEX6" title="Warrants exercisable"&gt;7.50&lt;/span&gt; per share, and warrants to purchase an aggregate
of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260527__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_zDswmSfHiF5d" title="Warrants to purchase common stock"&gt;1,418,444&lt;/span&gt; shares of common stock to the placement agent and its designees, exercisable at $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260527__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PlacementAgentAndItsDesigneesMember_z6vD0j5ksME8" title="Warrants exercisable"&gt;4.275&lt;/span&gt; per share, in each case expiring
five years from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDUyXobDhGHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of warrants
issued during the three months ended June 30, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zsRqf8G6UUo3"&gt;SCHEDULE
OF FAIR VALUE OF WARRANTS&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PIPE Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PA Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zU7vOHMPzKG4" title="Stock price"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zE0UnUoDNBB9" title="Stock price"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zCtW3o10Wim2" title="Eexercise price"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zhO7Zh5fKWF8" title="Eexercise price"&gt;4.275&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zabJwUd9WA0l" title="Risk-free interest rate"&gt;4.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zoaSXHSqp2Fk" title="Risk-free interest rate"&gt;4.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zcYaXVSS59fe" title="Expected term (in years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_za2mrFEsX8Tj" title="Expected term (in years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zUYm3EtP5229" title="Expected volatility"&gt;78.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zdTUMJcTfjZk" title="Expected volatility"&gt;78.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_z0mBS0iLH3lg" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zKI3vsEygtTc" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zBRTJ4mIm9re" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-05-262026-05-26" id="Fact001477">1-for-50</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2026-01-132026-01-13_custom_ConsultingAgreementMember_custom_HudsonGlobalVenturesLLCMember"
      decimals="INF"
      id="Fact001479"
      unitRef="Shares">24490</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-13_custom_ConsultingAgreementMember_custom_HudsonGlobalVenturesLLCMember"
      decimals="INF"
      id="Fact001481"
      unitRef="USDPShares">21</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-01-132026-01-13_custom_ConsultingAgreementMember_custom_HudsonGlobalVenturesLLCMember"
      decimals="0"
      id="Fact001483"
      unitRef="USD">514285</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2026-05-202026-05-20_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember"
      decimals="INF"
      id="Fact001485"
      unitRef="Shares">14085</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2026-05-20_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember"
      decimals="INF"
      id="Fact001487"
      unitRef="USDPShares">10.63</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-05-202026-05-20_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">149718</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-04-012026-06-30_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember"
      decimals="0"
      id="Fact001491"
      unitRef="USD">93990</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-01-012026-06-30_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember"
      decimals="0"
      id="Fact001493"
      unitRef="USD">93990</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2026-06-30_custom_MarketingServicesAgreementMember_custom_BoxCapitalIncMember"
      decimals="0"
      id="Fact001495"
      unitRef="USD">55728</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-02-122026-02-12_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001497"
      unitRef="Shares">46800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-02-12_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001499"
      unitRef="USDPShares">12.50</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-02-122026-02-12_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001501"
      unitRef="USD">585000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <MEDS:ClosingMarketSharePrice
      contextRef="AsOf2026-02-12_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001503"
      unitRef="USDPShares">14</MEDS:ClosingMarketSharePrice>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-02-122026-02-12_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001505"
      unitRef="USD">655200</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-03-092026-03-09_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Shares">82520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <MEDS:SettlementPrice
      contextRef="AsOf2026-03-09_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001509"
      unitRef="USDPShares">12.50</MEDS:SettlementPrice>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-03-092026-03-09_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001511"
      unitRef="USD">1031500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-09_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001513"
      unitRef="USDPShares">8.50</us-gaap:SharePrice>
    <MEDS:FairValueOfClosingMarketPriceAmount
      contextRef="From2026-03-092026-03-09_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001515"
      unitRef="USD">701420</MEDS:FairValueOfClosingMarketPriceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-012026-03-31_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001517"
      unitRef="USD">259880</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-03-232026-03-23_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001519"
      unitRef="Shares">8000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <MEDS:StockIssuedDuringPeriodSharesIssuedForSettlementFees
      contextRef="From2026-03-232026-03-23_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001521"
      unitRef="Shares">2000</MEDS:StockIssuedDuringPeriodSharesIssuedForSettlementFees>
    <MEDS:StockIssuedDuringPeriodSharesIssuedForLegalFees
      contextRef="From2026-03-232026-03-23_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001523"
      unitRef="Shares">6000</MEDS:StockIssuedDuringPeriodSharesIssuedForLegalFees>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-31_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001525"
      unitRef="USDPShares">6.50</us-gaap:SharePrice>
    <MEDS:StockIssuedDuringPeriodValueIssuedForSettlementFees
      contextRef="From2026-03-232026-03-23_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001527"
      unitRef="USD">13000</MEDS:StockIssuedDuringPeriodValueIssuedForSettlementFees>
    <MEDS:StockIssuedDuringPeriodValueIssuedForLegalFees
      contextRef="From2026-03-232026-03-23_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001529"
      unitRef="USD">39000</MEDS:StockIssuedDuringPeriodValueIssuedForLegalFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-04-012026-06-30_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001531"
      unitRef="Shares">125465</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-04-082026-04-08_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001533"
      unitRef="Shares">40000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-04-102026-04-10_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001535"
      unitRef="Shares">85465</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-04-032026-04-03_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001537"
      unitRef="USD">766392</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-04-08_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001539"
      unitRef="USDPShares">6.34</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2026-04-10_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="INF"
      id="Fact001541"
      unitRef="USDPShares">6.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-05-202026-05-20_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001543"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2026-05-20_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001545"
      unitRef="USDPShares">3.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-05-202026-05-20_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001547"
      unitRef="USD">325000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-05-20_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001549"
      unitRef="USDPShares">6.45</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2026-05-202026-05-20_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001551"
      unitRef="USD">645000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <MEDS:LossOnExtinguishmentOfVendorObligation
      contextRef="From2026-01-012026-06-30_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001553"
      unitRef="USD">320000</MEDS:LossOnExtinguishmentOfVendorObligation>
    <MEDS:LossOnExtinguishmentOfVendorObligation
      contextRef="From2026-04-012026-06-30_custom_SettlementAgreementMember_custom_SilverbackCapitalCorpMember"
      decimals="0"
      id="Fact001555"
      unitRef="USD">320000</MEDS:LossOnExtinguishmentOfVendorObligation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001556"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001558"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      id="Fact001560">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001561"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001563"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001565"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001567"
      unitRef="USDPShares">6.50</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001569"
      unitRef="USD">1300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">1289580</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001573"
      unitRef="USDPShares">6.50</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001575"
      unitRef="USDPShares">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      id="Fact001577">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001579"
      unitRef="Pure">1.860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001581"
      unitRef="Pure">0.0387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EquityFairValueAdjustment
      contextRef="From2026-03-182026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001583"
      unitRef="USD">2589580</us-gaap:EquityFairValueAdjustment>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001585"
      unitRef="USD">2000000</us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent>
    <us-gaap:FairValueOptionIneligibleItemsAggregateCarryingAmount
      contextRef="AsOf2026-03-18_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001587"
      unitRef="USD">589580</us-gaap:FairValueOptionIneligibleItemsAggregateCarryingAmount>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001589"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001591"
      unitRef="USDPShares">0.005</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <MEDS:IncrementalFairValue
      contextRef="From2026-01-012026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001593"
      unitRef="USD">10031</MEDS:IncrementalFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001595"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-06-30_custom_SettlementAgreementMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001597"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-06-30_custom_TwoThousandTwentyThrereEquityIncentivePlanMember_srt_MaximumMember"
      decimals="0"
      id="Fact001599"
      unitRef="USD">870121</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2026-01-012026-06-30_custom_NonEmployeeDirectorMember_custom_FirstCalendarYearMember"
      decimals="0"
      id="Fact001601"
      unitRef="USD">1000000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-07-012025-07-01_custom_NonEmployeeDirectorMember_custom_SubsequentCalandarYearMember"
      decimals="0"
      id="Fact001603"
      unitRef="USD">750000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001605">&lt;p id="xdx_89B_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zctc1tglw4Md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of restricted common stock activity for the six months ended June 30, 2026 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zFY15rlosze6" style="display: none"&gt;SCHEDULE OF RESTRICTED COMMON STOCKS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restricted &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Unvested shares as of December 31, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkXW74QkuPOf" title="Restricted Common Stock, Unvested shares, beginning balance"&gt;19,643&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zq1dFEDhk5b4" title="Weighted Average Fair Value, Unvested shares, beginning balance"&gt;131.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwpmvA57IO57" title="Restricted Common Stock, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkGhinNDMh4k" title="Weighted Average Fair Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1613"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zN9GFQJSEHHl" title="Restricted Common Stock, Vested"&gt;(8,929&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNwI96w6Bpv9" title="Weighted Average Fair Value, Vested"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Forfeited and cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFl6WiODAXW9" title="Restricted Common Stock, Forefeited and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zK06N8Fe3Tzj" title="Weighted Average Fair Value, Forefeited and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested shares as of June 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMd6qQ0gRIYi" title="Restricted Common Stock, Unvested shares ending balance"&gt;10,714&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNhsoOZFcpze" title="Weighted Average Fair Value, Unvested shares, ending balance"&gt;145.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001607"
      unitRef="Shares">19643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001609"
      unitRef="USDPShares">131.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001615"
      unitRef="Shares">8929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001617"
      unitRef="USDPShares">115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2026-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001623"
      unitRef="Shares">10714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2026-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001625"
      unitRef="USDPShares">145.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-04-012026-06-30_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001627"
      unitRef="USD">1096794</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001629"
      unitRef="USD">1291878</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001631"
      unitRef="USD">935222</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001633"
      unitRef="USD">28708643</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockMember_us-gaap_SellingAndMarketingExpense"
      decimals="0"
      id="Fact001635"
      unitRef="USD">65217</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockMember_us-gaap_SellingAndMarketingExpense"
      decimals="0"
      id="Fact001637"
      unitRef="USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockMember_us-gaap_GeneralAndAdministrativeExpense"
      decimals="0"
      id="Fact001639"
      unitRef="USD">870005</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockMember_us-gaap_GeneralAndAdministrativeExpense"
      decimals="0"
      id="Fact001641"
      unitRef="USD">28308643</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001643"
      unitRef="USD">27154489</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-03-142025-03-14_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001645"
      unitRef="Shares">187272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001647"
      unitRef="USD">1299049</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-01-012026-06-30_us-gaap_RestrictedStockMember"
      id="Fact001649">P2Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2026-01-012026-06-30_custom_NonEmployeeDirectorMember"
      decimals="INF"
      id="Fact001650"
      unitRef="Shares">4000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2026-01-012026-06-30_custom_NonEmployeeDirectorMember"
      id="Fact001652">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2026-02-042026-02-04_custom_IndependentDirectorMember"
      decimals="INF"
      id="Fact001654"
      unitRef="Shares">4000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2026-02-042026-02-04_custom_IndependentDirectorMember"
      id="Fact001656">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2026-02-042026-02-04_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001658"
      unitRef="USD">68000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharePrice
      contextRef="AsOf2026-02-04_custom_IndependentDirectorMember"
      decimals="INF"
      id="Fact001660"
      unitRef="USDPShares">17.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-02-042026-02-04_custom_IndependentDirectorMember"
      decimals="INF"
      id="Fact001662"
      unitRef="Shares">1200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2026-03-192026-03-19_custom_IndependentDirectorMember"
      decimals="INF"
      id="Fact001663"
      unitRef="Shares">4000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2026-03-192026-03-19_custom_IndependentDirectorMember"
      id="Fact001665">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2026-03-192026-03-19_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001667"
      unitRef="USD">23960</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-19_custom_IndependentDirectorMember"
      decimals="INF"
      id="Fact001669"
      unitRef="USDPShares">5.99</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-04-012026-06-30_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001671"
      unitRef="USD">7335</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-012026-06-30_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001673"
      unitRef="USD">10748</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2026-01-012026-06-30_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact001675"
      unitRef="USD">81212</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-01-012026-06-30_custom_IndependentDirectorMember"
      id="Fact001677">P3Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001679">&lt;p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zdHv9u70rFdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of warrant activity for the six months ended June 30, 2026 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z5DCfsoSVx7b" style="display: none"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Outstanding, December 31, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260630_zFeGdvAkMMgb" title="Warrants, Outstanding, Beginning balance"&gt;87,200&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWeightedAverageExercisePrice_iS_c20260101__20260630_zIaXX9UW1Df3" title="Weighted Average Excerise Price, Outstanding, Beginning balance"&gt;36.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260630_zo3ACnvh9ZOa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Issued"&gt;9,555,155&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630_zdiw1c53so4g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Excerise Price, Issued"&gt;6.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20260101__20260630_z39QBbqU2c5c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Excercised"&gt;(200,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630_z7BjvZ9x2rxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Excerise Price, Excercised"&gt;0.005&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Expired and cancelled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20260101__20260630_zMrXOQhvzzu6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Expired and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630_z8lV9R5qhuFc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Excerise Price, Expired and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1695"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Unvested shares as of June 30, 2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260630_zwthK3PLktt2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Unvested shares"&gt;9,442,355&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWeightedAverageExercisePrice_iE_pid_c20260101__20260630_zxdWoNk8FtC2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Excerise Price, Unvested shares"&gt;7.31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001681"
      unitRef="Shares">87200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <MEDS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001683"
      unitRef="USDPShares">36.00</MEDS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact001685"
      unitRef="Shares">9555155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <MEDS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact001687"
      unitRef="USDPShares">6.90</MEDS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact001689"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <MEDS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2026-01-01to2026-06-30"
      decimals="INF"
      id="Fact001691"
      unitRef="USDPShares">0.005</MEDS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact001697"
      unitRef="Shares">9442355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <MEDS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWeightedAverageExercisePrice
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact001699"
      unitRef="USDPShares">7.31</MEDS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      decimals="INF"
      id="Fact001701"
      unitRef="Shares">21953</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      decimals="INF"
      id="Fact001703"
      unitRef="USDPShares">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      id="Fact001705">2031-01-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-01-202026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      decimals="0"
      id="Fact001707"
      unitRef="USD">416965</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      decimals="INF"
      id="Fact001709"
      unitRef="USDPShares">19.50</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      decimals="INF"
      id="Fact001711"
      unitRef="USDPShares">20.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-01-012026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      id="Fact001713">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-01-012026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      decimals="INF"
      id="Fact001715"
      unitRef="Pure">1.969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-01-012026-01-20_custom_PlacementAgentAndItsDesigneesMember"
      decimals="INF"
      id="Fact001717"
      unitRef="Pure">0.0386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001719"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001721"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      id="Fact001723">2031-03-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-03-182026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001725"
      unitRef="USD">1289580</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001727"
      unitRef="USDPShares">6.45</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001729"
      unitRef="USDPShares">6.50</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001731"
      unitRef="USDPShares">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-03-182026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      id="Fact001733">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-03-182026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001735"
      unitRef="Pure">1.860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-03-182026-03-18_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001737"
      unitRef="Pure">0.0387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2026-06-30_us-gaap_WarrantMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001739"
      unitRef="USDPShares">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001741"
      unitRef="USD">10031</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-06-30_us-gaap_CommonStockMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001743"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-06-30_us-gaap_CommonStockMember_custom_ChairmanOfTheBoardPresidentAndInterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001745"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-05-27_us-gaap_CommonStockMember_custom_NotePurchaseAgreementMember"
      decimals="INF"
      id="Fact001747"
      unitRef="Shares">7914758</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-05-27_custom_NotePurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001749"
      unitRef="USDPShares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-05-27_us-gaap_CommonStockMember_custom_NotePurchaseAgreementMember_custom_PlacementAgentAndItsDesigneesMember"
      decimals="INF"
      id="Fact001751"
      unitRef="Shares">1418444</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-05-27_us-gaap_CommonStockMember_custom_NotePurchaseAgreementMember_custom_PlacementAgentAndItsDesigneesMember"
      decimals="INF"
      id="Fact001753"
      unitRef="USDPShares">4.275</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001755">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDUyXobDhGHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of warrants
issued during the three months ended June 30, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zsRqf8G6UUo3"&gt;SCHEDULE
OF FAIR VALUE OF WARRANTS&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PIPE Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PA Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zU7vOHMPzKG4" title="Stock price"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zE0UnUoDNBB9" title="Stock price"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zCtW3o10Wim2" title="Eexercise price"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zhO7Zh5fKWF8" title="Eexercise price"&gt;4.275&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zabJwUd9WA0l" title="Risk-free interest rate"&gt;4.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zoaSXHSqp2Fk" title="Risk-free interest rate"&gt;4.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zcYaXVSS59fe" title="Expected term (in years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_za2mrFEsX8Tj" title="Expected term (in years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_zUYm3EtP5229" title="Expected volatility"&gt;78.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zdTUMJcTfjZk" title="Expected volatility"&gt;78.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PrivateInvestmentPublicEquityWarrantMember_z0mBS0iLH3lg" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantsMember_zKI3vsEygtTc" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2026-06-30_us-gaap_WarrantMember_custom_PrivateInvestmentPublicEquityWarrantMember"
      decimals="INF"
      id="Fact001757"
      unitRef="USDPShares">3.16</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2026-06-30_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001759"
      unitRef="USDPShares">3.16</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2026-06-30_us-gaap_WarrantMember_custom_PrivateInvestmentPublicEquityWarrantMember"
      decimals="INF"
      id="Fact001761"
      unitRef="USDPShares">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2026-06-30_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001763"
      unitRef="USDPShares">4.275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PrivateInvestmentPublicEquityWarrantMember"
      decimals="INF"
      id="Fact001765"
      unitRef="Pure">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001767"
      unitRef="Pure">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PrivateInvestmentPublicEquityWarrantMember"
      id="Fact001769">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember"
      id="Fact001771">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PrivateInvestmentPublicEquityWarrantMember"
      decimals="INF"
      id="Fact001773"
      unitRef="Pure">0.780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001775"
      unitRef="Pure">0.780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PrivateInvestmentPublicEquityWarrantMember"
      decimals="INF"
      id="Fact001777"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2026-01-012026-06-30_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001779"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:TransactionBetweenEntitiesUnderCommonControlTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001781">&lt;p id="xdx_803_eus-gaap--TransactionBetweenEntitiesUnderCommonControlTextBlock_z9Axt2faxgKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10. &lt;span id="xdx_823_z8VPMb0MUTKf"&gt;PROPOSED TRANSACTION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 20, 2026, the Company entered into a Fully Binding Term Sheet, dated May 18, 2026, with EOS Technology Holdings, Inc. (&#x201c;EOS&#x201d;),
Scilex Holding Company (&#x201c;Scilex&#x201d;), Datavault AI Inc. (&#x201c;Datavault&#x201d;), HealthBridge Advisors, LLC (&#x201c;HBA&#x201d;),
and Fortitude Advisors, LLC (&#x201c;Fortitude&#x201d;). On July 29, 2026, the Company entered into an Amended and Restated Letter of Intent
(the &#x201c;LOI&#x201d;) with EOS, Scilex, Datavault, and HBA, which superseded and replaced the Term Sheet in its entirety. Fortitude
is not a party to the LOI, although the proposed transaction contemplates certain rights and obligations relating to Fortitude, as described
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the LOI, and subject to the negotiation and execution of definitive agreements, the Company would acquire or exclusively license certain
intellectual property assets from EOS and Scilex, expand its existing license arrangement with Datavault to include Datavault AI Health,
and acquire a controlling interest in Tollo Health, LLC through an exchange of membership interests with HBA, the controlling member
of Tollo Health, LLC. Consideration under the LOI consists solely of shares of the Company&#x2019;s common stock (&#x201c;Acquisition Stock&#x201d;).
No preferred stock, convertible securities, or contingent conversion features would be issued as consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
issuance of &lt;span id="xdx_90C_eus-gaap--SaleOfStockDescriptionOfTransaction_c20260520__20260520_zpCAsYSM2MP7" title="Description of transaction"&gt;the Acquisition Stock, EOS, Scilex, Datavault, and HBA are expected to own, in the aggregate, approximately 84.6% of the
Company&#x2019;s common stock, consisting of 19.9% for each of EOS, Scilex, and Datavault, and 24.9% for HBA. Fortitude is expected to
own approximately 5.0%, and the Company&#x2019;s existing public stockholders are expected to hold the remaining approximately 10.4%.
These percentages represent target post-closing ownership on a fully diluted basis and are subject to adjustment for a liability reduction
framework, financing transactions, conversion or settlement of convertible debt, transaction expenses, and other adjustments to be set
forth in the definitive agreements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
LOI contemplates that the Company will use one or more liability reduction or financing transactions to address outstanding Company liabilities
prior to closing. The LOI further contemplates that the definitive agreements will include a registration rights agreement covering the
resale of the Acquisition Stock, post-closing transfer restrictions, including a six-month lock-up period for certain holders, and certain
management and board changes, including the appointment of two new management team members and four board designees following closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Completion
of the proposed transaction is subject to a number of conditions, including completion of due diligence, negotiation and execution of
definitive agreements, receipt of a fairness opinion, approval by the Company&#x2019;s board of directors, applicable stockholder approvals,
availability of financing, and satisfaction of Nasdaq requirements, including approval of an initial listing application if the transaction
is treated as a change of control under Nasdaq Listing Rule 5110(a). Under the exclusivity provisions of the LOI, the parties have agreed
to negotiate exclusively with one another through September 30, 2026, subject to a 30-day due diligence period during which the Company
may terminate the LOI under specified circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, the Company had not entered into definitive agreements with respect to the proposed transaction. No Acquisition Stock
had been issued, and no assets, liabilities, or other financial statement effects had been recorded in connection with the Term Sheet
or the LOI. There can be no assurance that definitive agreements will be entered into, that the required approvals or financing will
be obtained, or that the proposed transaction will be consummated on the terms described above, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TransactionBetweenEntitiesUnderCommonControlTextBlock>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="From2026-05-202026-05-20" id="Fact001783">the Acquisition Stock, EOS, Scilex, Datavault, and HBA are expected to own, in the aggregate, approximately 84.6% of the
Company&#x2019;s common stock, consisting of 19.9% for each of EOS, Scilex, and Datavault, and 24.9% for HBA. Fortitude is expected to
own approximately 5.0%, and the Company&#x2019;s existing public stockholders are expected to hold the remaining approximately 10.4%.
These percentages represent target post-closing ownership on a fully diluted basis and are subject to adjustment for a liability reduction
framework, financing transactions, conversion or settlement of convertible debt, transaction expenses, and other adjustments to be set
forth in the definitive agreements.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001785">&lt;p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_z6zNyghi80mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11.&lt;span id="xdx_82D_z9MC7W2r1KP2"&gt; LEASE OBLIGATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
is classified by function on the consolidated statements of operations as general and administrative.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is or contains a lease at inception by evaluating potential lease agreements including services
and operating agreements to determine whether an identified asset exists that the Company controls over the term of the arrangement.
Lease commencement is determined to be when the lessor provides access to, and the right to control, the identified asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
rental payments for the Company&#x2019;s leases are typically structured as either fixed or variable payments. Fixed rent payments include
stated minimum rent and stated minimum rent with stated increases. The Company considers lease payments that cannot be predicted with
reasonable certainty upon lease commencement to be variable lease payments, which are recorded as incurred each period and are excluded
from the calculation of lease liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2024, the Company entered into a lease agreement for office space in Tampa, Florida. As a result, the Company recognized a right-of-use
asset and corresponding lease liability, calculated using a discount rate of &lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20240531__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zyXkRPBpFi93" title="Discount rate"&gt;8.36&lt;/span&gt;%. The lease includes a monthly base rent of $&lt;span id="xdx_90F_eus-gaap--PaymentsForRent_c20240501__20240531__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGx1DphS3sD7" title="Monthly base rent"&gt;18,792&lt;/span&gt;
and expired in June 2027. The lease required a security deposit by Wellgistics Health of $&lt;span id="xdx_90B_eus-gaap--SecurityDeposit_iI_c20240531__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zPie23Jmfyqb" title="Security deposit"&gt;35,855&lt;/span&gt; and Wellgistics, LLC of $&lt;span id="xdx_90F_eus-gaap--SecurityDeposit_iI_c20240531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WellgisticsLLCMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGFREi6HErLa" title="Security deposit"&gt;31,871&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 9, 2023, Intergra Pharma Solutions entered into First amendment to the Vector Collective lease, which is sublease to Wellgistics
Pharmacy. The lease includes a monthly base rent of $&lt;span id="xdx_909_eus-gaap--PaymentsForRent_pp2d_c20230609__20230609__dei--LegalEntityAxis__custom--IntergraPharmaSolutionsMember_zjMpCpQRMV4j" title="Monthly base rent"&gt;4,714.41&lt;/span&gt; from and after November 16, 2023 and expires on &lt;span id="xdx_90E_eus-gaap--LeaseExpirationDate1_dd_c20230609__20230609__dei--LegalEntityAxis__custom--IntergraPharmaSolutionsMember_z2cZJx4AlMIf" title="Expiration date"&gt;November 15, 2026&lt;/span&gt;. A right-of-use
asset and corresponding lease liability recognized calculated using a discount rate of &lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230609__dei--LegalEntityAxis__custom--IntergraPharmaSolutionsMember_z5bJ2gypp1qd" title="Discount rate"&gt;8.36&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2022, Wellgistics LLC entered into lease agreement for warehousing facility located in Lefrois, Florida, which has a lease term
of &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220131__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z9TBQhkv3VCa" title="Lease term"&gt;75&lt;/span&gt; months, set to expire in March 2028, with a monthly base rent of $&lt;span id="xdx_907_eus-gaap--PaymentsForRent_c20220101__20220131__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zAUyqym9MOvl" title="Monthly base rent"&gt;26,303&lt;/span&gt;. Wellgistics LLC recognized a right-of-use asset and corresponding
lease liability, calculated using a discount rate of&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20220131__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zd6baEp8kmtf" title="Discount rate"&gt; 6.21&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--OperatingLeasesOfLesseeTableTextBlock_zbOGT3ExXQI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the summary of operating lease assets and liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zxvcOP14xJV" style="display: none"&gt;SCHEDULE
OF OPERATING LEASE ASSETS AND LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260630_zjIewfS2bX4j" style="text-align: center; font-weight: bold"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20251231_z6wziiPrTrB6" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2026&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-weight: bold; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zhG7hHncbLfc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;719,645&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;966,893&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzBRA_zwwx7kg8l2sa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities, current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;566,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;569,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzBRA_znfTXMoOHZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Long-term lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;249,840&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;527,122&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzBRA_zeIDQBJHWoX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;816,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,096,373&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted Average Remaining Lease Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260630_zOKO0kDhAhV5" title="Weighted average remaining lease term"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z0zeDyoRMV1f" title="Weighted average remaining lease term"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted Average Discount Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260630_zUUJfypzttj1" title="Weighted average discount rate"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zFHrSiCwE8Ga" title="Weighted average discount rate"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z0hJTXPIiI9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zPF8F8sSHWai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the summary of future minimum payments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z8WL0THrRhZf" style="display: none"&gt;SCHEDULE OF SUMMARY OF FUTURE MINIMUM PAYMENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260630_zFaAyaeW95l2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOLLzeCb_zYDvRdvJ7Buk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;2026 (remaining 6 months)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;310,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzeCb_zQNdvqwqtSoh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzeCb_zsnkBsu0dPo2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;84,976&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzeCb_maLOLLPzoP8_zmYBXUMBEKr5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;854,073&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--LesseeOperatingLeaseLiabilityImputedInterest_iNI_di_msLOLLPzoP8_zRcXth1UGNZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(37,854&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzoP8_zSBeL0GHTjQa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;816,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zn0f3z1aThp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-05-31_custom_LeaseAgreementMember"
      decimals="INF"
      id="Fact001787"
      unitRef="Pure">0.0836</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:PaymentsForRent
      contextRef="From2024-05-012024-05-31_custom_LeaseAgreementMember"
      decimals="0"
      id="Fact001789"
      unitRef="USD">18792</us-gaap:PaymentsForRent>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2024-05-31_custom_LeaseAgreementMember"
      decimals="0"
      id="Fact001791"
      unitRef="USD">35855</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2024-05-31_custom_WellgisticsLLCMember_custom_LeaseAgreementMember"
      decimals="0"
      id="Fact001793"
      unitRef="USD">31871</us-gaap:SecurityDeposit>
    <us-gaap:PaymentsForRent
      contextRef="From2023-06-092023-06-09_custom_IntergraPharmaSolutionsMember"
      decimals="2"
      id="Fact001795"
      unitRef="USD">4714.41</us-gaap:PaymentsForRent>
    <us-gaap:LeaseExpirationDate1
      contextRef="From2023-06-092023-06-09_custom_IntergraPharmaSolutionsMember"
      id="Fact001797">2026-11-15</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-06-09_custom_IntergraPharmaSolutionsMember"
      decimals="INF"
      id="Fact001799"
      unitRef="Pure">0.0836</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2022-01-31_custom_LeaseAgreementMember"
      id="Fact001801">P75M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-01-31_custom_LeaseAgreementMember"
      decimals="0"
      id="Fact001803"
      unitRef="USD">26303</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-01-31_custom_LeaseAgreementMember"
      decimals="INF"
      id="Fact001805"
      unitRef="Pure">0.0621</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <MEDS:OperatingLeasesOfLesseeTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001807">&lt;p id="xdx_89B_ecustom--OperatingLeasesOfLesseeTableTextBlock_zbOGT3ExXQI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the summary of operating lease assets and liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zxvcOP14xJV" style="display: none"&gt;SCHEDULE
OF OPERATING LEASE ASSETS AND LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260630_zjIewfS2bX4j" style="text-align: center; font-weight: bold"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20251231_z6wziiPrTrB6" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2026&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-weight: bold; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zhG7hHncbLfc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;719,645&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;966,893&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzBRA_zwwx7kg8l2sa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities, current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;566,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;569,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzBRA_znfTXMoOHZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Long-term lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;249,840&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;527,122&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzBRA_zeIDQBJHWoX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;816,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,096,373&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted Average Remaining Lease Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260630_zOKO0kDhAhV5" title="Weighted average remaining lease term"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z0zeDyoRMV1f" title="Weighted average remaining lease term"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted Average Discount Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260630_zUUJfypzttj1" title="Weighted average discount rate"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zFHrSiCwE8Ga" title="Weighted average discount rate"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</MEDS:OperatingLeasesOfLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001809"
      unitRef="USD">719645</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001810"
      unitRef="USD">966893</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001812"
      unitRef="USD">566379</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001813"
      unitRef="USD">569251</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001815"
      unitRef="USD">249840</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001816"
      unitRef="USD">527122</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001818"
      unitRef="USD">816219</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001819"
      unitRef="USD">1096373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2026-06-30" id="Fact001821">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-12-31" id="Fact001823">P1Y11M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact001825"
      unitRef="Pure">0.0836</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001827"
      unitRef="Pure">0.0836</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001829">&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zPF8F8sSHWai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the summary of future minimum payments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z8WL0THrRhZf" style="display: none"&gt;SCHEDULE OF SUMMARY OF FUTURE MINIMUM PAYMENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260630_zFaAyaeW95l2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOLLzeCb_zYDvRdvJ7Buk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;2026 (remaining 6 months)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;310,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzeCb_zQNdvqwqtSoh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzeCb_zsnkBsu0dPo2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;84,976&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzeCb_maLOLLPzoP8_zmYBXUMBEKr5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;854,073&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--LesseeOperatingLeaseLiabilityImputedInterest_iNI_di_msLOLLPzoP8_zRcXth1UGNZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(37,854&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzoP8_zSBeL0GHTjQa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;816,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001831"
      unitRef="USD">310440</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001833"
      unitRef="USD">458657</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001835"
      unitRef="USD">84976</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001837"
      unitRef="USD">854073</us-gaap:OperatingLeaseLiability>
    <MEDS:LesseeOperatingLeaseLiabilityImputedInterest
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001839"
      unitRef="USD">37854</MEDS:LesseeOperatingLeaseLiabilityImputedInterest>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001841"
      unitRef="USD">816219</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001843">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zYHRtbMHkuq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12. &lt;span id="xdx_828_z7lemJ1Q2bR8"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has transactions with Scietech, LLC, where a significant investor is the spouse of one of the directors of the Company, which
qualifies as a related party. As of June 30, 2026 and December 31, 2025, accounts payable to Scietech, LLC was $&lt;span id="xdx_901_eus-gaap--AccountsPayableCurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ScietechLLCMember_zMD47486eAL2" title="Accounts payable related party"&gt;&lt;span id="xdx_909_eus-gaap--AccountsPayableCurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ScietechLLCMember_zPjjiVnxg85i" title="Accounts payable related party"&gt;25,500&lt;/span&gt;&lt;/span&gt;. No new transactions
occurred with Scietech, LLC during the three and six months ended June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company had an outstanding obligation of $&lt;span id="xdx_900_eus-gaap--OtherLiabilitiesCurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z3oLeiQzKFa8" title="Due to related parties"&gt;225,000&lt;/span&gt; due to its Chief Executive Officer, which was fully repaid
during the three months ended March 31, 2026. As of June 30, 2026, there were no amounts outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, the Company had outstanding advances of $&lt;span id="xdx_903_eus-gaap--OtherReceivablesNetCurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zodM7UVPftGf" title="Due from related parties"&gt;4,200&lt;/span&gt; due from an officer of the Company, representing amounts paid on behalf
of the Company for business purposes, which is included in due from related party in the unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gerald
Commissiong, who was appointed Interim Co-Chief Executive Officer of the Company effective May 20, 2026, also serves as Chief Executive
Officer of Tollo Health, LLC and as Managing Partner of Fortitude Advisors, LLC (&#x201c;Fortitude&#x201d;), which qualifies Tollo Health
and Fortitude as related parties of the Company effective May 20, 2026. Fortitude provides Chief Business Officer consulting services
to the Company under an existing consulting agreement. Tollo Health is a party to, and Fortitude is expected to receive an ownership
interest in connection with, the proposed transaction described in Note 10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and six months ended June 30, 2026, the Company incurred consulting fees to Fortitude of $&lt;span id="xdx_906_eus-gaap--ProfessionalFees_c20260401__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FortitudeAdvisorsLLCMember_z3Wgrp04NVJ3" title="Consulting fees"&gt;119,995&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ProfessionalFees_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FortitudeAdvisorsLLCMember_zyd7JjMC9Kvh" title="Consulting fees"&gt;169,995&lt;/span&gt;, respectively.
As of June 30, 2026, the Company had a receivable of $&lt;span id="xdx_90E_eus-gaap--OtherReceivablesNetCurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TolloHealthLLCMember_zcdSHoQGnfgd" title="Due from related parties"&gt;21,868&lt;/span&gt; due from Tollo Health, included in due from related party in the unaudited
condensed consolidated balance sheets. As of December 31, 2025, neither Tollo Health nor Fortitude was a related party of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and six months ended June 30, 2025, the Company had transactions with certain entities that were considered related parties
at that time, including Integra Pharma Solutions, LLC (&#x201c;IPS&#x201d;) and companies affiliated with Nomad Capital LLC. These entities
are no longer considered related parties as of the date of these financial statements. The following summarizes transactions with these
entities for the three and six months ended June 30, 2026 and 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z3nxYoX3EkH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zR4zxA78SXfj" style="display: none"&gt;SCHEDULE
OF RELATED PARTY TRANSACTION&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20260401__20260630_z7g3FoIHqhib" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250401__20250630_zXPwM6XdPhMj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260101__20260630_zNiuoF6c0fHa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250630_zk2CkYJt8g78" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IntegraPharmaSolutionsLLCMember_zIk2ck3Tc74l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Sales to Integra Pharma Solutions, LLC&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1862"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1863"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;503,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NomadCapitalLLCMember_zqsfAK2ZmpW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Management services fees paid to Nomad Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1866"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1867"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1868"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;160,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CingoSolutionsMember_zwtkTXin9kC4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;IT expenses paid to Cingo Solutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1873"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;199,440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RxERPMember_zZvJxIPaygSd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;SaaS expenses paid to RxERP&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1876"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RxERPMember_z7FMFbMpLLv7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Related party transaction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1881"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1883"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_zgn47CTEWrNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-06-30_custom_ScietechLLCMember"
      decimals="0"
      id="Fact001845"
      unitRef="USD">25500</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31_custom_ScietechLLCMember"
      decimals="0"
      id="Fact001847"
      unitRef="USD">25500</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001849"
      unitRef="USD">225000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2026-06-30_srt_OfficerMember"
      decimals="0"
      id="Fact001851"
      unitRef="USD">4200</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ProfessionalFees
      contextRef="From2026-04-012026-06-30_custom_FortitudeAdvisorsLLCMember"
      decimals="0"
      id="Fact001853"
      unitRef="USD">119995</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2026-01-012026-06-30_custom_FortitudeAdvisorsLLCMember"
      decimals="0"
      id="Fact001855"
      unitRef="USD">169995</us-gaap:ProfessionalFees>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2026-06-30_custom_TolloHealthLLCMember"
      decimals="0"
      id="Fact001857"
      unitRef="USD">21868</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001859">&lt;p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z3nxYoX3EkH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zR4zxA78SXfj" style="display: none"&gt;SCHEDULE
OF RELATED PARTY TRANSACTION&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20260401__20260630_z7g3FoIHqhib" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250401__20250630_zXPwM6XdPhMj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260101__20260630_zNiuoF6c0fHa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250630_zk2CkYJt8g78" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IntegraPharmaSolutionsLLCMember_zIk2ck3Tc74l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Sales to Integra Pharma Solutions, LLC&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1862"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1863"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;503,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NomadCapitalLLCMember_zqsfAK2ZmpW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Management services fees paid to Nomad Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1866"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1867"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1868"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;160,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CingoSolutionsMember_zwtkTXin9kC4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;IT expenses paid to Cingo Solutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1873"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;199,440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RxERPMember_zZvJxIPaygSd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;SaaS expenses paid to RxERP&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1876"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RxERPMember_z7FMFbMpLLv7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Related party transaction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1881"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1883"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-06-30_custom_IntegraPharmaSolutionsLLCMember"
      decimals="0"
      id="Fact001864"
      unitRef="USD">503730</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-06-30_custom_NomadCapitalLLCMember"
      decimals="0"
      id="Fact001869"
      unitRef="USD">160000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-04-012025-06-30_custom_CingoSolutionsMember"
      decimals="0"
      id="Fact001872"
      unitRef="USD">38440</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-06-30_custom_CingoSolutionsMember"
      decimals="0"
      id="Fact001874"
      unitRef="USD">199440</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-04-012025-06-30_custom_RxERPMember"
      decimals="0"
      id="Fact001877"
      unitRef="USD">150000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-06-30_custom_RxERPMember"
      decimals="0"
      id="Fact001879"
      unitRef="USD">150000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-04-012025-06-30_custom_RxERPMember"
      decimals="0"
      id="Fact001882"
      unitRef="USD">150000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-06-30_custom_RxERPMember"
      decimals="0"
      id="Fact001884"
      unitRef="USD">150000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001886">&lt;p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_z4UWAh6BORVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
13. &lt;span id="xdx_823_zBWI5JXuKho6"&gt;SEGMENT AND GEOGRAPHIC INFORMATION &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as &lt;span id="xdx_900_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zdnYJvnLG1P7" title="Number of reportable segments"&gt;&lt;span id="xdx_90A_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zXPJdkKwQDbh" title="Number of operating segments"&gt;one&lt;/span&gt;&lt;/span&gt; operating segment. The Company&#x2019;s CODM is its chief executive officer, who reviews financial information
presented on a consolidated basis. The CODM uses consolidated gross margin, operating income and net income to assess financial performance
and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the determination of the
rate at which the Company seeks to grow operating income and the allocation of budget between cost of revenues, sales and marketing,
general and administrative expenses or technology and development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zGytGsDEUVKc" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the three and
six months ended June 30, 2026 and 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zvKovaiKmBS7" style="display: none"&gt;SCHEDULE OF SEGMENT AND GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20260401__20260630_zH3KAvQr6fE6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250401__20250630_zsL7lclaDwB8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20260101__20260630_zLIoXYA22NPg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250630_z4hn3wNeZmKa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPz0H5_zj5GzMkO0Tld" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Net revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,779,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,790,865&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,339,423&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;18,654,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CostOfRevenue_msGPz0H5_zIL2ojP7GsR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cost of net revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,597,656&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,285,113&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,986,998&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,455,915&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--GrossProfit_iT_mtGPz0H5_maOILzYQF_zqeMqcgreV2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Gross profit (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;505,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;352,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,198,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zTipjgNK47y5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzWcc_z105qp0E3yh1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,056,671&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,859,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,925,606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,032,869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SellingAndMarketingExpense_i01_maOEzWcc_zBNyyTdQN06i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Sales and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;343,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,073,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;408,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DepreciationAndAmortization_i01_maOEzWcc_z8j9ttxmUvk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;356,597&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;802,796&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;713,421&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,605,668&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtOEzWcc_msOILzYQF_zF1EvZtXYSpd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,527,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,006,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,713,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,047,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_mtOILzYQF_maILFCOzDdj_zKohiisWzbS2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,345,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,500,376&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,360,592&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,848,744&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zhlnGcVRevcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income/(expense):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--InterestExpenseNonoperating_iN_di_msNIEzWVH_zU685eY1xzF4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest expense, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,561,240&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,184,040&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,633,919&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,278,530&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LossOnExtinguishmentOfVendorObligation_maNIEzWVH_z2FsfclGFahb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on extinguishment of vendor obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(320,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1950"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,120&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GainsLossesOnExtinguishmentOfDebt_maNIEzWVH_z6kUXoQAopDk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on extinguishment of debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,881,694&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1955"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,881,694&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1957"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--GainsLossesOnContractTerminationFee_i01_maNIEzWVH_zEsHkNE0Dfrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on contract termination fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(766,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(766,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--SettlementFees_iN_di_msNIEzWVH_zWl1DEO22clf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Settlement fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1967"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherNonoperatingIncome_maNIEzWVH_ziImG4lb6MBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;511,157&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,952&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;609,897&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,907&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01_mtNIEzWVH_maILFCOzDdj_zbf6IiphvDL5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total other expense, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,018,171&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,172,088&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,745,230&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,254,623&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzDdj_maNILzOJy_zdwuOskbcvuh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,363,225&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,672,464&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,105,822&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,103,367&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_msNILzOJy_z8ugxlInAyfg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1985"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1986"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1987"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzOJy_zul50PeYDXF5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,363,225&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,672,464&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(26,105,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(39,103,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zulMkoI88AP1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
revenues were within the U.S. region. See Note 1, &lt;i&gt;Organization and Summary of Significant Accounting Policies&lt;/i&gt; - &lt;i&gt;Revenue Recognition&lt;/i&gt;
for additional information about disaggregated revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LongLivedAssetsByGeographicAreasTableTextBlock_zxJSHZKzHPfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s long-lived tangible assets, as well as the Company&#x2019;s operating lease right-of-use assets recognized on the unaudited
condensed consolidated balance sheets were located as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zsh9nzspOIWi" style="display: none"&gt;SCHEDULE
OF LONG LIVED TANGIBLE ASSETS AND OPERATING LEASE RIGHT OF USE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260630_zT2huMFM1jn5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20251231_zzMj1efM0o86" style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-weight: bold; text-align: left"&gt;United States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zayWOtpY0CE2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;173,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;229,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zdwakjcpBbNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease, right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;719,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;966,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z7F5SZcWJMpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2026-01-012026-06-30_custom_SingleReportableSegmentMember"
      decimals="INF"
      id="Fact001888"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2026-01-012026-06-30_custom_SingleReportableSegmentMember"
      decimals="INF"
      id="Fact001890"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001892">&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zGytGsDEUVKc" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the three and
six months ended June 30, 2026 and 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zvKovaiKmBS7" style="display: none"&gt;SCHEDULE OF SEGMENT AND GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20260401__20260630_zH3KAvQr6fE6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250401__20250630_zsL7lclaDwB8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20260101__20260630_zLIoXYA22NPg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250630_z4hn3wNeZmKa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPz0H5_zj5GzMkO0Tld" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Net revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,779,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,790,865&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,339,423&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;18,654,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CostOfRevenue_msGPz0H5_zIL2ojP7GsR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cost of net revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,597,656&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,285,113&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,986,998&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,455,915&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--GrossProfit_iT_mtGPz0H5_maOILzYQF_zqeMqcgreV2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Gross profit (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;505,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;352,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,198,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zTipjgNK47y5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzWcc_z105qp0E3yh1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,056,671&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,859,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,925,606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,032,869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SellingAndMarketingExpense_i01_maOEzWcc_zBNyyTdQN06i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Sales and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;343,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,073,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;408,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DepreciationAndAmortization_i01_maOEzWcc_z8j9ttxmUvk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;356,597&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;802,796&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;713,421&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,605,668&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtOEzWcc_msOILzYQF_zF1EvZtXYSpd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,527,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,006,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,713,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,047,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_mtOILzYQF_maILFCOzDdj_zKohiisWzbS2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,345,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,500,376&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,360,592&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,848,744&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zhlnGcVRevcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income/(expense):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--InterestExpenseNonoperating_iN_di_msNIEzWVH_zU685eY1xzF4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest expense, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,561,240&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,184,040&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,633,919&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,278,530&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LossOnExtinguishmentOfVendorObligation_maNIEzWVH_z2FsfclGFahb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on extinguishment of vendor obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(320,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1950"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,120&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GainsLossesOnExtinguishmentOfDebt_maNIEzWVH_z6kUXoQAopDk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on extinguishment of debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,881,694&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1955"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,881,694&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1957"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--GainsLossesOnContractTerminationFee_i01_maNIEzWVH_zEsHkNE0Dfrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on contract termination fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(766,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(766,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--SettlementFees_iN_di_msNIEzWVH_zWl1DEO22clf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Settlement fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1967"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherNonoperatingIncome_maNIEzWVH_ziImG4lb6MBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;511,157&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,952&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;609,897&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,907&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01_mtNIEzWVH_maILFCOzDdj_zbf6IiphvDL5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total other expense, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,018,171&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,172,088&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,745,230&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,254,623&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzDdj_maNILzOJy_zdwuOskbcvuh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,363,225&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,672,464&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,105,822&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,103,367&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_msNILzOJy_z8ugxlInAyfg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1985"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1986"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1987"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzOJy_zul50PeYDXF5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,363,225&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,672,464&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(26,105,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(39,103,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001894"
      unitRef="USD">1779860</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001895"
      unitRef="USD">7790865</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001896"
      unitRef="USD">3339423</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001897"
      unitRef="USD">18654308</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001899"
      unitRef="USD">1597656</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001900"
      unitRef="USD">7285113</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001901"
      unitRef="USD">2986998</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001902"
      unitRef="USD">17455915</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001904"
      unitRef="USD">182204</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001905"
      unitRef="USD">505752</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001906"
      unitRef="USD">352425</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001907"
      unitRef="USD">1198393</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001914"
      unitRef="USD">7056671</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001915"
      unitRef="USD">4859949</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001916"
      unitRef="USD">11925606</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001917"
      unitRef="USD">36032869</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001919"
      unitRef="USD">113990</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001920"
      unitRef="USD">343383</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001921"
      unitRef="USD">1073990</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001922"
      unitRef="USD">408600</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001924"
      unitRef="USD">356597</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001925"
      unitRef="USD">802796</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001926"
      unitRef="USD">713421</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001927"
      unitRef="USD">1605668</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001929"
      unitRef="USD">7527258</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001930"
      unitRef="USD">6006128</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001931"
      unitRef="USD">13713017</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001932"
      unitRef="USD">38047137</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001934"
      unitRef="USD">-7345054</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001935"
      unitRef="USD">-5500376</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001936"
      unitRef="USD">-13360592</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001937"
      unitRef="USD">-36848744</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001944"
      unitRef="USD">1561240</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001945"
      unitRef="USD">1184040</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001946"
      unitRef="USD">3633919</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001947"
      unitRef="USD">2278530</us-gaap:InterestExpenseNonoperating>
    <MEDS:LossOnExtinguishmentOfVendorObligation
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001949"
      unitRef="USD">-320000</MEDS:LossOnExtinguishmentOfVendorObligation>
    <MEDS:LossOnExtinguishmentOfVendorObligation
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001951"
      unitRef="USD">-60120</MEDS:LossOnExtinguishmentOfVendorObligation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001954"
      unitRef="USD">-8881694</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001956"
      unitRef="USD">-8881694</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <MEDS:GainsLossesOnContractTerminationFee
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001959"
      unitRef="USD">-766394</MEDS:GainsLossesOnContractTerminationFee>
    <MEDS:GainsLossesOnContractTerminationFee
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001961"
      unitRef="USD">-766394</MEDS:GainsLossesOnContractTerminationFee>
    <MEDS:SettlementFees
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001966"
      unitRef="USD">13000</MEDS:SettlementFees>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001969"
      unitRef="USD">511157</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001970"
      unitRef="USD">11952</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001971"
      unitRef="USD">609897</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001972"
      unitRef="USD">23907</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001974"
      unitRef="USD">-11018171</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001975"
      unitRef="USD">-1172088</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001976"
      unitRef="USD">-12745230</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001977"
      unitRef="USD">-2254623</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001979"
      unitRef="USD">-18363225</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001980"
      unitRef="USD">-6672464</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001981"
      unitRef="USD">-26105822</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001982"
      unitRef="USD">-39103367</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact001989"
      unitRef="USD">-18363225</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001990"
      unitRef="USD">-6672464</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-06-30"
      decimals="0"
      id="Fact001991"
      unitRef="USD">-26105822</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30"
      decimals="0"
      id="Fact001992"
      unitRef="USD">-39103367</us-gaap:NetIncomeLoss>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact001994">&lt;p id="xdx_893_eus-gaap--LongLivedAssetsByGeographicAreasTableTextBlock_zxJSHZKzHPfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s long-lived tangible assets, as well as the Company&#x2019;s operating lease right-of-use assets recognized on the unaudited
condensed consolidated balance sheets were located as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zsh9nzspOIWi" style="display: none"&gt;SCHEDULE
OF LONG LIVED TANGIBLE ASSETS AND OPERATING LEASE RIGHT OF USE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260630_zT2huMFM1jn5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20251231_zzMj1efM0o86" style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-weight: bold; text-align: left"&gt;United States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zayWOtpY0CE2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;173,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;229,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zdwakjcpBbNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease, right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;719,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;966,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001996"
      unitRef="USD">173879</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001997"
      unitRef="USD">229376</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001999"
      unitRef="USD">719645</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact002000"
      unitRef="USD">966893</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact002002">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zgGuCuIZjtd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
14. &lt;span id="xdx_820_zXHQDqU2iyO5"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company is involved in legal proceedings arising from the normal course of business activities. The Company, in conjunction
with its legal counsel, assesses the need to record a liability for litigation or loss contingencies. A liability is recorded when and
if it is determined that such a liability for litigation or loss contingencies is both probable and estimable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Although
the results of legal proceedings and claims cannot be predicted with certainty, the Company is not currently a party to any legal proceedings,
which would, individually or in the aggregate, have a material adverse effect on its results of operations, cash flows, or financial
position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Legal
Matters&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 21, 2024, Blythe Global Advisors, LLC filed a demand for arbitration against the Company and the Chairman of the Board for breach
of contract, breach of the implied covenant of good faith and fair dealing, and breach of personal guaranty, claiming accounting services
of $&lt;span id="xdx_90C_eus-gaap--LitigationSettlementExpense_c20240821__20240821__dei--LegalEntityAxis__custom--BlytheGlobalAdvisorsLLCMember_zEfygPsRXRO7" title="Litigation settlement expense"&gt;377,947&lt;/span&gt; for which it has not been paid. The Company has answered the arbitration demand and is vigorously defending the matter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Relatedly,
Wellgistics, LLC, Wood Sage, LLC, Alliance Pharma Solutions, LLC, and Community Specialty Pharmacy, LLC, all subsidiaries of the Company,
have sued Blythe Global Advisors, LLC in the Circuit Court of the Thirteenth Judicial Circuit in and for Hillsborough County, Florida,
asserting claims of improper UCC-1 filings, tortious interference with business relationships, slander of title, and state RICO violations.
A motion to dismiss filed by Blythe remains pending. The Company is vigorously prosecuting its claims.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wellgistics,
LLC is a defendant in a legal proceeding initiated by Lifsa Drugs LLC in the United States District Court for the District of New Jersey.
The complaint alleges that Wellgistics, LLC failed to make payment for certain pharmaceutical products and seeks damages of approximately
$&lt;span id="xdx_90E_eus-gaap--OtherExpenses_c20240821__20240821__dei--LegalEntityAxis__custom--LifsaDrugsLLCMember_zSbTBCtgbE82"&gt;420,460&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
together with interest, legal fees, and other related costs. The underlying amount has been recorded as a liability and is included within
accounts payable in the accompanying condensed consolidated balance sheet. Lifsa&#x2019;s underlying claim was subject to a Claim Purchase Agreement,
dated January 28, 2026, between Silverback Capital Corporation (&#x201c;Silverback&#x201d;) and Lifsa, pursuant to which Silverback acquired
rights with respect to the claim in the amount of $&lt;span id="xdx_90F_eus-gaap--CommitmentsAndContingencies_iI_c20260128__dei--LegalEntityAxis__custom--LifsaDrugsLLCMember_zXk170fW84a7" title="Claim amount of broader settlement process"&gt;307,900&lt;/span&gt;, as part of the broader settlement process between the Company and Silverback
described in Note 9. On July 7, 2026, Silverback and Lifsa entered into a Claim Rights Confirmation and Payment Agreement, which the
Company executed solely to acknowledge its terms, confirming the claim amount of $&lt;span id="xdx_900_eus-gaap--CommitmentsAndContingencies_iI_c20260707__us-gaap--TypeOfArrangementAxis__custom--ClaimRightsConfirmationAndPaymentAgreementMember_zBa1rov19FRa" title="Claim amount of broader settlement process"&gt;307,900&lt;/span&gt; and providing for payment by Silverback of
$&lt;span id="xdx_906_eus-gaap--PaymentsForLegalSettlements_c20260707__20260709__us-gaap--TypeOfArrangementAxis__custom--ClaimRightsConfirmationAndPaymentAgreementMember_zEpygAdvTIQh" title="Payment of settlement"&gt;140,000&lt;/span&gt; on or before July 9, 2026, with the remaining balance of $&lt;span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_c20260707__us-gaap--TypeOfArrangementAxis__custom--ClaimRightsConfirmationAndPaymentAgreementMember_zXrezgPuhXS5" title="Payable of settlement"&gt;167,900&lt;/span&gt; payable within 90 days thereafter. Silverback paid the initial
$&lt;span id="xdx_90A_eus-gaap--PaymentsForLegalSettlements_c20260707__20260708__us-gaap--TypeOfArrangementAxis__custom--ClaimRightsConfirmationAndPaymentAgreementMember_zHqD5SR8lixb" title="Payment of settlement"&gt;140,000 &lt;/span&gt;installment on July 8, 2026. Upon payment of the claim in full, Lifsa has agreed to dismiss the litigation with prejudice, including
any claims in excess of the $&lt;span id="xdx_90F_eus-gaap--CommitmentsAndContingencies_iI_c20260128__dei--LegalEntityAxis__custom--LifsaDrugsLLCMember_zxNpRZYFT64i" title="Claim amount of broader settlement process"&gt;307,900&lt;/span&gt; confirmed amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2026, Brian Norton, who served as the Company&#x2019;s
Chief Executive Officer from February 28, 2025 until his resignation on October 6, 2025, and who was a seller of membership interests
in Wellgistics, LLC to the Company, filed suit against the Company in the Court of Chancery of the State of Delaware. Mr. Norton seeks
monetary damages and shares of common stock that he claims are due to him in connection with the sale of his membership interests in
Wellgistics, LLC, together with consequential damages allegedly arising from the Company&#x2019;s claimed nonpayment. The Company believes Mr.
Norton is not owed any such amounts and intends to vigorously defend the suit.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dispute
with Former Management&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 10, 2025, the Company initiated litigation in the Circuit Court of the Thirteenth Judicial Circuit in and for Hillsborough County,
Florida against certain former officers and/or directors of the Company. The complaint asserts claims including breach of fiduciary duty
of loyalty, breach of contract, tortious interference with a contract, tortious interference with business relationships, and other applicable
claims. In January 2026, the Company served a notice of additional claims against the former management parties for misrepresentations
and omissions of material fact in connection with an acquisition of certain limited liability company membership interests. The Company
intends to seek, among other relief, rescission and cancellation of any purported commitments related to or resulting from the misrepresentations
and omissions, as well as related equitable and monetary remedies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2025, defendants filed a motion to compel arbitration of all claims. A hearing on the motion was held on April 27, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2026, obligations associated with these arrangements are reflected as liabilities on the Company&#x2019;s condensed
consolidated balance sheet in the aggregate amount of approximately $&lt;span id="xdx_90B_eus-gaap--OtherLiabilities_iI_c20260630_zE3iCNnHlgy" title="Liabilities"&gt;17,500,000&lt;/span&gt;.
Of this amount, $&lt;span id="xdx_900_eus-gaap--AccruedUtilitiesCurrent_iI_c20260724__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteMember_zIWqPpxIWc26" title="Payable of pursuant to underlying promissory note"&gt;5,000,000&lt;/span&gt; was due and payable on July 24, 2026 pursuant to the terms of the underlying promissory note. Because
this matter remains in dispute, the Company has not made this payment as of the date of this Quarterly Report. Because the potential
resolution of this matter may result in a gain contingency, no amounts have been recognized in the accompanying condensed
consolidated financial statements for any potential recovery or reduction of the recorded liability. The Company will continue to
evaluate this matter and will adjust the related liability, if appropriate, based on developments in the litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Vendor
Demand Letter &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and certain of its subsidiaries have received demand letters from various vendors requesting payment for goods and services previously
provided. The aggregate amount referenced in these demand letters is approximately $&lt;span id="xdx_90A_eus-gaap--OtherCommitment_iI_pn5n6_c20260630__us-gaap--OtherCommitmentsAxis__custom--VendorDemandLetterMember_zWytvGEE19Xg" title="Other commitment"&gt;4.3&lt;/span&gt; million, of which approximately $&lt;span id="xdx_900_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20260630__us-gaap--OtherCommitmentsAxis__custom--VendorDemandLetterMember_zCmbupsgvWQg" title="Accounts payable"&gt;2.8&lt;/span&gt; million
is already recorded within accounts payable in the accompanying condensed consolidated balance sheet. The remaining $&lt;span id="xdx_90C_ecustom--OtherCommitmentRemainingAmount_iI_pn5n6_c20260630__us-gaap--OtherCommitmentsAxis__custom--VendorDemandLetterMember_zq3GglS10BDb" title="Other commitment remaining amount"&gt;1.5&lt;/span&gt; million relates
to claims that are not recorded as liabilities in the accompanying condensed consolidated financial statements. Based on management&#x2019;s
evaluation in accordance with ASC 450, Contingencies, a loss related to these unrecorded claims is not probable as of June 30, 2026.
Accordingly, no liability has been recognized for these amounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2024-08-212024-08-21_custom_BlytheGlobalAdvisorsLLCMember"
      decimals="0"
      id="Fact002004"
      unitRef="USD">377947</us-gaap:LitigationSettlementExpense>
    <us-gaap:OtherExpenses
      contextRef="From2024-08-212024-08-21_custom_LifsaDrugsLLCMember"
      decimals="0"
      id="Fact002005"
      unitRef="USD">420460</us-gaap:OtherExpenses>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-01-28_custom_LifsaDrugsLLCMember"
      decimals="0"
      id="Fact002007"
      unitRef="USD">307900</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-07-07_custom_ClaimRightsConfirmationAndPaymentAgreementMember"
      decimals="0"
      id="Fact002009"
      unitRef="USD">307900</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2026-07-072026-07-09_custom_ClaimRightsConfirmationAndPaymentAgreementMember"
      decimals="0"
      id="Fact002011"
      unitRef="USD">140000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2026-07-07_custom_ClaimRightsConfirmationAndPaymentAgreementMember"
      decimals="0"
      id="Fact002013"
      unitRef="USD">167900</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2026-07-072026-07-08_custom_ClaimRightsConfirmationAndPaymentAgreementMember"
      decimals="0"
      id="Fact002015"
      unitRef="USD">140000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-01-28_custom_LifsaDrugsLLCMember"
      decimals="0"
      id="Fact002017"
      unitRef="USD">307900</us-gaap:CommitmentsAndContingencies>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact002019"
      unitRef="USD">17500000</us-gaap:OtherLiabilities>
    <us-gaap:AccruedUtilitiesCurrent
      contextRef="AsOf2026-07-24_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact002021"
      unitRef="USD">5000000</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:OtherCommitment
      contextRef="AsOf2026-06-30_custom_VendorDemandLetterMember"
      decimals="-5"
      id="Fact002023"
      unitRef="USD">4300000</us-gaap:OtherCommitment>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-06-30_custom_VendorDemandLetterMember"
      decimals="-5"
      id="Fact002025"
      unitRef="USD">2800000</us-gaap:AccountsPayableCurrent>
    <MEDS:OtherCommitmentRemainingAmount
      contextRef="AsOf2026-06-30_custom_VendorDemandLetterMember"
      decimals="-5"
      id="Fact002027"
      unitRef="USD">1500000</MEDS:OtherCommitmentRemainingAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-01-01to2026-06-30" id="Fact002029">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zUxqcxUXxhNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
15. &lt;span id="xdx_82E_zdfReA7ZhBBe"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Corporate
Name and Trading Symbol Change&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 20, 2026, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary
of State of the State of Delaware to change its name from Wellgistics Health, Inc. to DataMeds AI, Inc. (the &#x201c;Name Change&#x201d;).
The Charter Amendment was duly approved by the Company&#x2019;s stockholders in accordance with Section 242 of the General Corporation
Law of the State of Delaware and became effective as of 12:01 a.m., Eastern Time, on July 22, 2026. In connection with the Name Change,
the Company&#x2019;s common stock began trading on The Nasdaq Capital Market under the new ticker symbol &#x201c;MEDS&#x201d; effective
July 22, 2026, replacing the Company&#x2019;s prior symbol &#x201c;WGRX.&#x201d; The Name Change and the change in trading symbol did not
affect the rights of the Company&#x2019;s stockholders, and the Company&#x2019;s CUSIP number remains unchanged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amended
and Restated Letter of Intent&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
previously disclosed, on May 20, 2026, the Company entered into a Fully Binding Term Sheet, dated May 18, 2026, with EOS Technology Holdings,
Inc. (&#x201c;EOS&#x201d;), Scilex Holding Company (&#x201c;Scilex&#x201d;), Datavault AI Inc. (&#x201c;Datavault&#x201d;), HealthBridge Advisors,
LLC (&#x201c;HBA&#x201d;), and Fortitude Advisors, LLC, as further described in Note 10. On July 29, 2026, the Company entered into an
Amended and Restated Letter of Intent (the &#x201c;LOI&#x201d;) with EOS, Scilex, Datavault, and HBA, which superseded and replaced the
May 18, 2026 Term Sheet in its entirety.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the LOI, subject to negotiation and execution of definitive agreements, the Company would acquire or exclusively license certain intellectual
property assets from EOS and Scilex, expand its existing license arrangement with Datavault, and acquire a controlling interest in Tollo
Health, LLC through an exchange of membership interests with HBA. Consideration under the LOI consists solely of shares of the Company&#x2019;s
common stock (&#x201c;Acquisition Stock&#x201d;), with no preferred stock or convertible securities to be issued. Upon issuance of the
Acquisition Stock, EOS, Scilex, Datavault, and HBA are expected to own, in the aggregate, approximately &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260729__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvesteesMember_zvj9K5PR5VW" title="Ownership percentage"&gt;84.6&lt;/span&gt;% of the Company&#x2019;s
common stock (EOS &#x2013; &lt;span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260729__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EOSTechnologyHoldingsIncMember_zXs3skvxCsC7" title="Interest rate"&gt;19.9&lt;/span&gt;%; Scilex &#x2013; &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260729__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ScilexHoldingCompanyMember_zDbIf2XN5A8b" title="Interest rate"&gt;19.9&lt;/span&gt;%; Datavault &#x2013; &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260729__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DatavaultAIIncMember_zLPjCnlngfE2" title="Interest rate"&gt;19.9&lt;/span&gt;%; HBA &#x2013; &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260729__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--HealthBridgeAdvisorsLLCMember_z6FePHpVY5Na" title="Interest rate"&gt;24.9&lt;/span&gt;%), with Fortitude Advisors, LLC expected
to own approximately &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260729__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FortitudeAdvisorsLLCMember_zKylyZocSvV8" title="Interest rate"&gt;5.0&lt;/span&gt;%, and the Company&#x2019;s existing public stockholders expected to hold the remaining approximately &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260729__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExistingPublicStockholdersMember_zNEjKTMlhMZb" title="Interest rate"&gt;10.4&lt;/span&gt;%, in
each case on a fully diluted, post-closing basis and subject to adjustment and the terms of definitive agreements. The LOI contemplates
post-closing registration rights, transfer restrictions, and management and board changes, and provides for exclusive negotiation among
the parties through September 30, 2026, subject to a 30-day due diligence termination right and other customary conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
proposed transaction remains subject to due diligence, negotiation and execution of definitive agreements, stockholder and other approvals,
financing availability, and other customary conditions, including potential Nasdaq change-of-control listing requirements. No assurance
can be given that definitive agreements will be entered into or that the proposed transaction will be consummated on the terms described
above or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dream
Bowl 2026 Meme Coin Distribution&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 27, 2026, the Company announced an updated record date of August 7, 2026 for the distribution of &#x201c;Dream Bowl 2026&#x201d; meme
coins to holders of the Company&#x2019;s common stock, pursuant to which stockholders as of the record date will be entitled to receive
fifty (50) Dream Bowl 2026 meme coins for each share of common stock held. The distribution date will be determined by subsequent resolution
in coordination with Datavault AI, Inc. As of the date these financial statements are issued, the Company had not yet distributed the
meme coins, and financial statement impact, if any, of the distribution had not yet been determined.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Subsidiary Rebranding&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On August 10, 2026, the Company announced that it
had completed the renaming of its pharmacy and pharmacy technology subsidiaries to Corexa Pharmacy, LLC (f/k/a Wellgistics Pharmacy,
LLC) and Corexa Tech &amp;amp; Hub, LLC (f/k/a Wellgistics Tech &amp;amp; Hub, LLC), respectively. The Company also renamed its pharmacy-focused
division to Corexa Health, LLC, under which Corexa Pharmacy and Corexa Tech &amp;amp; Hub operate as subsidiaries. The Company&#x2019;s wholesale
pharmaceutical distribution subsidiary continues to operate under the name Wellgistics, LLC.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_InvesteesMember"
      decimals="INF"
      id="Fact002031"
      unitRef="Pure">0.846</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_EOSTechnologyHoldingsIncMember"
      decimals="INF"
      id="Fact002033"
      unitRef="Pure">0.199</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_ScilexHoldingCompanyMember"
      decimals="INF"
      id="Fact002035"
      unitRef="Pure">0.199</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_DatavaultAIIncMember"
      decimals="INF"
      id="Fact002037"
      unitRef="Pure">0.199</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_HealthBridgeAdvisorsLLCMember"
      decimals="INF"
      id="Fact002039"
      unitRef="Pure">0.249</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_FortitudeAdvisorsLLCMember"
      decimals="INF"
      id="Fact002041"
      unitRef="Pure">0.050</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-07-29_us-gaap_SubsequentEventMember_custom_ExistingPublicStockholdersMember"
      decimals="INF"
      id="Fact002043"
      unitRef="Pure">0.104</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2026-04-012026-06-30" id="Fact002044">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2026-04-012026-06-30" id="Fact002045">false</ecd:NonRule10b51ArrAdoptedFlag>
    <MEDS:Rule10B51ArrModifiedFlag contextRef="From2026-04-012026-06-30" id="Fact002047">false</MEDS:Rule10B51ArrModifiedFlag>
    <MEDS:NonRule10B51ArrModifiedFlag contextRef="From2026-04-012026-06-30" id="Fact002049">false</MEDS:NonRule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2026-04-012026-06-30" id="Fact002050">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2026-04-012026-06-30" id="Fact002051">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
